WO2023288264A1 - Map4k1 inhibitors - Google Patents
Map4k1 inhibitors Download PDFInfo
- Publication number
- WO2023288264A1 WO2023288264A1 PCT/US2022/073718 US2022073718W WO2023288264A1 WO 2023288264 A1 WO2023288264 A1 WO 2023288264A1 US 2022073718 W US2022073718 W US 2022073718W WO 2023288264 A1 WO2023288264 A1 WO 2023288264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- cycloalkyl
- acceptable salt
- compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 324
- 150000003839 salts Chemical class 0.000 claims abstract description 122
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims abstract description 72
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims abstract description 71
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000035475 disorder Diseases 0.000 claims abstract description 17
- -1 C(O)Me Chemical group 0.000 claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 52
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 230000001419 dependent effect Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
- 150000001721 carbon Chemical group 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 229910052727 yttrium Inorganic materials 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 229910021386 carbon form Inorganic materials 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 23
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000011541 reaction mixture Substances 0.000 description 141
- 239000000243 solution Substances 0.000 description 130
- 239000000543 intermediate Substances 0.000 description 112
- 239000000203 mixture Substances 0.000 description 102
- 239000007787 solid Substances 0.000 description 91
- 239000012044 organic layer Substances 0.000 description 82
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 49
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 47
- 239000003921 oil Substances 0.000 description 39
- 229910052938 sodium sulfate Inorganic materials 0.000 description 36
- 229920006395 saturated elastomer Polymers 0.000 description 35
- 235000011152 sodium sulphate Nutrition 0.000 description 31
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 28
- 229910002027 silica gel Inorganic materials 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 238000004808 supercritical fluid chromatography Methods 0.000 description 19
- 239000007832 Na2SO4 Substances 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000012267 brine Substances 0.000 description 18
- 229940045207 immuno-oncology agent Drugs 0.000 description 18
- 239000002584 immunological anticancer agent Substances 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- 238000010828 elution Methods 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 208000009956 adenocarcinoma Diseases 0.000 description 13
- 235000019270 ammonium chloride Nutrition 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 201000009030 Carcinoma Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000003443 antiviral agent Substances 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910017906 NH3H2O Inorganic materials 0.000 description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 229910052681 coesite Inorganic materials 0.000 description 9
- 229910052906 cristobalite Inorganic materials 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 229910052682 stishovite Inorganic materials 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229910052905 tridymite Inorganic materials 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- WGTUNZACEMJZBT-UHFFFAOYSA-N 4-bromo-1,6-dichloro-2,7-naphthyridine Chemical compound Clc1cc2c(Br)cnc(Cl)c2cn1 WGTUNZACEMJZBT-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 8
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- XRTCEPHIEBOGMO-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(C)=O Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(C)=O XRTCEPHIEBOGMO-UHFFFAOYSA-N 0.000 description 6
- AIZAIHPDOLKPLZ-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(C)=O Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(C)=O AIZAIHPDOLKPLZ-UHFFFAOYSA-N 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- COACCVHPMXAPFR-UHFFFAOYSA-N OC1=CC=C2C(=N1)C(C(OC2=O)C)C Chemical compound OC1=CC=C2C(=N1)C(C(OC2=O)C)C COACCVHPMXAPFR-UHFFFAOYSA-N 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000001270 agonistic effect Effects 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 6
- 229910052805 deuterium Inorganic materials 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- NFUGVYITLAFRQT-UHFFFAOYSA-N BrC1=CN=C(C2=CN=C(C=C12)Cl)OC1CC1 Chemical compound BrC1=CN=C(C2=CN=C(C=C12)Cl)OC1CC1 NFUGVYITLAFRQT-UHFFFAOYSA-N 0.000 description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- LWYODLIWFGZCKQ-OAHLLOKOSA-N CCOC1=NC=C([C@@](C)(C2CC2)O)C2=CC(Cl)=NC=C12 Chemical compound CCOC1=NC=C([C@@](C)(C2CC2)O)C2=CC(Cl)=NC=C12 LWYODLIWFGZCKQ-OAHLLOKOSA-N 0.000 description 4
- LWYODLIWFGZCKQ-HNNXBMFYSA-N CCOC1=NC=C([C@](C)(C2CC2)O)C2=CC(Cl)=NC=C12 Chemical compound CCOC1=NC=C([C@](C)(C2CC2)O)C2=CC(Cl)=NC=C12 LWYODLIWFGZCKQ-HNNXBMFYSA-N 0.000 description 4
- BRCAMYMKSJJBCT-ZDUSSCGKSA-N CC[C@@H](C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O)O Chemical compound CC[C@@H](C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O)O BRCAMYMKSJJBCT-ZDUSSCGKSA-N 0.000 description 4
- WCPAUVQVKBHRSM-HNNXBMFYSA-N CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1NC1CC1)O Chemical compound CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1NC1CC1)O WCPAUVQVKBHRSM-HNNXBMFYSA-N 0.000 description 4
- DIZYSFFQQTYFLX-HNNXBMFYSA-N CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O DIZYSFFQQTYFLX-HNNXBMFYSA-N 0.000 description 4
- WGCUSTSVUCFHOA-ZDUSSCGKSA-N CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O Chemical compound CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O WGCUSTSVUCFHOA-ZDUSSCGKSA-N 0.000 description 4
- VRYWXYHGTFAXMA-AWEZNQCLSA-N CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC)O Chemical compound CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC)O VRYWXYHGTFAXMA-AWEZNQCLSA-N 0.000 description 4
- YLFAGXMDKHCMFA-FMTVUPSXSA-N CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C)C[C@@H](C)S(C)(=O)=O)O Chemical compound CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C)C[C@@H](C)S(C)(=O)=O)O YLFAGXMDKHCMFA-FMTVUPSXSA-N 0.000 description 4
- KIBXZZLNAVOLCJ-RVPKQNPDSA-N CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)O Chemical compound CC[C@@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)O KIBXZZLNAVOLCJ-RVPKQNPDSA-N 0.000 description 4
- WCPAUVQVKBHRSM-OAHLLOKOSA-N CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1NC1CC1)O Chemical compound CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1NC1CC1)O WCPAUVQVKBHRSM-OAHLLOKOSA-N 0.000 description 4
- DIZYSFFQQTYFLX-OAHLLOKOSA-N CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O DIZYSFFQQTYFLX-OAHLLOKOSA-N 0.000 description 4
- WGCUSTSVUCFHOA-CYBMUJFWSA-N CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O Chemical compound CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O WGCUSTSVUCFHOA-CYBMUJFWSA-N 0.000 description 4
- VRYWXYHGTFAXMA-CQSZACIVSA-N CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC)O Chemical compound CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC)O VRYWXYHGTFAXMA-CQSZACIVSA-N 0.000 description 4
- YLFAGXMDKHCMFA-SEDUGSJDSA-N CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C)C[C@@H](C)S(C)(=O)=O)O Chemical compound CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C)C[C@@H](C)S(C)(=O)=O)O YLFAGXMDKHCMFA-SEDUGSJDSA-N 0.000 description 4
- KIBXZZLNAVOLCJ-VGTOOOLASA-N CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)O Chemical compound CC[C@](C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)O KIBXZZLNAVOLCJ-VGTOOOLASA-N 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- LIJXNZHFTVQMMQ-ZDUSSCGKSA-N C[C@@](C(F)(F)F)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound C[C@@](C(F)(F)F)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O LIJXNZHFTVQMMQ-ZDUSSCGKSA-N 0.000 description 4
- RYESQBUFUULXGP-CQSZACIVSA-N C[C@@](C1CC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O Chemical compound C[C@@](C1CC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O RYESQBUFUULXGP-CQSZACIVSA-N 0.000 description 4
- HHTJJIVIMSNBOW-OAHLLOKOSA-N C[C@@](COC)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound C[C@@](COC)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O HHTJJIVIMSNBOW-OAHLLOKOSA-N 0.000 description 4
- LIJXNZHFTVQMMQ-CYBMUJFWSA-N C[C@](C(F)(F)F)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound C[C@](C(F)(F)F)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O LIJXNZHFTVQMMQ-CYBMUJFWSA-N 0.000 description 4
- RYESQBUFUULXGP-AWEZNQCLSA-N C[C@](C1CC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O Chemical compound C[C@](C1CC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)O RYESQBUFUULXGP-AWEZNQCLSA-N 0.000 description 4
- HHTJJIVIMSNBOW-HNNXBMFYSA-N C[C@](COC)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound C[C@](COC)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O HHTJJIVIMSNBOW-HNNXBMFYSA-N 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
- NELXSFILNMSDEK-UHFFFAOYSA-N ClC1=CC=C2C(=N1)C(C(OC2=O)C)C Chemical compound ClC1=CC=C2C(=N1)C(C(OC2=O)C)C NELXSFILNMSDEK-UHFFFAOYSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 229910019213 POCl3 Inorganic materials 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000005809 anti-tumor immunity Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 4
- 108091008042 inhibitory receptors Proteins 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 4
- 229940127084 other anti-cancer agent Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- MHCRLDZZHOVFEE-UHFFFAOYSA-N 4-(4-aminophenyl)morpholin-3-one Chemical compound C1=CC(N)=CC=C1N1C(=O)COCC1 MHCRLDZZHOVFEE-UHFFFAOYSA-N 0.000 description 3
- LZPSGXLLPAGRRX-UHFFFAOYSA-N 4-bromo-6-chloro-2H-2,7-naphthyridin-1-one Chemical compound Clc1cc2c(Br)c[nH]c(=O)c2cn1 LZPSGXLLPAGRRX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- CGEQEDQWAGSGIX-UHFFFAOYSA-N BrC1=CN=C(C2=CN=C(C=C12)Cl)OC Chemical compound BrC1=CN=C(C2=CN=C(C=C12)Cl)OC CGEQEDQWAGSGIX-UHFFFAOYSA-N 0.000 description 3
- IPKXEXGIMSVLPT-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)(F)F)=O IPKXEXGIMSVLPT-UHFFFAOYSA-N 0.000 description 3
- AGFAPTCGDTYTKB-AOOOYVTPSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)=O AGFAPTCGDTYTKB-AOOOYVTPSA-N 0.000 description 3
- NVVHHEWSVCBQIV-UHFFFAOYSA-N CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O)O Chemical compound CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O)O NVVHHEWSVCBQIV-UHFFFAOYSA-N 0.000 description 3
- QYFVCNPLAWCBQE-UHFFFAOYSA-N CCOC1=NC=C(C(C)=O)C2=CC(Cl)=NC=C12 Chemical compound CCOC1=NC=C(C(C)=O)C2=CC(Cl)=NC=C12 QYFVCNPLAWCBQE-UHFFFAOYSA-N 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- PSGKRRMWUPHGLJ-LBPRGKRZSA-N COC1=C(CNC2=CC=C3C(=N2)[C@@H](C(OC3=O)(C)C)C)C=CC(=C1)OC Chemical compound COC1=C(CNC2=CC=C3C(=N2)[C@@H](C(OC3=O)(C)C)C)C=CC(=C1)OC PSGKRRMWUPHGLJ-LBPRGKRZSA-N 0.000 description 3
- PSGKRRMWUPHGLJ-GFCCVEGCSA-N COC1=C(CNC2=CC=C3C(=N2)[C@H](C(OC3=O)(C)C)C)C=CC(=C1)OC Chemical compound COC1=C(CNC2=CC=C3C(=N2)[C@H](C(OC3=O)(C)C)C)C=CC(=C1)OC PSGKRRMWUPHGLJ-GFCCVEGCSA-N 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- QJWHOUAUQNKANR-QGZVFWFLSA-N C[C@@](C1CCC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound C[C@@](C1CCC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O QJWHOUAUQNKANR-QGZVFWFLSA-N 0.000 description 3
- QJWHOUAUQNKANR-KRWDZBQOSA-N C[C@](C1CCC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound C[C@](C1CCC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O QJWHOUAUQNKANR-KRWDZBQOSA-N 0.000 description 3
- YCUNIRONYLYFRX-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC)C=C Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC)C=C YCUNIRONYLYFRX-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 3
- 102100034980 ICOS ligand Human genes 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- BMXIYARVIUYGBF-UHFFFAOYSA-N NC1=CC=C2C(=N1)C1(COC2=O)CC1 Chemical compound NC1=CC=C2C(=N1)C1(COC2=O)CC1 BMXIYARVIUYGBF-UHFFFAOYSA-N 0.000 description 3
- RQPMVQXDADCNNA-LURJTMIESA-N NC1=CC=C2C(=N1)[C@@H](C(OC2=O)(C)C)C Chemical compound NC1=CC=C2C(=N1)[C@@H](C(OC2=O)(C)C)C RQPMVQXDADCNNA-LURJTMIESA-N 0.000 description 3
- RQPMVQXDADCNNA-ZCFIWIBFSA-N NC1=CC=C2C(=N1)[C@H](C(OC2=O)(C)C)C Chemical compound NC1=CC=C2C(=N1)[C@H](C(OC2=O)(C)C)C RQPMVQXDADCNNA-ZCFIWIBFSA-N 0.000 description 3
- YIJOONSXTJBKML-WDSKDSINSA-N NC1=CC=C2C(=N1)[C@H]([C@@H](OC2=O)C)C Chemical compound NC1=CC=C2C(=N1)[C@H]([C@@H](OC2=O)C)C YIJOONSXTJBKML-WDSKDSINSA-N 0.000 description 3
- 102000004473 OX40 Ligand Human genes 0.000 description 3
- 108010042215 OX40 Ligand Proteins 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 3
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 3
- IPMNRTRASIWTFO-UHFFFAOYSA-N methyl 2-(3-bromo-6-chloropyridin-2-yl)acetate Chemical compound COC(=O)Cc1nc(Cl)ccc1Br IPMNRTRASIWTFO-UHFFFAOYSA-N 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 108091006082 receptor inhibitors Proteins 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 3
- NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 description 2
- NUPRWPCQZXFRAV-NXEZZACHSA-N (2R,4R)-4-[tert-butyl(dimethyl)silyl]oxypentan-2-ol Chemical compound C[C@@H](O)C[C@@H](C)O[Si](C)(C)C(C)(C)C NUPRWPCQZXFRAV-NXEZZACHSA-N 0.000 description 2
- NUPRWPCQZXFRAV-VHSXEESVSA-N (2s,4r)-4-[tert-butyl(dimethyl)silyl]oxypentan-2-ol Chemical compound C[C@H](O)C[C@@H](C)O[Si](C)(C)C(C)(C)C NUPRWPCQZXFRAV-VHSXEESVSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 description 2
- LPBDZVNGCNTELM-UHFFFAOYSA-N 2-chloropyrimidin-4-amine Chemical compound NC1=CC=NC(Cl)=N1 LPBDZVNGCNTELM-UHFFFAOYSA-N 0.000 description 2
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- SGCMXKBMMUXENL-UHFFFAOYSA-N 5-amino-3-chloropyrazine-2-carbonitrile Chemical compound NC1=CN=C(C#N)C(Cl)=N1 SGCMXKBMMUXENL-UHFFFAOYSA-N 0.000 description 2
- ANQHWEVESFIYMW-UHFFFAOYSA-N 5-chloro-3-propan-2-yl-1,3-benzoxazol-2-one Chemical compound ClC1=CC=C2OC(=O)N(C(C)C)C2=C1 ANQHWEVESFIYMW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- DMHUCLZZXFIWGP-UHFFFAOYSA-N BrC=1C(=NC(=CC=1)Cl)C(CO)(C)C Chemical compound BrC=1C(=NC(=CC=1)Cl)C(CO)(C)C DMHUCLZZXFIWGP-UHFFFAOYSA-N 0.000 description 2
- LQGOYGRMKABWMO-UHFFFAOYSA-N BrC=1C(=NC(=CC=1)Cl)C1(CC1)C(=O)OC Chemical compound BrC=1C(=NC(=CC=1)Cl)C1(CC1)C(=O)OC LQGOYGRMKABWMO-UHFFFAOYSA-N 0.000 description 2
- SNGVMULRNAUIIC-UHFFFAOYSA-N BrC=1C(=NC(=CC=1)Cl)C1(CC1)C(C)(C)O Chemical compound BrC=1C(=NC(=CC=1)Cl)C1(CC1)C(C)(C)O SNGVMULRNAUIIC-UHFFFAOYSA-N 0.000 description 2
- ZMMWOEZTLUGZKR-UHFFFAOYSA-N BrC=1C(=NC(=CC=1)Cl)C1(CC1)C=O Chemical compound BrC=1C(=NC(=CC=1)Cl)C1(CC1)C=O ZMMWOEZTLUGZKR-UHFFFAOYSA-N 0.000 description 2
- ROEPTHRTZIAXDZ-UHFFFAOYSA-N BrC=1C(=NC(=CC=1)Cl)C1(CC1)CO Chemical compound BrC=1C(=NC(=CC=1)Cl)C1(CC1)CO ROEPTHRTZIAXDZ-UHFFFAOYSA-N 0.000 description 2
- UONDJDMVUWHURI-CMDGGOBGSA-N C(C)(C)(C)OC(=O)NC1=CC=CC(=N1)/C=C/C(=O)OC Chemical compound C(C)(C)(C)OC(=O)NC1=CC=CC(=N1)/C=C/C(=O)OC UONDJDMVUWHURI-CMDGGOBGSA-N 0.000 description 2
- NNUDYMLSCRCOBK-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1=NC(=C(C(=O)O)C=C1)CCC(C)(C)O Chemical compound C(C)(C)(C)OC(=O)NC1=NC(=C(C(=O)O)C=C1)CCC(C)(C)O NNUDYMLSCRCOBK-UHFFFAOYSA-N 0.000 description 2
- OZGLFNQUVNFXMI-UHFFFAOYSA-N C(C)OC(=C)C1=C2C=C(N=CC2=C(C=C1)OC)N Chemical compound C(C)OC(=C)C1=C2C=C(N=CC2=C(C=C1)OC)N OZGLFNQUVNFXMI-UHFFFAOYSA-N 0.000 description 2
- ZFPHCMZRSUFCKM-VMPITWQZSA-N C/C(=C\C)/C1=C(C(=O)OC)C=CC(=N1)OC Chemical compound C/C(=C\C)/C1=C(C(=O)OC)C=CC(=N1)OC ZFPHCMZRSUFCKM-VMPITWQZSA-N 0.000 description 2
- IGCYDTNLYSUFSP-UHFFFAOYSA-N CC(C(C)O1)C2=NC(OC)=CC=C2C1=O Chemical compound CC(C(C)O1)C2=NC(OC)=CC=C2C1=O IGCYDTNLYSUFSP-UHFFFAOYSA-N 0.000 description 2
- ZBZOCGZDBHNMQH-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1Cl)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1Cl)=O ZBZOCGZDBHNMQH-UHFFFAOYSA-N 0.000 description 2
- BDZXWLBNUKMIKB-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1NC)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1NC)=O BDZXWLBNUKMIKB-UHFFFAOYSA-N 0.000 description 2
- IDTOXAKKMLWILE-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1NC1CC1)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1NC1CC1)=O IDTOXAKKMLWILE-UHFFFAOYSA-N 0.000 description 2
- ZDRWNWPFSKRPQA-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1C(C)=O)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1C(C)=O)=O ZDRWNWPFSKRPQA-UHFFFAOYSA-N 0.000 description 2
- VCRMGYLSYASAJY-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)F)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)F)=O VCRMGYLSYASAJY-UHFFFAOYSA-N 0.000 description 2
- TZFGAUCVGWTEOQ-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1OCC1(CC1)F)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1OCC1(CC1)F)=O TZFGAUCVGWTEOQ-UHFFFAOYSA-N 0.000 description 2
- GOPXCOBTZOSPPQ-UHFFFAOYSA-N CC(C(F)F)(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O Chemical compound CC(C(F)F)(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O GOPXCOBTZOSPPQ-UHFFFAOYSA-N 0.000 description 2
- SACOSUCXMSVVSP-UHFFFAOYSA-N CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1NC)O Chemical compound CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1NC)O SACOSUCXMSVVSP-UHFFFAOYSA-N 0.000 description 2
- KTHSMTLLBHMCGD-UHFFFAOYSA-N CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1C(C)=O)O Chemical compound CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1C(C)=O)O KTHSMTLLBHMCGD-UHFFFAOYSA-N 0.000 description 2
- XGIFHGRFMQRCMM-UHFFFAOYSA-N CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CNC1)O Chemical compound CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CNC1)O XGIFHGRFMQRCMM-UHFFFAOYSA-N 0.000 description 2
- DYZNEBWJPRRXAB-UHFFFAOYSA-N CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC1(CC1)F)O Chemical compound CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC1(CC1)F)O DYZNEBWJPRRXAB-UHFFFAOYSA-N 0.000 description 2
- WMELZRDYTNTJRS-AOOOYVTPSA-N CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)O Chemical compound CC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1O[C@H](C1)C[C@H]1S(C)(=O)=O)O WMELZRDYTNTJRS-AOOOYVTPSA-N 0.000 description 2
- KECJFJGHVCRPMW-UHFFFAOYSA-N CC(C)=CC(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O Chemical compound CC(C)=CC(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O KECJFJGHVCRPMW-UHFFFAOYSA-N 0.000 description 2
- NCEBWPXKTCBLEO-UHFFFAOYSA-N CC(C)c1nc(N)cnc1C#N Chemical compound CC(C)c1nc(N)cnc1C#N NCEBWPXKTCBLEO-UHFFFAOYSA-N 0.000 description 2
- NMSYWGKBGFPLHH-UHFFFAOYSA-N CC1(CC=2NC(C=CC=2CO1)=O)C Chemical compound CC1(CC=2NC(C=CC=2CO1)=O)C NMSYWGKBGFPLHH-UHFFFAOYSA-N 0.000 description 2
- WYCHYXSEZOVCIX-UHFFFAOYSA-N CC1C2(C3=NC(=CC=C3C(O1)=O)NC(OC(C)(C)C)=O)CC2 Chemical compound CC1C2(C3=NC(=CC=C3C(O1)=O)NC(OC(C)(C)C)=O)CC2 WYCHYXSEZOVCIX-UHFFFAOYSA-N 0.000 description 2
- HCANKBLATFAIRY-UHFFFAOYSA-N CCC(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O Chemical compound CCC(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O HCANKBLATFAIRY-UHFFFAOYSA-N 0.000 description 2
- RIUPHRVUGQQNAB-UHFFFAOYSA-N CCC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1Cl)O Chemical compound CCC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1Cl)O RIUPHRVUGQQNAB-UHFFFAOYSA-N 0.000 description 2
- DRXGKKYFKFYZOQ-UHFFFAOYSA-N CCC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O Chemical compound CCC(C)(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O DRXGKKYFKFYZOQ-UHFFFAOYSA-N 0.000 description 2
- VPPJCHYBCCQFCS-UHFFFAOYSA-N CCOC(C(C1=C2)=CN=C2Cl)=NC=C1Br Chemical compound CCOC(C(C1=C2)=CN=C2Cl)=NC=C1Br VPPJCHYBCCQFCS-UHFFFAOYSA-N 0.000 description 2
- TZIVNHSUOJHQMQ-UHFFFAOYSA-N CCOC(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1C(C)=O)=C Chemical compound CCOC(C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1C(C)=O)=C TZIVNHSUOJHQMQ-UHFFFAOYSA-N 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- QNIKCAVUHJOQGT-UHFFFAOYSA-N CNC(C(C1=C2)=CN=C2Cl)=NC=C1Br Chemical compound CNC(C(C1=C2)=CN=C2Cl)=NC=C1Br QNIKCAVUHJOQGT-UHFFFAOYSA-N 0.000 description 2
- QLMXURSNXLCSOH-UHFFFAOYSA-N COC(CCC1=CC=CC(=N1)NC(=O)OC(C)(C)C)=O Chemical compound COC(CCC1=CC=CC(=N1)NC(=O)OC(C)(C)C)=O QLMXURSNXLCSOH-UHFFFAOYSA-N 0.000 description 2
- PSGKRRMWUPHGLJ-UHFFFAOYSA-N COC1=C(CNC2=CC=C3C(=N2)C(C(OC3=O)(C)C)C)C=CC(=C1)OC Chemical compound COC1=C(CNC2=CC=C3C(=N2)C(C(OC3=O)(C)C)C)C=CC(=C1)OC PSGKRRMWUPHGLJ-UHFFFAOYSA-N 0.000 description 2
- SVIIYBMTIBUHBL-UHFFFAOYSA-N COC1=NC=C(C(CO)O)C2=CC(Cl)=NC=C12 Chemical compound COC1=NC=C(C(CO)O)C2=CC(Cl)=NC=C12 SVIIYBMTIBUHBL-UHFFFAOYSA-N 0.000 description 2
- ADVDHPPUXIUHTM-UHFFFAOYSA-N COCC(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O Chemical compound COCC(C(C1=CC(Cl)=NC=C11)=CN=C1OC)O ADVDHPPUXIUHTM-UHFFFAOYSA-N 0.000 description 2
- YOBPOUFNQJREQO-UHFFFAOYSA-N CS(N(C1)CC1OC(C(C1=C2)=CN=C2Cl)=NC=C1Br)(=O)=O Chemical compound CS(N(C1)CC1OC(C(C1=C2)=CN=C2Cl)=NC=C1Br)(=O)=O YOBPOUFNQJREQO-UHFFFAOYSA-N 0.000 description 2
- OKUHJXCZQFRRLX-UHFFFAOYSA-N CS(N(C1)CC1OC1=NC=C(C=O)C2=CC(Cl)=NC=C12)(=O)=O Chemical compound CS(N(C1)CC1OC1=NC=C(C=O)C2=CC(Cl)=NC=C12)(=O)=O OKUHJXCZQFRRLX-UHFFFAOYSA-N 0.000 description 2
- HBXHALBHLGTGKB-LURJTMIESA-N C[C@@H](CC1)N1C1=NC=CC(N)=N1 Chemical compound C[C@@H](CC1)N1C1=NC=CC(N)=N1 HBXHALBHLGTGKB-LURJTMIESA-N 0.000 description 2
- AXZJACJNYBXEGM-ZETCQYMHSA-N C[C@@H](CCC1)N1C1=NC=CC(N)=N1 Chemical compound C[C@@H](CCC1)N1C1=NC=CC(N)=N1 AXZJACJNYBXEGM-ZETCQYMHSA-N 0.000 description 2
- LOZNPGQVBHVEDI-UONOGXRCSA-N C[C@@H](C[C@@H](C)O[Si](C)(C)C(C)(C)C)OC(C(C=C1)=CC=C1[N+]([O-])=O)=O Chemical compound C[C@@H](C[C@@H](C)O[Si](C)(C)C(C)(C)C)OC(C(C=C1)=CC=C1[N+]([O-])=O)=O LOZNPGQVBHVEDI-UONOGXRCSA-N 0.000 description 2
- PXVRHFXJIGEQGI-KBPBESRZSA-N C[C@@H]([C@H](C)O1)C2=NC(NC3=CC4=C(C(C)(C)O)C=NC(OC(C5)CN5S(C)(=O)=O)=C4C=N3)=CC=C2C1=O Chemical compound C[C@@H]([C@H](C)O1)C2=NC(NC3=CC4=C(C(C)(C)O)C=NC(OC(C5)CN5S(C)(=O)=O)=C4C=N3)=CC=C2C1=O PXVRHFXJIGEQGI-KBPBESRZSA-N 0.000 description 2
- GGYGGSHNUYSOCR-RYUDHWBXSA-N C[C@@H]([C@H](C)O1)C2=NC(NCC(C=CC(OC)=C3)=C3OC)=CC=C2C1=O Chemical compound C[C@@H]([C@H](C)O1)C2=NC(NCC(C=CC(OC)=C3)=C3OC)=CC=C2C1=O GGYGGSHNUYSOCR-RYUDHWBXSA-N 0.000 description 2
- WPWKQOTWDXINTG-PHDIDXHHSA-N C[C@H](C[C@@H](C)S(C)(=O)=O)O Chemical compound C[C@H](C[C@@H](C)S(C)(=O)=O)O WPWKQOTWDXINTG-PHDIDXHHSA-N 0.000 description 2
- CCZQOQBIEHZOIF-GHMZBOCLSA-N C[C@H](C[C@@H](C)S(C)(=O)=O)O[Si](C)(C)C(C)(C)C Chemical compound C[C@H](C[C@@H](C)S(C)(=O)=O)O[Si](C)(C)C(C)(C)C CCZQOQBIEHZOIF-GHMZBOCLSA-N 0.000 description 2
- QLRCHZSLGYVHBW-GHMZBOCLSA-N C[C@H](C[C@@H](C)SC)O[Si](C)(C)C(C)(C)C Chemical compound C[C@H](C[C@@H](C)SC)O[Si](C)(C)C(C)(C)C QLRCHZSLGYVHBW-GHMZBOCLSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- WABJFHPOSNBBLY-UHFFFAOYSA-N ClC(C=C12)=NC=C1C(NC1CC1)=NC=C2Br Chemical compound ClC(C=C12)=NC=C1C(NC1CC1)=NC=C2Br WABJFHPOSNBBLY-UHFFFAOYSA-N 0.000 description 2
- SVPKNVCTQGAXAO-UHFFFAOYSA-N ClC(C=C12)=NC=C1C(OC1CNC1)=NC=C2Br Chemical compound ClC(C=C12)=NC=C1C(OC1CNC1)=NC=C2Br SVPKNVCTQGAXAO-UHFFFAOYSA-N 0.000 description 2
- KQALAFGXSSMIOD-UHFFFAOYSA-N ClC1=CC=C2C(=N1)CC(OC2)(C)C Chemical compound ClC1=CC=C2C(=N1)CC(OC2)(C)C KQALAFGXSSMIOD-UHFFFAOYSA-N 0.000 description 2
- VIMQPSFZSWZRPU-UHFFFAOYSA-N ClC1=CC=C2C(=N1)CC(OC2=O)(C)C Chemical compound ClC1=CC=C2C(=N1)CC(OC2=O)(C)C VIMQPSFZSWZRPU-UHFFFAOYSA-N 0.000 description 2
- NELXSFILNMSDEK-WDSKDSINSA-N ClC1=CC=C2C(=N1)[C@H]([C@@H](OC2=O)C)C Chemical compound ClC1=CC=C2C(=N1)[C@H]([C@@H](OC2=O)C)C NELXSFILNMSDEK-WDSKDSINSA-N 0.000 description 2
- IKGCQTMTHJQUOQ-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(=C)OCC Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(=C)OCC IKGCQTMTHJQUOQ-UHFFFAOYSA-N 0.000 description 2
- CVDDXXZOGHCRSY-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(C)(C)O Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(C)(C)O CVDDXXZOGHCRSY-UHFFFAOYSA-N 0.000 description 2
- FZQJDUBFQXZQPY-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(C)O Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC)C(C)O FZQJDUBFQXZQPY-UHFFFAOYSA-N 0.000 description 2
- PXYNXTNVPUFPAP-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC)C=O Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC)C=O PXYNXTNVPUFPAP-UHFFFAOYSA-N 0.000 description 2
- UIYTVTPYKQYLHM-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(=C)C Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(=C)C UIYTVTPYKQYLHM-UHFFFAOYSA-N 0.000 description 2
- IFVDHXHFDKZZEY-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(C)(C)O Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(C)(C)O IFVDHXHFDKZZEY-UHFFFAOYSA-N 0.000 description 2
- LOIVESJDOQNJTC-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(C)(O)C1CC1 Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(C)(O)C1CC1 LOIVESJDOQNJTC-UHFFFAOYSA-N 0.000 description 2
- GLYOGYGNGFWEAX-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(CO)(C)O Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C(CO)(C)O GLYOGYGNGFWEAX-UHFFFAOYSA-N 0.000 description 2
- UUUPFMNDWXKCOQ-UHFFFAOYSA-N ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C1(OC1)C Chemical compound ClC=1C=C2C(=CN=C(C2=CN=1)OC1CC1)C1(OC1)C UUUPFMNDWXKCOQ-UHFFFAOYSA-N 0.000 description 2
- CTPXCMNTEDAATM-UHFFFAOYSA-N ClC=1N=CC2=C(C=CC(=C2C=1)C(C)(C)O)OC Chemical compound ClC=1N=CC2=C(C=CC(=C2C=1)C(C)(C)O)OC CTPXCMNTEDAATM-UHFFFAOYSA-N 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100037354 Ectodysplasin-A Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- ROZPTDXECJSCAH-UHFFFAOYSA-N FC(C)(C)C1=NC=CC(=N1)N Chemical compound FC(C)(C)C1=NC=CC(=N1)N ROZPTDXECJSCAH-UHFFFAOYSA-N 0.000 description 2
- GZZYDJMZFISZTM-UHFFFAOYSA-N FC(COC(C(C1=C2)=CN=C2Cl)=NC=C1Br)F Chemical compound FC(COC(C(C1=C2)=CN=C2Cl)=NC=C1Br)F GZZYDJMZFISZTM-UHFFFAOYSA-N 0.000 description 2
- ZWJOLEAEYAHBJF-UHFFFAOYSA-N FC1(COC(C(C2=C3)=CN=C3Cl)=NC=C2Br)CC1 Chemical compound FC1(COC(C(C2=C3)=CN=C3Cl)=NC=C2Br)CC1 ZWJOLEAEYAHBJF-UHFFFAOYSA-N 0.000 description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 description 2
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102100028193 Mitogen-activated protein kinase kinase kinase kinase 3 Human genes 0.000 description 2
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- PPQFYMJUVSQCTG-ZCFIWIBFSA-N NC1=CC=C2C(=N1)C([C@H](OC2=O)C)(C)C Chemical compound NC1=CC=C2C(=N1)C([C@H](OC2=O)C)(C)C PPQFYMJUVSQCTG-ZCFIWIBFSA-N 0.000 description 2
- CHQJGUBFHHPQEF-UHFFFAOYSA-N NC1=CC=C2C(=N1)C1(C(OC2=O)(C)C)CC1 Chemical compound NC1=CC=C2C(=N1)C1(C(OC2=O)(C)C)CC1 CHQJGUBFHHPQEF-UHFFFAOYSA-N 0.000 description 2
- WXEQQAMGBHPYRY-UHFFFAOYSA-N NC1=CC=C2C(=N1)CC(OC2=O)(C)C Chemical compound NC1=CC=C2C(=N1)CC(OC2=O)(C)C WXEQQAMGBHPYRY-UHFFFAOYSA-N 0.000 description 2
- YVMPKWFWKDABNK-UHFFFAOYSA-N NC1=CC=C2C(=N1)CCC(OC2=O)(C)C Chemical compound NC1=CC=C2C(=N1)CCC(OC2=O)(C)C YVMPKWFWKDABNK-UHFFFAOYSA-N 0.000 description 2
- WRAFRQUEKNAXRW-UHFFFAOYSA-N NC1=CC=C2C(=N1)CCOC2=O Chemical compound NC1=CC=C2C(=N1)CCOC2=O WRAFRQUEKNAXRW-UHFFFAOYSA-N 0.000 description 2
- YIJOONSXTJBKML-PHDIDXHHSA-N NC1=CC=C2C(=N1)[C@@H]([C@H](OC2=O)C)C Chemical compound NC1=CC=C2C(=N1)[C@@H]([C@H](OC2=O)C)C YIJOONSXTJBKML-PHDIDXHHSA-N 0.000 description 2
- SEFFVCFUVDRMOD-UHFFFAOYSA-N NC=1N=C(C(=NC=1)C#N)C(=C)C Chemical compound NC=1N=C(C(=NC=1)C#N)C(=C)C SEFFVCFUVDRMOD-UHFFFAOYSA-N 0.000 description 2
- CAHRPRCBMTWELN-UHFFFAOYSA-N NC=1N=CC2=C(C=CC(=C2C=1)C(C)=O)OC Chemical compound NC=1N=CC2=C(C=CC(=C2C=1)C(C)=O)OC CAHRPRCBMTWELN-UHFFFAOYSA-N 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 description 2
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 2
- 229950000971 baricitinib Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 230000006028 immune-suppresssive effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KBEMFSMODRNJHE-JFWOZONXSA-N lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- WDMMBHZPESWUCL-UHFFFAOYSA-N methyl 2-chloro-6-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(OC)N=C1Cl WDMMBHZPESWUCL-UHFFFAOYSA-N 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N methylsulphonylmethane Natural products CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000011682 nervous system cancer Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 208000023747 urothelial carcinoma Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- UFEYSMRZZLYOCP-UHFFFAOYSA-N (1-fluorocyclopropyl)methanol Chemical compound OCC1(F)CC1 UFEYSMRZZLYOCP-UHFFFAOYSA-N 0.000 description 1
- XYLPKCDRAAYATL-OAHLLOKOSA-N (11S)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-11-pyridin-2-yl-9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-2-one Chemical compound CC1=NOC(C)=C1C1=CC=C2C3=C1OC[C@H](C=1N=CC=CC=1)N3C(=O)N2 XYLPKCDRAAYATL-OAHLLOKOSA-N 0.000 description 1
- DWYRIWUZIJHQKQ-SANMLTNESA-N (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine Chemical compound Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1 DWYRIWUZIJHQKQ-SANMLTNESA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 1
- RCSZIBSPHRZNRQ-BTZXMIIFSA-N (2S)-2-amino-6-[6-[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(2S)-3-(1H-indol-3-yl)-1-(oxazinan-2-yl)-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylamino]hexanoylamino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCNC(=O)CCCCCN(C)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(=O)N1OCCCC1)CC1=CNC2=CC=CC=C12 RCSZIBSPHRZNRQ-BTZXMIIFSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- GTCCGKPBSJZVRZ-RFZPGFLSSA-N (2r,4r)-pentane-2,4-diol Chemical compound C[C@@H](O)C[C@@H](C)O GTCCGKPBSJZVRZ-RFZPGFLSSA-N 0.000 description 1
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 1
- WYQBCZUEZOFZFT-WCCKRBBISA-N (2s)-2-methylazetidine;hydrochloride Chemical compound Cl.C[C@H]1CCN1 WYQBCZUEZOFZFT-WCCKRBBISA-N 0.000 description 1
- RGHPCLZJAFCTIK-YFKPBYRVSA-N (2s)-2-methylpyrrolidine Chemical compound C[C@H]1CCCN1 RGHPCLZJAFCTIK-YFKPBYRVSA-N 0.000 description 1
- JNEIFWYJFOEKIM-JEDNCBNOSA-N (2s)-2-methylpyrrolidine;hydrochloride Chemical compound Cl.C[C@H]1CCCN1 JNEIFWYJFOEKIM-JEDNCBNOSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- ONKCBKDTKZIWHZ-MRWFHJSOSA-N (4r)-4-[[(2r)-6-amino-2-[[(2r)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2r)-1-amino-6-[bis[2-[[4-[2-(1h-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxope Chemical compound C([C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(N)=O)NC(=O)C=1C=CC(NC(=S)NN)=CC=1)C1=CC=C(O)C=C1 ONKCBKDTKZIWHZ-MRWFHJSOSA-N 0.000 description 1
- HINZVVDZPLARRP-YSVIXOAZSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 HINZVVDZPLARRP-YSVIXOAZSA-N 0.000 description 1
- ODAOIEZTCKINBJ-UHFFFAOYSA-N (5-bromo-2-methoxyphenyl)methanamine Chemical compound COC1=CC=C(Br)C=C1CN ODAOIEZTCKINBJ-UHFFFAOYSA-N 0.000 description 1
- KPJDVVCDVBFRMU-AREMUKBSSA-N (6r)-6-(2-fluorophenyl)-n-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Chemical compound COCCNCCC1=CC=CC(NC=2N=C3C4=CC=CC=C4[C@H](C=4C(=CC=CC=4)F)CC3=CN=2)=C1 KPJDVVCDVBFRMU-AREMUKBSSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- CSJAIVZAJZXEAW-UHFFFAOYSA-N 1-(3-hydroxyazetidin-1-yl)ethanone Chemical compound CC(=O)N1CC(O)C1 CSJAIVZAJZXEAW-UHFFFAOYSA-N 0.000 description 1
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- WBPWDDPSYSUQJA-VQTJNVASSA-N 1-[[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound COCC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 WBPWDDPSYSUQJA-VQTJNVASSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- WLAVZAAODLTUSW-UHFFFAOYSA-N 1-n'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=O)C4(CC4)C(=O)NC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 WLAVZAAODLTUSW-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- ASOMNDIOOKDVDC-UHFFFAOYSA-N 1h-indol-2-yl-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl]methanone Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=CC=C3C=2)CC1 ASOMNDIOOKDVDC-UHFFFAOYSA-N 0.000 description 1
- VOGSDFLJZPNWHY-UHFFFAOYSA-N 2,2-difluoroethanol Chemical compound OCC(F)F VOGSDFLJZPNWHY-UHFFFAOYSA-N 0.000 description 1
- BWMNOXJVRHGUQM-UHFFFAOYSA-N 2,2-dimethyloxan-4-one Chemical compound CC1(C)CC(=O)CCO1 BWMNOXJVRHGUQM-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- ULRUQDDLPPKCBD-UHFFFAOYSA-N 2-(4-aminopyrimidin-2-yl)propan-2-ol Chemical compound CC(C)(O)C1=NC=CC(N)=N1 ULRUQDDLPPKCBD-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- HEZPWTQUZJEVQF-BQYQJAHWSA-N 2-[(z)-but-2-en-2-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C\C=C(/C)B1OC(C)(C)C(C)(C)O1 HEZPWTQUZJEVQF-BQYQJAHWSA-N 0.000 description 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
- UHTQHHLSGVOGQR-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-4-ium-1-yl]ethanesulfonate Chemical compound OCCN1CCN(CCS(O)(=O)=O)CC1.OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 UHTQHHLSGVOGQR-UHFFFAOYSA-N 0.000 description 1
- KOLQINCWMXQEOF-UHFFFAOYSA-N 2-[6-(6,7-dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide Chemical compound COC=1C=C2C=C(C=NC2=CC=1OC)C1=CC=C(C=N1)CC(=O)NC1=CC(=NO1)C(C(F)(F)F)(C)C KOLQINCWMXQEOF-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- XUMALORDVCFWKV-IBGZPJMESA-N 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 XUMALORDVCFWKV-IBGZPJMESA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- OYUNTGBISCIYPW-UHFFFAOYSA-N 2-chloroprop-2-enenitrile Chemical compound ClC(=C)C#N OYUNTGBISCIYPW-UHFFFAOYSA-N 0.000 description 1
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- DTFBHJWQTDQBEM-UHFFFAOYSA-N 3-bromo-6-chloro-2-methylpyridine Chemical compound CC1=NC(Cl)=CC=C1Br DTFBHJWQTDQBEM-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- LWXHOCHDERDUID-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(2-methylprop-1-enyl)-1,3,2-dioxaborolane Chemical compound CC(C)=CB1OC(C)(C)C(C)(C)O1 LWXHOCHDERDUID-UHFFFAOYSA-N 0.000 description 1
- LMHXDKYPKRJWKS-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(3-methylbut-2-en-2-yl)-1,3,2-dioxaborolane Chemical compound CC(C)=C(C)B1OC(C)(C)C(C)(C)O1 LMHXDKYPKRJWKS-UHFFFAOYSA-N 0.000 description 1
- NVSHVYGIYPBTEZ-UHFFFAOYSA-N 4,5-dimethyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazole-3-carboxamide Chemical compound CC1=NNC(C(=O)NC=2C=C3C=C(NC3=NC=2)C=2C=CC=CC=2)=C1C NVSHVYGIYPBTEZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- IXLVUUFUDRJUSL-RPBOFIJWSA-N 5-[[4-(3-acetamidophenyl)phenyl]methyl]-n-[(1s,2r)-2-phenylcyclopropyl]-1,3-oxazole-4-carboxamide Chemical class CC(=O)NC1=CC=CC(C=2C=CC(CC3=C(N=CO3)C(=O)N[C@@H]3[C@H](C3)C=3C=CC=CC=3)=CC=2)=C1 IXLVUUFUDRJUSL-RPBOFIJWSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- LRIFNGNTKRMFFU-UHFFFAOYSA-N 5-bromo-8-methoxyisoquinolin-3-amine Chemical compound NC1=NC=C2C(OC)=CC=C(Br)C2=C1 LRIFNGNTKRMFFU-UHFFFAOYSA-N 0.000 description 1
- ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)-pyrimidin-4-ylamine Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 description 1
- ALJYDCYFBWNNLH-UHFFFAOYSA-N 6-chloro-2h-2,7-naphthyridin-1-one Chemical compound C1=CNC(=O)C2=C1C=C(Cl)N=C2 ALJYDCYFBWNNLH-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- BHXJPWCPEFXWMH-UHFFFAOYSA-N 8-bromo-2,4-dichloroquinazoline Chemical compound C1=CC=C(Br)C2=NC(Cl)=NC(Cl)=C21 BHXJPWCPEFXWMH-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 description 1
- 101150051155 Akt3 gene Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000937413 Axia Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- SCKPMGAWWBWOPG-UHFFFAOYSA-N BrC=1C(=NC(=CC=1)Cl)C1(CC1)C(C)O Chemical compound BrC=1C(=NC(=CC=1)Cl)C1(CC1)C(C)O SCKPMGAWWBWOPG-UHFFFAOYSA-N 0.000 description 1
- CBJBKFYLPMJLEX-UHFFFAOYSA-N BrC=1C=CC(=NC=1CCC(C)(C)O)NC(OC(C)(C)C)=O Chemical compound BrC=1C=CC(=NC=1CCC(C)(C)O)NC(OC(C)(C)C)=O CBJBKFYLPMJLEX-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- QPOBQUBHTIYCTG-UHFFFAOYSA-N CC(C(C1=CC(Cl)=NC=C11)=CN=C1O)=O Chemical compound CC(C(C1=CC(Cl)=NC=C11)=CN=C1O)=O QPOBQUBHTIYCTG-UHFFFAOYSA-N 0.000 description 1
- HVZHWSXCTOGMFY-UHFFFAOYSA-N CC(C)(C(OC)=O)C1=NC(Cl)=CC=C1Br Chemical compound CC(C)(C(OC)=O)C1=NC(Cl)=CC=C1Br HVZHWSXCTOGMFY-UHFFFAOYSA-N 0.000 description 1
- MFMINXDVPVHOTM-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1OC(C(C1=C2)=CN=C2Cl)=NC=C1Br)=O Chemical compound CC(C)(C)OC(N(C1)CC1OC(C(C1=C2)=CN=C2Cl)=NC=C1Br)=O MFMINXDVPVHOTM-UHFFFAOYSA-N 0.000 description 1
- SIJAAEAGTSVPDY-UHFFFAOYSA-N CC(C1=CC=CC=C1)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O Chemical compound CC(C1=CC=CC=C1)(C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1)O SIJAAEAGTSVPDY-UHFFFAOYSA-N 0.000 description 1
- ARONHSITSLRZER-UHFFFAOYSA-N CC(C1CC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)F)O Chemical compound CC(C1CC1)(C(C1=CC(Cl)=NC=C11)=CN=C1OCC(F)F)O ARONHSITSLRZER-UHFFFAOYSA-N 0.000 description 1
- OSVJQLCVCAZFKY-UHFFFAOYSA-N CC1(CCC2=NC(=CC=C2C(O1)=O)NC(OC(C)(C)C)=O)C Chemical compound CC1(CCC2=NC(=CC=C2C(O1)=O)NC(OC(C)(C)C)=O)C OSVJQLCVCAZFKY-UHFFFAOYSA-N 0.000 description 1
- BRCAMYMKSJJBCT-CYBMUJFWSA-N CC[C@H](C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O)O Chemical compound CC[C@H](C(C1=CC(Cl)=NC=C11)=CN=C1OC(C1)CN1S(C)(=O)=O)O BRCAMYMKSJJBCT-CYBMUJFWSA-N 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 229940121697 CD27 agonist Drugs 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 229940123189 CD40 agonist Drugs 0.000 description 1
- 229940122551 CD40 antagonist Drugs 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- WFRBILYXPPMOQI-UHFFFAOYSA-N COC1=C(CNC2=CC=C3C(=N2)CC(OC3=O)(C)C)C=CC(=C1)OC Chemical compound COC1=C(CNC2=CC=C3C(=N2)CC(OC3=O)(C)C)C=CC(=C1)OC WFRBILYXPPMOQI-UHFFFAOYSA-N 0.000 description 1
- WYCHYXSEZOVCIX-SECBINFHSA-N C[C@@H]1C2(C3=NC(=CC=C3C(O1)=O)NC(OC(C)(C)C)=O)CC2 Chemical compound C[C@@H]1C2(C3=NC(=CC=C3C(O1)=O)NC(OC(C)(C)C)=O)CC2 WYCHYXSEZOVCIX-SECBINFHSA-N 0.000 description 1
- WYCHYXSEZOVCIX-VIFPVBQESA-N C[C@H]1C2(C3=NC(=CC=C3C(O1)=O)NC(OC(C)(C)C)=O)CC2 Chemical compound C[C@H]1C2(C3=NC(=CC=C3C(O1)=O)NC(OC(C)(C)C)=O)CC2 WYCHYXSEZOVCIX-VIFPVBQESA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- SPVXUHXWRWVLAW-UHFFFAOYSA-N ClC=1N=CC2=C(C=CC(=C2C=1)C(C)=O)OC Chemical compound ClC=1N=CC2=C(C=CC(=C2C=1)C(C)=O)OC SPVXUHXWRWVLAW-UHFFFAOYSA-N 0.000 description 1
- 229910020323 ClF3 Inorganic materials 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010009253 Clear cell sarcoma of the kidney Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 201000002847 Cowden syndrome Diseases 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- CUDVHEFYRIWYQD-UHFFFAOYSA-N E-3810 free base Chemical compound C=1C=C2C(C(=O)NC)=CC=CC2=CC=1OC(C1=CC=2OC)=CC=NC1=CC=2OCC1(N)CC1 CUDVHEFYRIWYQD-UHFFFAOYSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055191 EphA3 Receptor Proteins 0.000 description 1
- 108010055334 EphB2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 101150009958 FLT4 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001059989 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 1
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 1
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101710093458 ICOS ligand Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010070665 Mesoblastic nephroma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 101710144521 Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- MHXGEROHKGDZGO-UHFFFAOYSA-N N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-6-imidazo[1,2-b]pyridazinamine Chemical compound C1CN(C)CCC1CNC1=NN2C(C=3C=C(OC(F)(F)F)C=CC=3)=CN=C2C=C1 MHXGEROHKGDZGO-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- PPQFYMJUVSQCTG-UHFFFAOYSA-N NC1=CC=C2C(=N1)C(C(OC2=O)C)(C)C Chemical compound NC1=CC=C2C(=N1)C(C(OC2=O)C)(C)C PPQFYMJUVSQCTG-UHFFFAOYSA-N 0.000 description 1
- PPQFYMJUVSQCTG-LURJTMIESA-N NC1=CC=C2C(=N1)C([C@@H](OC2=O)C)(C)C Chemical compound NC1=CC=C2C(=N1)C([C@@H](OC2=O)C)(C)C PPQFYMJUVSQCTG-LURJTMIESA-N 0.000 description 1
- YJLKXWBRRTYKCV-LURJTMIESA-N NC1=CC=C2C(=N1)C1([C@@H](OC2=O)C)CC1 Chemical compound NC1=CC=C2C(=N1)C1([C@@H](OC2=O)C)CC1 YJLKXWBRRTYKCV-LURJTMIESA-N 0.000 description 1
- YJLKXWBRRTYKCV-ZCFIWIBFSA-N NC1=CC=C2C(=N1)C1([C@H](OC2=O)C)CC1 Chemical compound NC1=CC=C2C(=N1)C1([C@H](OC2=O)C)CC1 YJLKXWBRRTYKCV-ZCFIWIBFSA-N 0.000 description 1
- DAJCQTITRPOBNJ-ZETCQYMHSA-N NC=1N=C(C(=NC=1)C#N)N1[C@H](CCC1)C Chemical compound NC=1N=C(C(=NC=1)C#N)N1[C@H](CCC1)C DAJCQTITRPOBNJ-ZETCQYMHSA-N 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- IPMARPMXSFFZFG-MHZLTWQESA-N N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CCO Chemical compound N[C@@](C)(C1=CC=C(C=C1)F)C=1C=NC(=NC=1)N1CCN(CC1)C1=NC=NN2C1=CC(=C2)C=1C=NN(C=1)CCO IPMARPMXSFFZFG-MHZLTWQESA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102100035487 Nectin-3 Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- BYYQDEOVMILBQT-XZJROXQQSA-N O1C=2C=3N([C@@H]4CCC[C@H]14)CC1=CC(F)=CN=C1O[C@@H](C)CNC(=O)C1=C(N=3)N(C=2)N=C1 Chemical compound O1C=2C=3N([C@@H]4CCC[C@H]14)CC1=CC(F)=CN=C1O[C@@H](C)CNC(=O)C1=C(N=3)N(C=2)N=C1 BYYQDEOVMILBQT-XZJROXQQSA-N 0.000 description 1
- PDNLDOKJQDKNCP-UHFFFAOYSA-N O=C1OCC2(C3=NC(=CC=C31)C(=O)O)CC2 Chemical compound O=C1OCC2(C3=NC(=CC=C31)C(=O)O)CC2 PDNLDOKJQDKNCP-UHFFFAOYSA-N 0.000 description 1
- HIQGRZKQESLXBO-UHFFFAOYSA-N O=C1OCC2(C3=NC(=CC=C31)C(=O)OC)CC2 Chemical compound O=C1OCC2(C3=NC(=CC=C31)C(=O)OC)CC2 HIQGRZKQESLXBO-UHFFFAOYSA-N 0.000 description 1
- WSBSVTPUJCHPDO-UHFFFAOYSA-N O=C1OCC2(C3=NC(=CC=C31)NC(OC(C)(C)C)=O)CC2 Chemical compound O=C1OCC2(C3=NC(=CC=C31)NC(OC(C)(C)C)=O)CC2 WSBSVTPUJCHPDO-UHFFFAOYSA-N 0.000 description 1
- KQSWWKQNIOMZTK-UHFFFAOYSA-N OC(CCC1=CC=CC(=N1)NC(OC(C)(C)C)=O)(C)C Chemical compound OC(CCC1=CC=CC(=N1)NC(OC(C)(C)C)=O)(C)C KQSWWKQNIOMZTK-UHFFFAOYSA-N 0.000 description 1
- SRVLMFAZODWGPL-UHFFFAOYSA-N OC1(CCOCC1)C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1 Chemical compound OC1(CCOCC1)C(C1=CC(Cl)=NC=C11)=CN=C1OC1CC1 SRVLMFAZODWGPL-UHFFFAOYSA-N 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 229940123751 PD-L1 antagonist Drugs 0.000 description 1
- 229940124780 PI3K delta inhibitor Drugs 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 1
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000018795 RELT Human genes 0.000 description 1
- 108010052562 RELT Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 1
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 108091005729 TAM receptors Proteins 0.000 description 1
- 102000016946 TWEAK Receptor Human genes 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- GOSKUPVUQITBGK-WDEREUQCSA-N [(2s,4r)-4-[tert-butyl(dimethyl)silyl]oxypentan-2-yl] methanesulfonate Chemical compound CC(C)(C)[Si](C)(C)O[C@H](C)C[C@H](C)OS(C)(=O)=O GOSKUPVUQITBGK-WDEREUQCSA-N 0.000 description 1
- NELXSFILNMSDEK-PHDIDXHHSA-N [C@H]1(C)C2=NC(Cl)=CC=C2C(=O)O[C@@H]1C Chemical compound [C@H]1(C)C2=NC(Cl)=CC=C2C(=O)O[C@@H]1C NELXSFILNMSDEK-PHDIDXHHSA-N 0.000 description 1
- OEQAMZQWBVDKJR-UHFFFAOYSA-M [OH-].[Li+].O=C1OCC2(C3=NC(=CC=C31)C(=O)O)CC2 Chemical compound [OH-].[Li+].O=C1OCC2(C3=NC(=CC=C31)C(=O)O)CC2 OEQAMZQWBVDKJR-UHFFFAOYSA-M 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 150000001500 aryl chlorides Chemical class 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229950009576 avapritinib Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- GHQPBDDZGPAVJP-UHFFFAOYSA-N azanium;methanol;hydroxide Chemical compound N.O.OC GHQPBDDZGPAVJP-UHFFFAOYSA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 229950000080 birabresib Drugs 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229950005852 capmatinib Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229950009240 crenolanib Drugs 0.000 description 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- OOKFLLNDYNWCHK-UHFFFAOYSA-N difluoromethyl(trimethyl)silane Chemical compound C[Si](C)(C)C(F)F OOKFLLNDYNWCHK-UHFFFAOYSA-N 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 229940125021 eganelisib Drugs 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- ARUMINUDFDUGNU-UHFFFAOYSA-N ethyl 2-amino-2-iminoacetate;hydrochloride Chemical compound Cl.CCOC(=O)C(N)=N ARUMINUDFDUGNU-UHFFFAOYSA-N 0.000 description 1
- YHDZCFILDSOJRF-UHFFFAOYSA-N ethyl 4-aminopyrimidine-2-carboxylate Chemical compound CCOC(=O)C1=NC=CC(N)=N1 YHDZCFILDSOJRF-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- MGZKYOAQVGSSGC-DLBZAZTESA-N fisogatinib Chemical compound COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1 MGZKYOAQVGSSGC-DLBZAZTESA-N 0.000 description 1
- 229940121561 fisogatinib Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 230000006867 granzyme B production Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 208000024596 kidney oncocytoma Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229950004697 lasinavir Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 229950005339 lobucavir Drugs 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 229950003557 lodenosine Drugs 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229950004231 lucitanib Drugs 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- QRUDPBHCPMSJFN-UHFFFAOYSA-M magnesium;cyclobutane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]C1 QRUDPBHCPMSJFN-UHFFFAOYSA-M 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- WUKLXKBMAFRNKC-UHFFFAOYSA-N n-(1,2,4-triazol-4-yl)cycloheptanimine Chemical compound C1CCCCCC1=NN1C=NN=C1 WUKLXKBMAFRNKC-UHFFFAOYSA-N 0.000 description 1
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 1
- PTORCEYGCGXHDH-OVMXCRKPSA-N n-[(7r)-4-[(3r,4r,5s)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5h-cyclopenta[b]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Chemical compound C1[C@@H](N)[C@H](O)[C@@H](C)CN1C1=C(CC[C@H]2O)C2=NC=C1NC(=O)C1=CC=C(F)C(C=2C(=CC=CC=2F)F)=N1 PTORCEYGCGXHDH-OVMXCRKPSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- VRQXRVAKPDCRCI-ZNMIVQPWSA-N n-[4-[(1r,3s,5s)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Chemical compound C1[C@H](C)C[C@H](N)C[C@@H]1C1=CC=NC=C1NC(=O)C1=CC=C(F)C(C=2C(=CC=CC=2F)F)=N1 VRQXRVAKPDCRCI-ZNMIVQPWSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- KXVFTZOZYASDRU-UHFFFAOYSA-N n-methyl-1-(4-nitrophenyl)methanimine Chemical compound CN=CC1=CC=C([N+]([O-])=O)C=C1 KXVFTZOZYASDRU-UHFFFAOYSA-N 0.000 description 1
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- GCWIQUVXWZWCLE-INIZCTEOSA-N pelabresib Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229950005769 pilaralisib Drugs 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940121597 pralsetinib Drugs 0.000 description 1
- GBLBJPZSROAGMF-BATDWUPUSA-N pralsetinib Chemical compound CO[C@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 GBLBJPZSROAGMF-BATDWUPUSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HCJTYESURSHXNB-UHFFFAOYSA-N propynamide Chemical compound NC(=O)C#C HCJTYESURSHXNB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108010083755 proto-oncogene proteins pim Proteins 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000005039 renal oncocytoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- CEFJVGZHQAGLHS-UHFFFAOYSA-N ripretinib Chemical compound O=C1N(CC)C2=CC(NC)=NC=C2C=C1C(C(=CC=1F)Br)=CC=1NC(=O)NC1=CC=CC=C1 CEFJVGZHQAGLHS-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- WZDMEUOIVUZTPB-UHFFFAOYSA-N tert-butyl n-(6-bromopyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(Br)=N1 WZDMEUOIVUZTPB-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- HJOAXCLZLHDZDX-UHFFFAOYSA-N tris(1,2,2-trifluoroethenyl) borate Chemical compound FC(F)=C(F)OB(OC(F)=C(F)F)OC(F)=C(F)F HJOAXCLZLHDZDX-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- MAP4K1 INHIBITORS RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application Serial No. 63/222,341, filed July 15, 2021, the entire teachings of which are incorporated herein by reference. FIELD This application is directed to MAP4K1 inhibitors and methods for their use, such as to control the activity of MAP4K1 in a subject.
- BACKGROUND MAP4K1 also known as hematopoietic progenitor kinase 1 (HPKl) was originally cloned from hematopoietic progenitor cells (Hu, M.C., et al., Genes Dev, 1996.10(18): p. 2251-64).
- MAP4K1 is of particular interest as a target, because it is predominantly expressed in hematopoietic cells such as T cells, B cells, macrophages, dendritic cells, neutrophils, and mast cells (Hu, M.C., et al, Genes Dev, 1996.10(18): p.2251-64; Kiefer, F., et al, EMBO J, 1996.15(24): p.7013-25).
- TCR T cell receptors
- BCR B cell receptors
- TGF- R transforming growth factor receptor
- EGF- R Gs-coupled PGE2 receptors
- MAP4K1 regulates diverse functions of various immune cells.
- MAP4K1 is important in regulating the functions of various immune cells and it has been implicated in autoimmune diseases and anti-tumor immunity (Shui, J.W., et al, Nat Immunol, 2007.8(1): p.84-91; Wang, X., et al, J Biol Chem, 2012.287(14): p.11037-48).
- Those observations suggested that attenuation of MAP4K1 activity may contribute to autoimmunity in patients.
- MAP4K1 may also control anti-tumor immunity via T cell-dependent mechanisms.
- BMDCs bone marrow derived dendritic cells
- MAP4K1 knockout mice were more efficient to mount a T cell response to eradicate Lewis lung carcinoma as compared to wild-type BMDCs (Alzabin, S., et al., J Immunol, 2009.182(10): p.6187-94).
- Data obtained from MAP4K1 kinase dead mice demonstrated that MAP4K1 kinase activity is critical in conferring suppressive functions of MAP4K1 in a wide range of immune cells including CD4+, CD8+, DC, NK to T regulatory cells (Tregs) and inactivation of kinase domain was sufficient to elict robust anti-tumor immune responses.
- MAP4K1 as a novel drug target for enhancing antitumor immunity. Accordingly, there is a need for new compounds that modulate MAP4K1 activity for the treatment of MAP4K1-dependent diseases or disorders such as cancer, viral infection, and other diseases and disorders. Of particular importance is the need for new compounds that selectively modulate MAP4K1 activity.
- the IC50 values for inhibition of MAP4K1 provided in Table 3 demonstrate that these compounds are potent inhibitors of MAP4K1. Also disclosed are methods of using the compounds and compositions described herein for treating cancer and viral infection.
- a first embodiment of the disclosure is a compound represented by Formula I: I, or a pharmaceutically acceptable salt thereof, wherein: A 1 is selected from N and CH; A 2 is selected from CH and N; X is selected from C 1-3 alkyl, OR 3 , NHR 4 and halogen; B is selected from CR 5 and N, Y is CR 6 , or Y and B, taken together, form a 5 to 7-membered heterocycle or C 5-6 cycloalkyl, wherein said heterocycle or cycloalkyl is optionally substituted with 1-6 R 7 ; R 1 and R 2 are each independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkyl substituted with OR 8 , phenyl, C 3-6 cycloalkyl and 4 to 6-membered heterocycle, or R 1 and R 2 , taken together with the atoms to which they are attached, form a C 3-6 cycloalkyl or 4 to 6-membered heterocycle;
- R 11 is selected from C 1-6 alkyl and C 3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R 18 ;
- R 12 and R 13 are each is independently selected from C 1-6 alkyl and C 3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R 18 ;
- R 14 is selected from C 1-6 alkyl and C 3-6 cycloalky
- Another embodiment of the disclosure is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound disclosed herein or a pharmaceutically acceptable salt thereof.
- Another embodiment of the disclosure is a method of inhibiting MAP4K1 in a subject in need thereof, comprising contacting MAP4K1 with an effective amount of the compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof.
- Another embodiment of the disclosure is a method for enhancing an immune response in a subject in need thereof, comprising administering to said subject an effective amount of the compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof.
- Another embodiment of the disclosure is a method of treating a MAP4K1-dependent disorder or disease (e.g., treating a cancer) in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound(s).
- Another embodiment of the disclosure is the use of a compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound(s), for the preparation of a medicament for treating a MAP4K1-dependent disorder or disease (e.g., treating a cancer) in a subject in need thereof.
- Another embodiment of the disclosure is a compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound(s), for use in treating a MAP4K1-dependent disorder or disease (e.g., treating a cancer) in a subject in need thereof.
- a MAP4K1-dependent disorder or disease e.g., treating a cancer
- the disclosed compounds or pharmaceutically acceptable salts thereof are MAP4K1 inhibitors, which can be used for treating a MAP4K1-dependent disorder or disease.
- diseases or disorders include cancer and viral infection.
- Compound Embodiments Example embodiments include: First embodiment: a compound represented by Formula I: I, or a pharmaceutically acceptable salt thereof. The variables in Formula I are described in the summary above. Second embodiment: a compound represented by Formula II: or a pharmaceutically acceptable salt thereof.
- a compound represented by Formula V or a pharmaceutically acceptable salt thereof, wherein Y and B, taken together, form a 5 to 7- membered heterocycle or C 5-6 cycloalkyl, and said heterocycle or cycloalkyl is optionally substituted with 1-6 R 7 .
- the variables in Formula V are described above in the first embodiment.
- each R 7 is independently selected from C 1-3 alkyl, halogen and OH, wherein said alkyl is optionally substituted with 1-3 halogen, or two R 7 attached to the same carbon atom taken together with the carbon atom to which they are attached form a C 3-5 cycloalkyl; n is 0, 1, 2, 3, 4, 5 or 6; and m is 0, 1 or 2.
- n is 0, 1, 2, 3, 4, 5 or 6
- m is 0, 1 or 2.
- the remainder of the variables in Formula VI are described above in the first embodiment.
- the remainder of the variables in Formula VII are described above in the first and/or sixth embodiment.
- Eighth embodiment a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein X is NHR 4 , and R 4 is CH 3 or cyclopropyl.
- the remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth and/or seventh embodiments.
- Ninth embodiment a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein X is OR 3 .
- Tenth embodiment a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 are each independently selected from hydrogen, C 1-2 alkyl, C 1-2 haloalkyl, C 1-3 alkyl substituted with OR 8 , phenyl and C 3-4 cycloalkyl, or R 1 and R 2 , taken together with the atoms to which they are attached, form a 4 to 6-membered heterocycle; and R 8 is C1-2 alkyl.
- R 1 and R 2 are each independently selected from hydrogen, CH 3 , CH 2 CH 3 , CH 2 OCH 3 , CHF 2 , CF 3 , cyclobutyl, cyclopropyl and phenyl, or R 1 and R 2 , taken together with the atoms to which they are attached, form .
- Fifteenth embodiment a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: R 3 is selected from CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , cyclopropyl, cyclobutyl, azetidinyl, each optionally substituted with 1-3 R 9 ; and each R 9 is independently selected from CH3, F, C(O)Me and SO2Me.
- the remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, ninth, tenth, eleventh and/or twelfth embodiments.
- Sixteenth embodiment a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from CH3, CH 2 CH 3 , CH 2 CHF 2 , CH 2 CF 3 , CH 2 CH 2 CH 3 , cyclopropyl, : and The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, ninth, tenth, eleventh and/or twelfth embodiments. Seventeenth embodiment: a compound represented by Formulae I, II, III or IV(B), or a pharmaceutically acceptable salt thereof, wherein R 5 is CN.
- Eighteenth embodiment a compound represented by Formulae I, II, III, IV(A) or IV(B), or a pharmaceutically acceptable salt thereof, wherein: R 6 is selected from C 1-4 alkyl, and 4 to 5-membered heterocycle, wherein said alkyl or heterocycle is optionally substituted with 1-4 halogen or R 15 ; and R 15 is C1-2 alkyl.
- Twentieth embodiment a compound represented by Formulae I, II, III, IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: each R 7 is independently CH 3 , or two R 7 attached to the same carbon form an oxo, or two R 7 attached to the same carbon atom taken together with the carbon atom to which they are attached form cyclopropyl.
- each R 7 is independently CH 3 , or two R 7 attached to the same carbon form an oxo, or two R 7 attached to the same carbon atom taken together with the carbon atom to which they are attached form cyclopropyl.
- the remainder of the variables in Formulae I, II, III, IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth and/or sixteenth embodiments.
- Twentyfirst emboidment a compound represented by Formulae I, II, III, IV(B) or V, or a pharmaceutically acceptable salt thereof, wherein Y and B, taken together, form: and wherein represents a bond to A 2 , and ⁇ represents a bond to N.
- the remainder of the variables in Formulae I, II, III, IV(B), V, VI and VII are describe above in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth and/or sixteenth embodiments.
- the Compounds 71-74 in Table 4, and pharmaceutically acceptable salts thereof, are excluded from the disclosure.
- the disclosure also includes the compounds depicted in Table 1 and prepared in the Exemplification, both the neutral form and pharmaceutically acceptable salts thereof.
- the synthetic protocol used to prepare compounds in Table 1 is listed in the last column of Table 1 and full details for each synthetic protocol are described in Scheme 1 in the General Synthetic Methods and Intermediates section. Table 1
- compositions disclosed herein including compounds 1-70 disclosed in Table 1 and Exemplification
- pharmaceutically acceptable salts of the compounds disclosed herein including compounds 1-70 disclosed in Table 1 and Exemplification
- Another embodiment of the disclosure is a compound disclosed herein, including a compound of Formulae I, II, III, IV(A), IV(B), V, VI or VII or a compound in Table 1 or in the exemplification or a pharmaceutically acceptable salt of any of the foregoing, in which one or more hydrogen atoms is replaced with deuterium.
- the deuterium enrichment at any one of the sites where hydrogen has been replaced by deuterium is at least 50%, 75%, 85%, 90%, 95%, 98% or 99%.
- Deuterium enrichment is a mole percent and is obtained by dividing the number of compounds with deuterium enrichment at the site of enrichment with the number of compounds having hydrogen or deuterium at the site of enrichment.
- pharmaceutically acceptable salt refers to pharmaceutical salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describes pharmacologically acceptable salts in J. Pharm. Sci. (1977) 66:1-19.
- Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, nitric, and sulfuric acids) and of organic acids (such as acetic acid, benzenesulfonic, benzoic, methanesulfonic, and p-toluenesulfonic acids).
- Compounds of the present teachings with acidic groups can form pharmaceutically acceptable salts with pharmaceutically acceptable base(s).
- Suitable pharmaceutically acceptable basic salts include ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).
- alkali metal salts such as sodium and potassium salts
- alkaline earth metal salts such as magnesium and calcium salts.
- alkyl used alone or as part of a larger moiety, such as “alkoxy”, “hydroxyalkyl” and the like, means a saturated aliphatic straight-chain or branched monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group typically has 1 to 6 carbon atoms (C 1-6 alkyl), (i.e., 1, 2, 3, 4, 5 or 6) alternatively, 1 to 3 carbon atoms (C 1-3 alkyl) (i.e., 1, 2 or 3).
- C 1 – 6 alkyl is means a radical having 1 to 6 carbon atoms in a linear or branched arrangement, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like.
- alkylene means a bivalent alkyl group, for example C1-C6 alkyl is a group ⁇ (CH2)n ⁇ where n is 1 to 6, C1-C3 alkyl is a group ⁇ (CH2)n ⁇ where n is 1 to 3, unless otherwise specified.
- Cycloalkyl means a saturated aliphatic cyclic hydrocarbon ring radical.
- a cycloalkyl has 3 to 8 ring carbon atoms (C3-8 cycloalkyl) (i.e., 3, 4, 5, 6, 7, or 8), alternatively, 3 to 6 ring carbon atoms (C 3 - 6 cycloalkyl) (i.e., 3, 4, 5, or 6), alternatively, 3 to 5 carbon atoms (C 3-5 cycloalkyl) (i.e., 3, 4, or 5).
- C 3 - 6 Cycloalkyl means a radical having from 3 to 6 carbon atoms arranged in a monocyclic ring.
- a C 3-6 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- a C 3-5 cycloalkyl includes cyclopropyl, cyclobutyl, and cyclopentyl.
- the term “cycloalkyl” also means to include a saturated aliphatic cyclic hydrocarbon fused to an aromatic group such as in Formula (I) wherein “Y and B taken together form a C5-6cycloalkyl.”
- halogen or “halo” means fluorine or fluoro (F), chlorine or chloro (Cl), bromine or bromo (Br), or iodine or iodo (I).
- heterocycle refers to a monocyclic non-aromatic ring radical containing unless otherwise specified, 3 to 8 ring atoms (i.e., “3, 4, 5, 6, 7, or 8 membered”) selected from carbon atom and 1 or 2 heteroatoms.
- Each heteroatom is independently selected from nitrogen, quaternary nitrogen, oxidized nitrogen (e.g., NO); oxygen; and sulfur, including sulfoxide and sulfone.
- 4-6 membered heterocycle containing nitrogen refers to a monocyclic non-aromatic ring radical containing 2-5 carbon atoms and 1 or 2 nitrogen atoms
- 4-6 membered heterocycle containing oxygen atoms refers to a monocyclic non-aromatic ring radical containing 2-5 carbon atoms and 1 or 2 oxygen.
- heterocycles include azetidinyl, morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
- hydroxyl or “hydroxy” refers to the group OH.
- substituted refers to the replacement of a hydrogen substituent in a given structure with a non-hydrogen substituent.
- a substituted alkyl is an alkyl wherein at least one non-hydrogen substituent is in the place of a hydrogen substituent on the alkyl group.
- monofluoroalkyl is an alkyl substituted with a fluoro substituent
- difluoroalkyl is an alkyl substituted with two fluoro substituents. It should be recognized that if there is more than one substitution on a substituent, each non-hydrogen substituent can be identical or different (unless otherwise stated).
- a group can be either (1) not substituted or (2) substituted. If a group is described as optionally substituted with up to a particular number of non- hydrogen substituents, that group can be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a group is described as a cycloalkyl optionally substituted with up to 3 non-hydrogen substituents, then any cycloalkyl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen substituents as the cycloalkyl has substitutable positions.
- stereoisomers are compounds that differ only in their spatial arrangement. Stereoisomers include all diastereomeric and enantiomeric forms of a compound. Enantiomers are stereoisomers that are non-superimposable mirror images of each other. Diastereomers are stereoisomers having two or more chiral centers that are not identical and are not mirror images of each other.
- the stereochemical configuration at a chiral center in a compound having one or more chiral centers is depicted by its chemical name (e.g., where the configuration is indicated in the chemical name by “ ” or “S”) or structure (e.g., the configuration is indicated by “wedge” bonds), the enrichment of the indicated configuration relative to the opposite configuration is greater than 50%, 60%, 70%, 80%, 90%, 99% or 99.9% (except when the designation “rac” or “racemate accompanies the structure or name, as explained in the following two paragraphs).
- “Enrichment of the indicated configuration relative to the opposite configuration” is a mole percent and is determined by dividing the number of compounds with the indicated stereochemical configuration at the chiral center(s) by the total number of all of the compounds with the same or opposite stereochemical configuration in a mixture.
- the stereochemical configuration at a chiral center in a compound is depicted by chemical name (e.g., where the configuration is indicated in the name by “R” or “S”) or structure (e.g., the configuration is indicated by “wedge” bonds) and the designation “rac” or “racemate” accompanies the structure or is designated in the chemical name, a racemic mixture is intended.
- stereoisomers When two or more stereoisomers are depicted by their chemical names or structures, and the names or structures are connected by an “or”, one or the other of the two or more stereoisomers is intended, but not both.
- the enrichment of one stereoisomer relative to the other is as indicated above.
- a disclosed compound having a chiral center is depicted by a structure without showing a configuration at that chiral center, the structure is meant to encompass the compound with the S configuration at that chiral center, the compound with the R configuration at that chiral center, or the compound with a mixture of the R and S configuration at that chiral center.
- a disclosed compound having a chiral center is depicted by its chemical name without indicating a configuration at that chiral center with “S” or “R”, the name is meant to encompass the compound with the S configuration at that chiral center, the compound with the R configuration at that chiral center or the compound with a mixture of the R and S configuration at that chiral center.
- a racemic mixture means a mixture of 50% of one enantiomer and 50% of its corresponding enantiomer.
- the present teachings encompass all enantiomerically-pure, enantiomerically-enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures, and diastereomeric mixtures of the compounds described herein.
- Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
- Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods.
- Peak 1 or “first eluting isomer” in the Experimental section refers to an intended reaction product compound obtained from a chromatography separation/purification that elutes earlier than a second intended reaction product compound from the same preceding reaction.
- the second intended product compound is referred to as “peak 2” or “second eluting isomer”.
- peak 2 or “second eluting isomer”.
- a compound is designated by a name or structure that indicates a single enantiomer, unless indicated otherwise, the compound is at least 60%, 70%, 80%, 90%, 99% or 99.9% optically pure (also referred to as “enantiomerically pure”).
- Optical purity is the weight in the mixture of the named or depicted enantiomer divided by the total weight in the mixture of both enantiomers.
- stereochemistry of a disclosed compound is named or depicted by structure, and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair), it is to be understood that, unless otherwise indicated, one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers are included. It is to be further understood that the stereoisomeric purity of the named or depicted stereoisomers at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight. The stereoisomeric purity in this case is determined by dividing the total weight in the mixture of the stereoisomers encompassed by the name or structure by the total weight in the mixture of all of the stereoisomers.
- MAP4K1 inhibitors are MAP4K1 inhibitors.
- the use of the word “inhibitor” means that a compound or a pharmaceutically acceptable salt thereof inhibits activity of MAP4K1.
- inhibitor herein is meant to decrease the activity of the target enzyme as compared to the activity of that enzyme in the absence of the inhibitor.
- the term “inhibit” means a decrease in MAP4K1 activity of at least 5%, at least 10%, at least 20%, at least 50%, at least 60%, at least 79%, at least 80%, at least 90% or at least 95%.
- inhibit means a decrease in MAP4K1 activity of 5% to 25%, 25% to 50%, 50 to 70%, 75 to 100%.
- inhibit means a decrease in MAP4K1 activity about 95% to 100%, e.g., a decrease in activity of 95%, 96%, 97%, 98%, 99%, or 100%.
- Such decreases can be measured using a variety of techniques that would be recognizable by one of skill in the art, including in vitro kinase assays.
- Compounds of the disclosure are selective MAP4K1 inhibitors.
- a “selective MAP4K1 inhibitor” refers to a compound or a pharmaceutically acceptable salt thereof, which has the ability to selectively inhibit MAP4K1 kinase over other targets.
- a selective MAP4K1 inhibitor has the ability to selectively inhibit MAP4K1 over another kinase.
- a selective MAP4K1 inhibitor has the ability to selectively reduce target signaling activity relative to off-target signaling activity, via direct or indirect interaction with the target.
- the ability to selectively target MAP4K1 with a compound or pharmaceutically acceptable salt thereof provides advantages in terms of improved potency, less off-target activity and an increased probability of clinical success in comparison with a non-selective compound or salt.
- a MAP4K1 inhibitor that selectively inhibits MAP4K1 may have an activity that is at least 2-fold relative to another kinase (e.g., at least 10-fold; at least 15-fold; at least 20-fold; at least 30-fold; at least 40-fold selectivity; at least 50-fold; at least 60-fold; at least 70-fold; at least 80-fold; at least 90-fold; at least 100-fold; at least 125-fold; at least 150-fold; at least 175-fold; or at least 200-fold.
- another kinase e.g., at least 10-fold; at least 15-fold; at least 20-fold; at least 30-fold; at least 40-fold selectivity; at least 50-fold; at least 60-fold; at least 70-fold; at least 80-fold; at least 90-fold; at least 100-fold; at least 125-fold; at least 150-fold; at least 175-fold; or at least 200-fold.
- a selective MAP4K1 inhibitor exhibits at least 15-fold selectivity over another kinase, e.g., LCK and MAP4K family members (MAP4K4 (HGK) and MAP4K3 (GLK)).
- the selective MAP4K1 inhibitors are selective over EGFR and L858R/T790M EGFR.
- the selective MAP4K1 inhibitors of the disclosure are selective over BTK.
- the selective MAP4K1 inhibitors of the disclosure are selective over JNK.
- the disclosure provides methods of modulating (e.g., inhibiting) MAP4K1 activity in a subject in need thereof, said method comprising administering to the subject a compound provided herein, or a pharmaceutically acceptable salt thereof.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for therapeutic administration to enhance, stimulate and/or increase immunity in subjects in need thereof, e.g., in cancer patients or patients with viral infection.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof reduce, inhibit, or otherwise diminish pSLP76.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for therapeutic administration to enhancing at least one of activation, priming, migration, proliferation, survival and cytolytic activity of T cells relative to prior to administration.
- T cell activation is characterized by enhanced levels of IL- 2, IFN-gamma, or granzyme B production by T cells relative to prior to administration of the compound or pharmaceutically acceptable salt thereof.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for therapeutic administration to induce a change in cell cycle or cell viability.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for improving function of T effector cells.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for inhibiting the suppressive effects of T regulatory cells or improving the T cell response to immune suppressive factors including adenosine and PGE2.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for increasing the frequency of CD8+ tumor infiltrating lymphocytes (TILS).
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for enhancing CD3+/Treg ratios.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for enhancing cytokines.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for enhancing cytokines with no impact on IL-6.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof indirectly inhibit the growth of cancer cells.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are useful for priming of the immune response (i.e., vaccines) to tumors or viruses for booting or generating anti-viral/anti-tumor immunity.
- the compounds of the disclosure, or pharmaceutically acceptable salts thereof are used for enhancing or boosting response to a vaccine (such as a cancer vaccine or a personalized cancer vaccine (PCV)) or a CAR-T cell therapy.
- Methods of treating a MAP4K1-dependent disease or disorder can include administering to a subject in need thereof a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof.
- the MAP4K1- dependent disease or disorder is a cancer.
- cancer encompasses all forms of cancer including, but not limited to, all forms of carcinoma, melanomas, blastomas, sarcomas, lymphomas, leukemias.
- cancer includes metastatic forms.
- the disclosure includes refractory or recurrent malignancies whose growth may be inhibited using the compounds of the disclosure.
- any of the compounds of the disclosure, or pharmaceutically acceptable salts thereof, may be used alone or in combination with other therapeutic agents.
- the treatment results in a sustained response in the subject after cessation of the treatment.
- sustained response refers to the sustained effect on reducing tumor growth after cessation of a treatment.
- the tumor size may remain the same or smaller as compared to the size at the beginning of the administration phase.
- the sustained response has a duration at least the same as the treatment duration, at least 1.5X, 2.0X, 2.5X, or 3.0X length of the treatment duration.
- the treatment methods disclosed herein may result in a partial or complete response.
- CR complete response
- PR partial response
- SD stable disease
- ORR all response rate
- progression free survival refers to the length of time during and after treatment during which the disease being treated (e.g., cancer) does not get worse. Progression-free survival may include the amount of time subjects have experienced a complete response or a partial response, as well as the amount of time subjects have experienced stable disease. As used herein, “overall survival” (OS) refers to the percentage of subjects in a group who are likely to be alive after a particular duration of time.
- cancers treatable with compounds of the disclosure or pharmaceutically acceptable salt thereof include colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, bladder cancer, stomach cancer, liver cancer, gastric cancer, cancer of the head and neck, lymphoma, leukemia, urothelial carcinoma, merkel cell carcinoma, gastroesophageal junction carcinoma, esophageal squamous cell carcinoma, skin squamous cell carcinoma and melanoma.
- cancers treatable with compounds of the disclosure or pharmaceutically acceptable salts thereof include colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, bladder cancer, stomach cancer, liver cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.
- cancers that are treatable using the compounds of the disclosure or pharmaceutically acceptable salts thereof include, but are not limited to, solid tumors, including prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, brain cancer, and bladder cancer and hematological cancer, including lymphoma, leukemia (chronic and acute forms) such as ALL, AML, CLL, CML, DLBCL, mantle cell lymphoma, Non-Hodgkin’s lymphoma (NHL), including relapsed or refractory NHL and recurrent follicular, Hodgkin’s lymphoma and multiple myeloma, and myeloproliferative diseases.
- solid tumors including prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer,
- diseases and indications that are treatable using the compounds of the disclosure or pharmaceutically acceptable salts thereof include, but are not limited to hematological cancer, sarcomas, respiratory cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, and skin cancer.
- Exemplary hematological cancer includes, for example, lymphomas and leukemias such as ALL, AML, acute promyelocyte leukemia (APL), CLL, CML, DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (NHL), including Primary mediastinal B-cell lymphoma (PMBCL), relapsed or refractory NHL, recurrent follicular, and primary CNS lymphoma, Hodgkin’s lymphoma, myeloproliferative diseases, including, primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma, and Bur
- Exemplary respiratory tract cancer includes, for example, lung cancer such as non- small cell lung cancer (NSCLC), small cell lung cancer, epidermoid cancer, bronchogenic carcinoma, including squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma, alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, and pleuropulmonary blastoma.
- NSCLC non- small cell lung cancer
- small cell lung cancer small cell lung cancer
- epidermoid cancer epidermoid cancer
- bronchogenic carcinoma including squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma, alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, and pleuropulmonary blastoma.
- Exemplary gastrointestinal cancer includes, for example, cancers of the esophagus, including squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; stomach, including carcinoma, lymphoma, and leiomyosarcoma; pancreas, including ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; small instestine, including adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; large intestine, including adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma; colon; and gall bladder, including adenocarcinoma; and intestinal
- Exemplary genitourinary tract cancer includes, for example, cancers of the kidney, including adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma, urothelial carcinoma, juxtaglomerular cell tumor (reninoma), angiomyolipoma, renal oncocytoma, Bellinio duct carcinoma, clear-cell sarcoma of the kidney, and mesoblastic nephroma; adrenal gland; renal pelvis; bladder, including transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma, and small cell carcinoma; urethra, including squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; prostate, including adenocarcinoma, sarcoma, and carcinoma; testis, including seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, inter
- Exemplary liver cancer includes, for example, hepatoma, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, biliary tract cancer, and hemangioma.
- hepatoma including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, biliary tract cancer, and hemangioma.
- Exemplary bone cancer includes, for example, osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, including reticulum cell sarcoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, including osteocartilaginous exostoses, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors
- Exemplary nervous system cancer includes, for example, cancer of the skull, including osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; meninges including, meningioma, meningiosarcoma, and gliomatosis; brain, including astrocytoma, meduoblastoma, glioma, epen
- Exemplary gynecological cancer includes, for example, cancer of the uterus, including endometrial carcinoma; cervix, including cervical carcinoma, pre-tumor cervical dysplasia, squamouse cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, glassy cell carcinoma and villoglandular adenocarcinoma; ovaries, including ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, endometroid tumor, high-grade serous carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma, and arrhenoblastoma; vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; vagina, including clear
- Exemplary skin cancer includes, for example, melanoma, sebaceous gland carcinoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.
- breast cancer include, for example, ER+/HER2- breast cancer, triple- negative breast cancer (TNBC), invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
- Exemplary head and neck cancer includes, for example, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, throat cancer, including oropharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancer, salivary gland cancer, mouth cancer, eye cancer, acoustic neuroma, pituitary adenoma, hypopharngx, and thyroid (medullary and papillary) and parathyroid cancer.
- glioblastoma melanoma
- rhabdosarcoma lymphosarcoma
- osteosarcoma squamous cell carcinomas
- adenocarcinomas adenocarcinomas
- oral cancer throat cancer, including oropharyngeal cancer, laryngeal cancer, nasopharynge
- cancers include, for example, sweat gland cancer, spinal axis tumor, chest cancer, sickle cell anemia, and environmentally induced cancers including those induced by asbestos.
- compounds of the disclosure or pharmaceutically acceptable salts thereof are for the treatment of advanced melanoma, advanced NSCLC, or advanced head and neck squamous cell cancer, including where the subject was refractory to, or had a partial response to, immune checkpoint inhibitor therapy.
- the MAP4K1-dependent disease or disorder is a viral infection, such as infection caused by hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella zoster virus, coxsackie virus, and human immunodeficiency virus (HIV).
- HBV hepatitis B virus
- HCV hepatitis C virus
- HPV human papilloma virus
- CMV cytomegalovirus
- CMV cytomegalovirus
- HSV herpes simplex virus
- EBV Epstein-Barr virus
- varicella zoster virus coxsackie virus
- coxsackie virus coxsackie virus
- HMV human immunodeficiency virus
- the other anti-cancer agents are immune-oncology agent, anticancer agents that are enzyme/protein/receptor inhibitors, radiation or chemotherapy.
- Compounds of the disclosure or pharmaceutically acceptable salts thereof can be co- formulated with an immuno-oncology agent.
- Immuno-oncology agents include, for example, a small molecule drug, antibody, or other biologic or small molecule.
- biologic immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines.
- the antibody is a monoclonal antibody.
- the monoclonal antibody is humanized or human.
- the antibody is a bispecific antibody.
- the immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co-inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses (often referred to as immune checkpoint regulators, in some instances immune checkpoint inhibitors).
- a stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF).
- B7 family includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6.
- B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6 includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6.
- TNF family of molecules that bind to cognate TNF receptor family members which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fnl4, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTfiR, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2,TNFRl, Lymphotoxin ⁇ / ⁇ , TNFR2, TNF a, LT R, Lymphotoxin a 1 ⁇ 2, FAS,
- T cell responses can be stimulated by a combination of a compound of the disclosure and one or more of (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4, and (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.
- an antagonist of a protein that inhibits T cell activation e.g., immune checkpoint inhibitor
- compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered in combination with at least one other immune checkpoint inhibitor.
- compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered for the treatment of immune checkpoint inhibitor-resistant NSCLC, including where the subject is refractory to, or had a partial response to, platinium and/or paclitaxel and/or docetaxel therapy.
- compounds of the diclosure or pharmaceutically acceptable salts thereof can be administered in combination with at least one other anti-cancer agent, such as paclitaxel, docetaxel or platinum anticancer therapy.
- Compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered for the first line treatment of NSCLC expressing high PD-L1 ( ⁇ 50% Tumor Proportion Score (TPS), wild-type EGFR, or wild-type ALK).
- Other agents that can be combined with compounds of the disclosure for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells.
- compounds of the disclosure can be combined with antagonists of KIR, such as lirilumab.
- Yet other agents for combination therapies include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 or FPA-008.
- compounds of the disclosure or pharmaceutically acceptable salts thereof can be used with one or more of agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-Ll/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti- CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
- agonistic agents that ligate positive costimulatory receptors e.g., blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more
- the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonistic CTLA-4 antibody.
- Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.
- the immuno-oncology agent is a PD-1 antagonist, such as an antagonistic PD-1 antibody.
- Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP- 514; WO2012/145493).
- the immuno-oncology agent may also include pidilizumab (CT- 011), though its specificity for PD-1 binding has been questioned.
- the immuno-oncology agent is a PD-L1 antagonist, such as an antagonistic PD-L1 antibody.
- Suitable PD-L1 antibodies include, for example, TECENTRIQ (atezolizumab) (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS-936559 (WO2007/005874), and MSB0010718C (WO2013/79174).
- the immuno-oncology agent is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody.
- Suitable LAG3 antibodies include, for example, BMS-986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601, WO09/44273).
- the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody.
- Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (W012/32433).
- the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody.
- Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06/105021, WO09/009116) and MK-4166 (WOl 1/028683).
- the immuno-oncology agent is an IDO antagonist. Suitable IDO antagonists include, for example, INCB-024360 (WO2006/122150, WO07/75598, WO08/36653, WO08/36642), indoximod, or NLG-919 (WO09/73620, WO09/1156652, WOl1/56652, W012/142237).
- the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody.
- Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469.
- the immuno-oncology agent is an OX40L antagonist, such as an antagonistic OX40 antibody.
- Suitable OX40L antagonists include, for example, RG-7888 (WO06/029879).
- the immuno-oncology agent is a CD40 agonist, such as an agonistic CD40 antibody.
- the immuno-oncology agent is a CD40 antagonist, such as an antagonistic CD40 antibody.
- Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab.
- the immuno-oncology agent is a CD27 agonist, such as an agonistic CD27 antibody.
- Suitable CD27 antibodies include, for example, varlilumab.
- the immuno-oncology agent is MGA271 (to B7H3) (WOl 1/109400).
- the compounds of the disclosure or pharmaceutically acceptable salts thereof can be used in combination with anticancer agents that are enzyme/protein/receptor inhibitors, exhibiting different preferences in the targets which they modulate the activities of, to treat such conditions. Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
- the compounds of the disclosure or pharmaceutically acceptable salts thereof can be used in combination with one or more other enzyme/protein/receptor inhibitors for the treatment of cancer.
- the compounds of the disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF- ⁇ , PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFotR, PDGFpR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3,
- the compounds of the disclosure or pharmaceutically acceptable salts thereof can be combined with one or more of the following inhibitors for the treatment of cancer.
- inhibitors that can be combined with the compounds of the disclosure or pharmaceutically acceptable salts thereof for treatment of cancers include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., fisogatinib, AZD4547, BAY 1187982, ARQ087, BGJ398, BIBF1120, TKI258, lucitanib, dovitinib, TAS- 120, J J-42756493, Debiol347, INCB54828, INCB62079, and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib, or itacitinib (INCB39110)), an IDO inhibitor (e.g., epacadostat and NLG919),
- Inhibitors of HDAC such as panobinostat and vorinostat can be combined with the compounds of the disclosure.
- Inhibitors of c-Met such as onartumzumab, tivantnib, and capmatinib (INC-280) be combined with the compounds of the disclosure.
- Inhibitors of BTK such as ibrutinib can be combined with the compounds of the present disclosure.
- Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus can be combined with the compounds of the present disclosure.
- Inhibitors of Raf such as vemurafenib and dabrafenib can be combined with the compounds of the present disclosure.
- Inhibitors of MEK such as trametinib, selumetinib and GDC-0973 can be combined with the compounds of the present disclosure.
- Inhibitors of KIT including avapritinib, BLU-263, imatinib, sunitinib, regorafenib, ripritinib (DCC2618), PLX9486, PLX3397, crenolanib, CDX-0158, CDX-0159.
- Inhibitors of RET including pralsetinib, selperctinib, alectinib, levatinib, cabozantinib, BOS172738 (DS-5010), SL-1001, TPX-0046, sitravatinib (MGCD516), and RXDX-105.
- Inhibitors of Hsp90 e.g., tanespimycin
- cyclin dependent kinases e.g., palbociclib
- PARP e.g., olaparib
- Pim kinases LGH447, INCB053914, and SGI-1776
- the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent.
- alkylating agent examples include bendamustine, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes, uracil mustard, chlormethine, cyclophosphamide (CYTOXAN), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
- the proteasome inhibitor is carfilzomib.
- the corticosteroid is dexamethasone (DEX).
- chemotherapeutics include any of: abarelix, abiraterone, afatinib, aflibercept, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab, bexarotene, baricitinib, bicalutamide, bleomycin, bortezombi, bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carmustine, cediranib, cetuximab, chlorambucil, cladribine, clofarabine,
- anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin).
- Compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered as the sole pharmaceutical agent or in combination with one or more anti-viral agents for the treatment of chronic viral infections, where the combination causes no unacceptable adverse effects.
- Chronic viral infections include, but are not limited to, diseases caused by: hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella zoster virus, coxsackie virus, human immunodeficiency virus (HIV).
- HCV hepatitis C virus
- HPV human papilloma virus
- CMV cytomegalovirus
- HSV herpes simplex virus
- EBV Epstein-Barr virus
- varicella zoster virus coxsackie virus
- coxsackie virus human immunode
- Suitable antiviral agents contemplated for use in combination with the compound of the disclosure or a pharmaceutically acceptable salt thereof can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.
- NRTIs nucleoside and nucleotide reverse transcriptase inhibitors
- NRTIs non-nucleoside reverse transcriptase inhibitors
- protease inhibitors and other antiviral drugs.
- Suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-I0652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2',3'-dicleoxy-5-fluoro-cytidene); DAPD, ((- )-beta-D-2,6-diamino-purine dioxolane); and lodenosine (FddA).
- ZT zidovudine
- ddl didanosine
- ddC zalcitabine
- stavudine d4T
- NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721 ; AG-1549; MKC-442 (l-(ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)- (2,4(lH,3H)-pyrirnidinedione); and (+)-calanolide A (NSC-675451) and B.
- Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK- 639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1549.
- Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607. When more than one pharmaceutical agent is administered to a subject, they can be administered simultaneously, separately, sequentially, or in combination (e.g., for more than two agents).
- the disclosed compounds or pharmaceutically acceptable salts thereof when administered together with an additional anti-cancer or antiviral agent, can be administered simultaneously in the same pharmaceutical formulation or simultaneously in separate pharmaceutical formulations. Alternatively, when administered together with an additional anti-cancer or antiviral agent, the disclosed compounds or pharmaceutically acceptable salts thereof can be administered at separate times, depending the dosing requirements of the additional anti-cancer or antiviral agent.
- Pharmaceutical compositions include one or more compounds provided herein (such as the compound of Formulas I, II, III, IV(A), IV(B), V, VI and VII), and typically at least one additional substance, such as an excipient, a known therapeutic other than those of the disclosure, and combinations thereof.
- the disclosed compounds or pharmaceutically acceptable salts thereof can be used in combination with other agents known to have beneficial activity targeting diseases or disorders listed above.
- disclosed compounds or pharmaceutically acceptable salts thereof can be administered alone or in combination with one or more anti-cancer or antiviral agent.
- the terms “administer”, “administering”, “administration”, and the like, as used herein, refer to methods that may be used to enable delivery of compositions to the desired site of biological action. These methods include, but are not limited to, intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, orally, topically, intrathecally, inhalationally, transdermally, rectally, and the like.
- a “subject” is a mammal in need of medical treatment, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- companion animals e.g., dogs, cats, and the like
- farm animals e.g., cows, sheep, pigs, horses, and the like
- laboratory animals e.g., rats, mice, guinea pigs, and the like.
- an “effective amount” to the subject will depend on the mode of administration, the type, and severity of the disease or condition, and on the characteristics of the subject, such as general health, age, sex, body weight, and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
- an “effective amount” of any additional therapeutic agent(s) will depend on the type of drug used.
- Suitable dosages are known for approved therapeutic agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of a compound of the disclosure or a pharmaceutically acceptable salt thereof being used by following, for example, dosages reported in the literature and recommended in the Physician’s Desk Reference (57th ed., 2003).
- the term “effective amount” means an amount when administered to the subject which results in beneficial or desired results, including clinical results, e.g., inhibits, suppresses or reduces the symptoms of the condition being treated in the subject as compared to a control.
- a therapeutically effective amount can be given in unit dosage form (e.g., 0.1 mg to about 50 g per day, alternatively from 1 mg to about 5 grams per day; and in another alternatively from 10 mg to 1 gram per day).
- the particular mode of administration and the dosage regimen will be selected by the attending clinician, taking into account the particulars of the case (e.g. the subject, the disease, the disease state involved, the particular treatment, and whether the treatment is prophylactic). Treatment can involve daily or multi-daily or less than daily (such as weekly or monthly etc.) doses over a period of a few days to months, or even years.
- the pharmaceutical composition of the disclosure is formulated to be compatible with its intended route of administration.
- the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings.
- the pharmaceutical composition is formulated for intravenous administration.
- “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the formulation and/or administration of an active agent to and/or absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the subject.
- Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer’s solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.
- Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with or interfere with the activity of the compounds provided herein.
- auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with or interfere with the activity of the compounds provided herein.
- auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with or interfere with the activity of the compounds provided herein.
- auxiliary agents such
- Suitable solvents can be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent’s freezing temperature to the solvent’s boiling temperature.
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan.
- Preparation of compounds of the disclosure can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
- spectroscopic means such as nuclear magnetic resonance (NMR) spectroscopy (e.g., 1 H or 13 C), infrared (IR) spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry (MS), or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
- NMR nuclear magnetic resonance
- IR infrared
- MS mass spectrometry
- HPLC high performance liquid chromatography
- TLC thin layer chromatography
- LC-MS liquid chromatography-mass spectrometry
- Preparative HPLC was performed on a Shimadzu Discovery VP® Preparative system fitted with a Luna 5u C18(2) 100A, AXIA packed, 250 x 21.2 mm reverse-phase column at 22.4 degrees Celsius.
- the mobile phase consisted of a mixture of solvent 0.1% FA in water and 0.1% FA in ACN.
- a constant gradient from 95% aqueous/5% organic to 5% aqueous/95% organic mobile phase over the course of 25 minutes was utilized.
- the flow rate was constant at 20 mL/min. Reactions carried out in a microwave were done so in a Biotage Initiator microwave unit.
- Example 1 Synthesis of arylamine intermediates Example 1a Intermediates 1 and 2: (7S,8R)-2-Amino-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one (Intermediate 1) and (7R,8S)-2-amino-7,8-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one (Intermediate 2)
- the reaction mixture was stirred under N 2 at 70 °C for 2 h.
- the reaction mixture was diluted with water (300 mL) and extracted with EA (250 mL x 3).
- the organic layers were combined and dried over sodium sulfate, then filtered and concentrated in vacuo to give the residue.
- the residue was purified by prep-HPLC (ACN-H 2 O gradient with 0.1% TFA additive).
- the combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated to give the title compound (37.0 g, 167 mmol, 88.7% yield) as a yellow oil.
- Step 2 2-Methoxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one
- a solution of methyl (E)-2-(but-2-en-2-yl)-6-methoxynicotinate (37.0 g, 167 mmol, 1.00 eq) in TfOH (171 g, 1.15 mol, 101 mL, 6.85 eq) was stirred at 80 °C for 0.5 h. The mixture was then cooled to ambient temperature, poured into saturated aqueous NaHCO 3 solution (1000 mL) and extracted with EA (300 mL x 5). The organic layers were dried over sodium sulfate, filtered, and concentrated to give a residue.
- reaction mixture was stirred at 100 °C for 12 h, then was cooled to ambient temperature and concentrated under vacuum.
- the residue was purified by flash-column chromatography on silica gel (gradient elution, 1% to 10% MeOH-DCM) to afford the title compounds as a mixture of isomers that were used in the next step without further purification.
- Step 5 rac-(7S,8S)-2-Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5- one and rac-(7S,8R)-2-chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one
- a mixture of rac-(7S,8S)-2-hydroxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one and rac-(7S,8R)-2-hydroxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one (26.0 g, 134 mmol, 1 equiv) in POCl 3 (150 mL, 1.61 mol, 11.9 equiv) was stirred at 100 °C for 1 h.
- reaction mixture was then cooled to ambient temperature and poured into saturated aqueous NaHCO3 solution (2 L) at 0-10 °C.
- the quenched mixture was extracted with EA (300 mL x 3) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated.
- the cis-and trans- racemic isomers were separated by prep-HPLC (column: Phenomenex luna C18250*50mm*10 um; mobile phase: [water(0.1%TFA)-ACN];B%: 35% ACN-55% CAN over 20min).
- Step 6 (7S,8R)-2-Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one and (7R,8S)-2-chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one rac-(7S,8R)-2-Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one was separated by SFC (column: DAICEL CHIRALPAK AD (250mm x 50mm,10um); mobile phase: MeOH in CO 2 ) to give the first eluting isomer (peak 1) as a white solid and second eluting isomer (peak 2) as a white solid.
- SFC columnumn: DAICEL CHIRALPAK AD (250mm x 50mm,10um); mobile phase: MeOH in CO 2
- Step 7 (7S,8R)-2-((2,4-Dimethoxybenzyl)amino)-7,8-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one DIPEA (7.48 g, 57.8 mmol, 10.1 mL, 2.50 eq) and DMBNH2 (5.03 g, 30.1 mmol, 4.53 mL, 1.30 eq) were added to a solution of (7S,8R)-2-chloro-7,8-dimethyl-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-5-one (1 st eluting isomer (peak 1) from Step 6 above) (4.90 g, 23.1 mmol, 1.00 eq) in NMP (50.0 mL).
- Step 8 (7S,8R)-2-Amino-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one
- a solution of (7S,8R)-2-((2,4-Dimethoxybenzyl)amino)-7,8-dimethyl-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-5-one (7.93 g, 23.1 mmol, 1.00 eq) in HCl/dioxane (4.00 M, 50.0 mL, 8.64 eq) was stirred at 70 °C for 1 h.
- Steps 9 and 10 (7R,8S)-2-Amino-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one
- the title compound (Intermediate 2) was prepared separately from (7R,8S)-2-chloro- 7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (the second eluting isomer (peak 2) of Step 6) using the same two-step procedure as described in Steps 7 and 8 for Intermediate 2.
- MS (ES+) C10H12N2O2 requires: 192, found: 193[M+H] + .
- Steps 1-5 rac 2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one
- the title compound was prepared from methyl 2-chloro-6-methoxynicotinate and 4,4,5,5-tetramethyl-2-(3-methylbut-2-en-2-yl)-1,3,2-dioxaborolane using similar procedures as described above in Steps 1-3 and 5-7 for Intermediate 1.
- Step 6 (R)-2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one and (S)-2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8- dihydro-5H-pyrano[4,3-b]pyridin-5-one
- Rac 2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one was separated by SFC (column: DAICEL CHIRALPAK AS-H (250mm*30mm,5um); mobile phase: [0.1% NH4OH MeOH in CO2]) to give (R)-2-((2,4- dimethoxybenzyl)amino)-7,7,8-trimethyl-7,
- Step 7 and 8 (R)-2-amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5- one and (S)-2-amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one
- the title compounds (Intermediates 3 and 4) were prepared separately from the 1 st and 2 nd eluting isomers, i.e., (R)-2-((2,4-dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-5-one and (S)-2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl- 7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one, using the
- Step 4 2-((2,4-Dimethoxybenzyl)amino)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one (2,4-Dimethoxyphenyl) methanamine (160 g, 957 mmol, 1.50 eq) was added to a solution of 2-chloro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (135 g, 638 mmol, 1.00 eq) and DIPEA (222 mL, 1.28 mol, 2.00 eq) in NMP (1.08 L) at ambient temperature.
- the reaction mixture was heated to 140 °C for 2 h, and then was cooled to ambient temperature.
- the reaction mixture was then partitioned between water (700 mL) and EA.
- the layers were separated, and the aqueous layer was further extracted with EA (500 mL x 3).
- the organic layers were combined and washed with brine (400 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound as a yellow solid (160 g).
- the crude product was used for next step directly.
- Step 5 2-Amino-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one HCl (4.0 M in dioxane, 1.20 L, 11.0 equiv) was added to : 2-((2,4-dimethoxybenzyl) amino)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (150 g, 438 mmol, 1.00 eq) at 20 °C. The reaction mixture was heated to 60 °C for 2 h, then was cooled to ambient temperature and concentrated under vacuum.
- Step 1 Methyl 2-(3-bromo-6-chloropyridin-2-yl)acetate LiHMDS (1 M, 388 mL) was added to a solution of 3-bromo-6-chloro-2- methylpyridine (20.0 g, 96.9 mmol) in THF (300 mL) at 25 °C under nitrogen. After 2.5 h, dimethyl carbonate (14.0 g, 155 mmol) was added to the mixture and stirred at 25 °C for 13.5 h. The reaction mixture was then was added to saturated aqueous NH4Cl (1000 mL) and extracted with EA (60 mL ⁇ 3).
- Step 3 (1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)methanol
- Diisobutylaluminium hydride (1 M, 56 mL) was added to a solution of methyl 1-(3- bromo-6-chloropyridin-2-yl)cyclopropane-1-carboxylate (5.40 g, 18.6 mmol) in DCM (80 mL) at –78 °C under nitrogen.
- the reaction mixture was stirred at –78 °C for 0.5 h, then was quenched by addition of aqueous saturated NH 4 Cl solution (50 mL), diluted with water (200 mL) and extracted with EA (200 mL ⁇ 3).
- Step 4 Methyl 5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridine]-2'- carboxylate
- Triethylamine (2.31 g, 22.9 mmol) and Pd(dppf)Cl2 were added to a solution of (1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)methanol in MeOH (25 mL) and DMF (25 mL) under nitrogen atmosphere.
- Step 5 5'-Oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridine]-2'-carboxylic acid
- Lithium hydroxide 555 mg, 23.2 mmol
- methanol 30 mL
- water 10 mL
- the reaction mixture was stirred at 25 °C for 0.5 h, then was concentrated to remove the methanol.
- the mixture was diluted with water (60 mL) and extracted with EA (50 mL ⁇ 3).
- the aqueous layer was acidified by addition aqueous hydrochloric acid solution (6 M, 5 mL), then the mixture was extracted with EA (50 mL ⁇ 3).
- the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (1.20 g, 71% yield) as a brown solid that was used without further purification.
- Step 6 tert-Butyl (5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'- yl)carbamate
- Triethylamine (831 mg, 8.21 mmol) and diphenyl phosphoryl azide (2.26 g, 8.21 mmol) were added to a solution of 5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridine]-2'-carboxylic acid (1.20 g, 5.47 mmol) in tert-butanol (20 mL).
- the reaction mixture was stirred at 100 °C for 1 h, then was cooled to ambient temperature, diluted with water (60 mL), and extracted with EA (50 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0% to 50% EA- petroleum ether) to give the title compound (330 mg, 19% yield) as a yellow solid and 2'- amino-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-5'-one (420 mg, 28% yield) as a yellow oil.
- Step 7 2'-Amino-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-5'-one HCl in dioxane (4.0 M, 0.5 mL) was added to a solution of tert-butyl (5'-oxo-5'H,7'H- spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate (100 mg, 344 ⁇ mol) in dioxane (1.5 mL) at 25 °C. The reaction mixture was stirred for 10 min, then was concentrated.
- Step 2 1-(1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)ethan-1-ol Methylmagnesium bromide (3 M, 17 mL) was added to a solution of 1-(3-bromo-6- chloropyridin-2-yl)cyclopropane-1-carbaldehyde (2.60 g, 9.98 mmol) in THF (80 mL) at 0 °C. The reaction mixture was stirred for 10 min, then was quenched by addition of aqueous saturated NH4Cl solution (80 mL), diluted with water (40 mL) and extracted with EA (80 mL ⁇ 3).
- Steps 3-5 tert-Butyl (7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridin]-2'-yl)carbamate
- the title compound was prepared from 1-(1-(3-bromo-6-chloropyridin-2- yl)cyclopropyl)ethan-1-ol using a similar procedure as described in Steps 4-6 for Intermediate 7 above.
- Step 6 tert-Butyl (R)-(7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridin]-2'-yl)carbamate and tert-butyl (S)-(7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane- 1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate tert-Butyl (7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]- 2'-yl)carbamate (400 mg) was separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm ⁇ 50 mm, 10 um), EtOH gradient in CO 2 with 0.1% NH 4 OH)
- Step 7 One of (R or S)-2'-amino-7'-methyl-5'H,7'H-spiro[cyclopropane-1,8'- pyrano[4,3-b]pyridin]-5'-one TFA (2.31 g, 20.3 mmol) was added to a solution of one of tert-butyl (R or S)-(7'- methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate (first eluting isomer from Step 6, 100 mg) in DCM (6 mL).
- Step 8 The remaining one of (R or S)-2'-amino-7'-methyl-5'H,7'H- spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-5'-one
- the title compound (Intermediate 9) was prepared from one of tert-butyl (R or S)-(7'- methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate (second eluting isomer from Step 6) using the same procedure as described in Step 7 for Intermediate 8.
- Step 1 2-(1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)propan-2-ol
- MeMgBr 3 M, 14.9 mL
- Steps 2-5 2'-Amino-7',7'-dimethyl-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridin]-5'-one
- the title compound was prepared from 2-(1-(3-Bromo-6-chloropyridin-2-yl) cyclopropyl)propan-2-ol using a similar procedure as described in Steps 4-6 for Intermediate 7 and Step 7 of Intermediate 8 above.
- the reaction mixture was stirred at 100 °C for 1 h, then was diluted EA (200 mL) and washed with brine (200 mL ⁇ 3). The organic layers were dried over sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 10% to 33% EA-petroleum ether) to give the title compound (7.00 g, 39% yield) as a yellow solid.
- Step 2 Methyl 3-(6-((tert-butoxycarbonyl)amino)pyridin-2-yl)propanoate Pd/C (100 mg, 10% purity) was added to a solution of methyl (E)-3-(6-((tert-butoxy carbonyl)amino)pyridin-2-yl)acrylate (7.00 g, 25.2 mmol) in methanol (100 mL). The mixture was stirred at 25 °C for 12 h under hydrogen, then was filtered and concentrated to give a residue.
- Step 3 tert-Butyl (6-(3-hydroxy-3-methylbutyl)pyridin-2-yl)carbamate Methyl magnesium bromide (3 M, 35.7 mL) was added to a solution of methyl 3-(6- ((tert-butoxycarbonyl)amino)pyridin-2-yl)propanoate (6.00 g, 21.4 mmol) in tetrahydrofuran (100 mL) at 0°C.
- the reaction mixture was stirred at 25 °C for 0.5 h, then was poured into water (200 mL) and extracted with EA (50 mL ⁇ 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 15% to 50% EA-petroleum ether) to give the title compound (5.00 g, 15.9 mmol, 74 % yield) as a yellow solid.
- Step 4 tert-Butyl (5-bromo-6-(3-hydroxy-3-methylbutyl)pyridin-2-yl)carbamate N-Bromosuccinimide (3.17 g, 17.8 mmol) in acetonitrile (50 mL) was added to a solution of tert-butyl (6-(3-hydroxy-3-methylbutyl)pyridin-2-yl)carbamate (5.00 g, 17.8 mmol) in acetonitrile (50 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 1 h, then was poured into water (200 mL) and extracted with EA (50 mL ⁇ 3).
- Step 5 6-((tert-Butoxycarbonyl)amino)-2-(3-hydroxy-3-methylbutyl)nicotinic acid
- n-Butyllithium 2.5 M, 11.1 mL
- tert-butyl (5-bromo-6-(3- hydroxy-3-methylbutyl)pyridin-2-yl)carbamate 2.00 g, 5.57 mmol
- tetrahydrofuran 50 mL
- the reaction mixture was stirred at -78 °C for 10 min, then carbon dioxide was added, and the mixture was stirred at -78 °C for 20 min.
- reaction mixture was then poured into water (100 mL) and extracted with ethyl acetate (30 mL ⁇ 3). The organic layers were discarded, and aqueous ammonium chloride solution was added to the aqueous layer to adjust pH ⁇ 7. The mixture was extracted with EA (30 mL ⁇ 5), and the combined organic layers was dried over sodium sulfate, filtered and concentrated to give the title compound (200 mg, crude) as a yellow solid.
- Step 6 tert-Butyl (7,7-dimethyl-5-oxo-5,7,8,9-tetrahydrooxepino[4,3-b]pyridin-2- yl)carbamate
- Dicyclohexylcarbodiimide (229 mg, 1.11 mmol, 225 ⁇ L) was added to a solution of 6-((tert-butoxycarbonyl)amino)-2-(3-hydroxy-3-methylbutyl)nicotinic acid (180 mg, crude) and 4-N,N-dimethylaminopyridine (33.9 mg, 277 ⁇ mol) in dichloromethane (20 mL). The reaction mixture was stirred at 25 °C for 12 h, then was concentrated to give the residue.
- the reaction mixture was stirred for 15 minutes at 0 °C, then iodomethane (7.38 g, 51.9 mmol) was added.
- the reaction mixture was warmed to 25 °C and stirred for 45 minutes, then was quenched with water (30 mL) and extracted with EA (30 mL ⁇ 2).
- the combined organic layers were concentrated to give a residue.
- the residue was purified by flash-column chromatography on silica gel (gradient elution, 0% to 10% EA-petroleum ether) to give the title compound (5.5 g, 90% yield) as a yellow oil.
- Step 2 2-(3-Bromo-6-chloropyridin-2-yl)-2-methylpropan-1-ol
- the title compound was prepared from methyl 2-(3-bromo-6-chloropyridin-2-yl)-2- methylpropanoate using a procedure similar to that described in Step 3 of Intermediate 7.
- Steps 3-7 (rac)-2-Amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-on
- the title compound was prepared from 2-(3-bromo-6-chloropyridin-2-yl)-2- methylpropan-1-ol using a similar procedure as described in Steps 1-5 of Intermediate 8.
- C 11 H 14 N 2 O 2 requires: 206, found: 207 [M+H] + .
- Step 8 (R)-2-Amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one or (S)-2-amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (rac)-2-Amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (120 mg) was separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm ⁇ 50 mm, 10 um), MeOH gradient in CO2 with 0.1% NH4OH) to give two peaks separately.
- SFC columnumn: REGIS (s,s) WHELK-O1 (250 mm ⁇ 50 mm, 10 um), MeOH gradient in CO2 with 0.1% NH4OH
- the mixture was allowed to warm to 25 °C and stirred at 25 °C for 6 h.
- the reaction mixture was concentrated, and the residue was partitioned between water (10.0 L) and EA (5.0 L). The layers were separated, and the aqueous layer was extracted with EA (5.0 L x 2). The organic layers were combined and dried over Na2SO4. The dried solution was filtered, and the filtrate was concentrated to give the title compound (270 g, crude) as a dark brown solid.
- Step 2 2-(4-Aminopyrimidin-2-yl)propan-2-ol Methylmagnesium bromide (900 mL, 3.0 M, 5.0 eq) was added to a solution of ethyl 4-aminopyrimidine-2-carboxylate (90.0 g, 538 mmol, 1.00 eq) in 2-MeTHF (1.00 L) at -20 °C. The reaction mixture was allowed warm to 0 °C and stirred at that temperature for 1 h. The reaction mixture was diluted with saturated aqueous ammonium chloride solution (10.0 L) and the aqueous layer was extracted with EA (3.0 L x 4).
- Step 3 2-(2-Fluoropropan-2-yl)pyrimidin-4-amine DAST (414 mL, 3.13 mol, 10.0 eq) was added to a solution of 2-(4-aminopyrimidin- 2-yl)propan-2-ol (48.0 g, 313 mmol, 1.00 eq) in DCM (1.30 L) at 0°C. The reaction mixture was stirred at 0°C for 0.5 h, and then was diluted with water (4.50 L).
- the reaction mixture was then cooled to ambient temperature and diluted with EA (800 mL) and H 2 O (300 mL).
- the biphasic mixture was then filtered through celite, then partitioned.
- the organic layer was washed with brine (500 mL x 4), and then the organic layer was dried over Na 2 SO 4 , filtered and concentrated under vacuum.
- the residue was purified by flash-column chromatography on silica gel (gradient elution, 10% to 33% EA-petroleum ether) to give the title compound (41.0 g, 39.0% yield) as a light yellow solid.
- Step 2 5-Amino-3-isopropylpyrazine-2-carbonitrile Pd/C (10 wt%, 10.0 g) was added to a solution of 5-amino-3-(prop-1-en-2- yl)pyrazine-2-carbonitrile (45.0 g, 281 mmol, 1.00 eq) in MeOH (800 mL). The suspension was degassed under vacuum and purged with H 2 three times. The reaction mixture was stirred under H 2 (15 psi) at 25 °C for 16 h. The mixture was filtered through celite and the filtrate was concentrated under vacuum. The residue was treated with petroleum ether/EA (110 mL, 10:1) and stirred at 25°C for 10 min, then filtered.
- Pd/C 10 wt%, 10.0 g
- Example 2 Synthesis of arylchloride intermediates
- Example 2a 4-Bromo-1,6-dichloro-2,7-naphthyridine Step 1: 4-Bromo-6-chloro-2,7-naphthyridin-1(2H)-one NBS (70.9 g, 398 mmol, 1.20 eq) was added to a solution of 6-chloro-2,7- naphthyridin-1(2H)-one (60.0 g, 332 mmol, 1.00 eq) in DMF (600 mL).
- Example 2b Intermediate 20: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-ol
- Step 1 4-Bromo-6-chloro-1-methoxy-2,7-naphthyridine
- K2CO3 111 g, 809 mmol, 3.00 eq
- Step 2 6-Chloro-4-(1-ethoxyvinyl)-1-methoxy-2,7-naphthyridine
- 4-bromo-6-chloro-1-methoxy-2,7-naphthyridine (47.0 g, 171 mmol, 1.00 eq)
- tributyl(1-ethoxyvinyl)stannane (74.4 g, 206 mmol, 69.6 mL, 1.20 eq)
- Pd(PPh3)4 (19.8 g, 17.1 mmol, 0.10 eq) in toluene (500 mL) was stirred at 80 °C for 16 h under N2.
- Step 3 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-one
- Aqueous HCl (1.50 M, 20.1 mL, 0.10 eq) was added to a solution of 6-chloro-4-(1- ethoxyvinyl)-1-methoxy-2,7-naphthyridine (80.0 g, 302 mmol, 1.00 eq) in THF (480 mL) and H 2 O (80 mL).
- the reaction mixture was stirred at 25 °C for 1 h.
- the reaction mixture was then poured into saturated aqueous NaHCO3 solution (500 mL) and extracted with EA (300 mL x 2).
- Step 4 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-ol
- MeOH MeOH
- NaBH4 120 mg, 3.17 mmol
- the mixture was stirred at 25 °C for 10 min, then was quenched by addition of water (5 mL) and extracted with EA (5mL x 3). The combined organic layers were concentrated to give a residue.
- Step 1 4-Bromo-6-chloro-N-methyl-2,7-naphthyridin-1-amine
- DMF dimethyl-2,7-naphthyridin-1(2H)-one
- Step 4 2-(6-Chloro-1-(methylamino)-2,7-naphthyridin-4-yl)propan-2-ol
- 1-(6-chloro-1-(methylamino)-2,7-naphthyridin-4-yl)ethan-1-one 100 mg, 424 umol
- MeMgBr 3 M, 424 uL
- the reaction mixture was stirred at 0 °C for 0.5 h, then was quenched by addition of water (17 mL) and extracted with EA (15 mL ⁇ 3).
- Step 1 6-Chloro-1-methoxy-4-vinyl-2,7-naphthyridine
- 4-bromo-6-chloro-1-methoxy-2,7-naphthyridine (23.5 g, 85.9 mmol)
- Potassium trifluoro(vinyl)borate (15.0 g, 112 mmol)
- Et3N 17.4 g, 172 mmol
- Pd(dppf)Cl 2 (6.29 g, 8.59 mmol) in H 2 O (48 mL) and EtOH (480 mL) was stirred at 80 °C for 12 h.
- the reaction mixture was then diluted with EA (300 mL) and brine (100 mL).
- Step 2 6-Chloro-1-methoxy-2,7-naphthyridine-4-carbaldehyde A solution of 6-chloro-1-methoxy-4-vinyl-2,7-naphthyridine (800 mg, 3.63 mmol) in DCM (6 mL) and MeOH (1 mL) was cooled to -78 °C, then ozone was bubbled into the reaction mixture.
- Step 3 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)propan-1-ol
- 6-chloro-1-methoxy-2,7-naphthyridine-4-carbaldehyde 100 mg, 284 umol
- EtMgBr 5.65 g, 39.8 mmol
- the reaction mixture was stirred at 20 °C for 1 h, then was quenched with water (20 mL) and extracted with EA (20 mL ⁇ 3).
- reaction mixture was stirred at 25 °C for 12 h, then was quenched with saturated aqueous Na 2 SO 3 aqueous solution (100 mL). The mixture was filtered, and the filtrate was concentrated to remove the organic solvents. The water layer was extracted with EA (3 x 200 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give the title compound (9.8 g, crude) as a yellow solid that was used in the next step without further purification.
- Step 2 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)-2-methoxyethan-1-ol
- 1-(6-chloro-1-methoxy-2,7-naphthyridin-4-yl)ethane-1,2-diol (1 g, 3.93 mmol) and TBAB (127 mg, 393 umol) in H 2 O (4 mL) and THF (20 mL) was added a solution of NaOH (471 mg, 11.8 mmol) in H2O (4 mL), then Me2SO4 (594 mg, 4.71 mmol) was added.
- the mixture was separated by chiral SFC (column: Daicel Chiralpak AD (250 mm*30 mm, 10 um); mobile phase: [0.1%NH3H2O ETOH]; B%: 25%-25%) to give the title compound as the second eluting peak.
- Step 1 4-Bromo-6-chloro-N-cyclopropyl-2,7-naphthyridin-1-amine
- the reaction mixture was then poured into water (200 mL) and filtered.
- the filter cake was dried to give the title compound (2.50 g, crude) as a yellow solid that was used in the next step without further purification.
- Steps 2-3 1-(6-Chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)ethan-1-one
- the title compound was prepared from 4-bromo-6-chloro-N-cyclopropyl-2,7- naphthyridin-1-amine using a procedure similar to the that described in Steps 2-3 of Intermediate 20.
- Step 4 (R)-2-(6-Chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol
- EtMgBr 3 M, 3 mL
- racemate was separated by chiral SFC (column: Daicel Chiralpak IC (250mm*30mm, 10um); mobile phase: [0.1%NH 3 H 2 O MEOH]; B%: 40%-40%) to give the first of (R)-2-(6-chloro-1- (cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1- (cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol (peak 1, Intermediate 27, 120 mg, 33 % yield) as a yellow solid and the second one of (R)-2-(6-chloro-1-(cyclopropylamino)-2,7- naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-
- Step 2 5-Bromo-8-methoxyisoquinolin-3-amine N-(5-Bromo-2-methoxybenzyl)-2,2-diethoxyacetimidamide (11 g, 31.9 mmol) was added to H 2 SO 4 (111.61 g, 1.1 mol, 60.6 mL, 98% purity) at 0 °C, and then the mixture was stirred at 25 °C for 3 h under an atmosphere of N2. The reaction mixture was quenched by addition of NaOH (120 g) in H2O (5 L) at 0 °C and extracted with 2-MeTHF (1L ⁇ 2).
- Step 3 5-(1-Ethoxyvinyl)-8-methoxyisoquinolin-3-amine Pd(PPh3)4 (1.02 g, 884.8 ⁇ mol) and tributyl(1-ethoxyvinyl)stannane (6.79 g, 18.8 mmol, 6.3 mL) were added to a solution of 5-bromo-8-methoxyisoquinolin-3-amine (2.8 g, 11.1 mmol) in toluene (30 mL) under N2 atmosphere. The mixture was stirred at 100 °C for 4 h under N2 atmosphere.
- reaction mixture was quenched by addition of aqueous CsF solution (60 mL) at 0 °C and extracted with EA (40 mL ⁇ 3). The combined organic layers were washed with saturated aqueous NaCl solution (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give the title compound (2.7 g, crude) as a brown oil which was used in the next step without further purification.
- Step 4 1-(3-Amino-8-methoxyisoquinolin-5-yl)ethan-1-one
- a mixture of 5-(1-ethoxyvinyl)-8-methoxyisoquinolin-3-amine (2.7 g, 11.1 mmol) in THF (20 mL) and HCl (1M, 11 mL) was stirred at 25 °C for 30 min under N2 atmosphere.
- the reaction mixture was filtered to give the title compound (1.1 g, crude) as a yellow solid which was used in the next step without further purification.
- Step 5 1-(3-Chloro-8-methoxyisoquinolin-5-yl)ethan-1-one Pyridine hydrochloride (1.03 g, 8.9 mmol), CuCl (25.2 mg, 254.3 umol, 6.08 uL) and NaNO 2 (614.2 mg, 8.9 mmol) were added to a solution of 1-(3-amino-8-methoxyisoquinolin- 5-yl)ethan-1-one (550 mg, 2.5 mmol) in DCM (5 mL) under N2 atmosphere.
- Step 6 2-(3-Chloro-8-methoxyisoquinolin-5-yl)propan-2-ol MeMgBr (3M in THF, 1.41 mL) was added to a solution of 1-(3-Chloro-8- methoxyisoquinolin-5-yl)ethan-1-one (200 mg, 848.7 umol) in THF (2 mL) under N 2 atmosphere, and the reaction mixture was stirred at 25 °C for 1 h under N 2 atmosphere. The reaction mixture was quenched by the addition of H2O (10 mL) at 0 °C. The reaction mixture was filtered and concentrated under reduced pressure to give a residue.
- reaction mixture was stirred at 60 °C for 16 h, then additional cyclopropanol (4.39 g, 75.6 mmol) was added to the reaction mixture and it was heated to 70 °C for another 3 h.
- the reaction mixture was then concentrated to give a residue.
- the residue was diluted with water (200 mL), filtered and the filter cake was dried to give the title compound (11.3 g, 99% yield) as a yellow solid.
- Steps 2-3 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one
- the title compound was prepared from 4-bromo-6-chloro-1-cyclopropoxy-2,7- naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20.
- Step 4 2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)propan-2-ol
- the title compound was prepared from 1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin- 4-yl)ethan-1-one using a procedure similar to the that described in Step 1 of Intermediate 22.
- Steps 2-3 1-(6-Chloro-1-ethoxy-2,7-naphthyridin-4-yl)ethan-1-one
- the title compound was prepared from 4-bromo-6-chloro-1-ethoxy-2,7-naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20.
- Step 4 (R)-2-(6-Chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6- chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol
- the racemate of the title compound was prepared from 1-(6-Chloro-1-ethoxy-2,7- naphthyridin-4-yl)ethan-1-one using a procedure similar to the that described in Step 4 of Intermediate 27.
- Step 2 6-Chloro-1-cyclopropoxy-4-(2-methyloxiran-2-yl)-2,7-naphthyridine
- mCPBA 7.07 g, 32.8 mmol, 80% purity
- Step 3 2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)propane-1,2-diol
- a solution of 6-chloro-1-cyclopropoxy-4-(2-methyloxiran-2-yl)-2,7-naphthyridine (2.2 g, 7.95 mmol) in THF (16 mL) was added a solution of H 2 SO 4 (780 mg, 7.95 mmol) in H2O (4 mL) dropwise at 25 °C.
- the reaction mixture was stirred at 60 °C for 0.5 h, then was poured into saturated aqueous NaHCO3 solution (50 mL) and extracted with EA (100 mL).
- Step 4 (S)-2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-methoxypropan-2- ol and (R)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-methoxypropan-2-ol
- 2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)propane-1,2-diol 500 mg, 1.33 mmol
- THF 10 mL
- NaH 133 mg, 3.33 mmol, 60% purity
- Steps 2-3 1-(6-Chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridin-4- yl)ethan-1-one
- the title compound was prepared from 4-bromo-6-chloro-1-((1-fluorocyclopropyl) methoxy)-2,7-naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20.
- Step 4 2-(6-Chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridin-4-yl)propan- 2-ol
- 1-(6-chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridin-4- yl)ethan-1-one 310 mg, 1.05 mmol
- MeMgBr 3 mol, 1.75mL
- the reaction mixture was stirred at 70 °C for 1 h, then was quenched by addition of water (30 mL) at 20 °C.
- the mixture was extracted with EA (30 mL ⁇ 2), and the combined organic layers were washed with water (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue.
- the residue purified by prep-HPLC (column: Phenomenex luna C18150 ⁇ 40 mm ⁇ 15 um; mobile phase: [water (0.1% TFA)-ACN]; B%: 47%-77%, 11 min) to give a racemic mixture of the title compounds (110 mg, 27% yield) as a yellow oil.
- Step 1 1-(3-((4-Bromo-6-chloro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one
- Sodium hydride (2.15 g, 53.8 mmol, 60 wt%) was added to a solution of 1-(3- hydroxyazetidin-1-yl)ethan-1-one (Combi-Blocks #ST-8959) (5.16 g, 44.8 mmol) in THF (200 mL) at 0 °C.
- Step 2 1-(3-((6-Chloro-4-(1-ethoxyvinyl)-2,7-naphthyridin-1-yl)oxy)azetidin-1- yl)ethan-1-one
- a mixture of compound tributyl(1-ethoxyvinyl)stannane (9.14 g, 25.3 mmol1-(3-((4- bromo-6-chloro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one (8.20 g, 23.0 mmol) and Pd(PPh 3 ) 4 (2.66 g, 2.30 mmol) in toluene (150 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 100 °C for 16 h.
- reaction mixture was cooled to ambient temperature, quenched by addition aqueous saturated KF (300 mL), diluted with water (100 mL), and extracted with EA (200 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel to give the title compound (7.50 g, 94% yield) as a yellow solid.
- Step 3 1-(3-((4-Acetyl-6-chloro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one
- Aqueous hydrochloric acid (6 M, 0.5 mL) was added to a solution of 1-(3-((6-chloro- 4-(1-ethoxyvinyl)-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one (6.90 g, 19.8 mmol) in THF (105 mL) and water (35 mL) at 20 °C.
- the reaction mixture was stirred at 20 °C for 1 h, then was diluted with water (300 mL) and extracted with EA (200 mL ⁇ 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0% to 100% EA-PE) to give the title compound (5.00 g, 79% yield) as a yellow solid.
- Steps 4 and 5 1-(3-((6-Chloro-4-(2-hydroxypropan-2-yl)-2,7-naphthyridin-1- yl)oxy)azetidin-1-yl)ethan-1-one Methylmagnesium bromide (3 M in diethyl ether, 14 mL) was added to a solution of 1-(3-((4-acetyl-6-chl oro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one (4.50 g, 14.1 mmol) in THF (200 mL) at 0 °C.
- Step 1 4-Bromo-6-chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridine NaH (60 wt%, 0.863 g, 21.6 mmol) was added to a solution of 2,2-difluoroethan-1-ol (1.624 g, 19.79 mmol) in DMF (36 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then 4-bromo-1,6-dichloro-2,7-naphthyridine (5.0 g, 18 mmol) was added in one portion. The reaction mixture was removed from the cooling bath and stirred at 25 °C for 3 h.
- reaction mixture was then diluted with EA and washed with saturated aqueous sodium bicarbonate solution, brine, dried over sodium sulfate, filtered, and concentrated.
- the residue was purified by flash-column chromatography on silica gel (20-100% EA-Hexanes) to give the title compound (2.1 g, 36% yield) as a yellow solid.
- Steps 2-3 1-(6-Chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1-one
- the title compound was prepared from 4-bromo-6-chloro-1-(2,2-difluoroethoxy)-2,7- naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20.
- Step 4 1-(6-Chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridin-4-yl)-1- cyclopropylethan-1-ol Cyclopropylmagnesium bromide (0.5 M, 3.49 mL, 1.74 mmol) was added to a solution of 1-(6-chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1-one (0.25 g, 0.87 mmol) at 25 °C.
- reaction mixture was stirred at 20 °C for 15 min, then was quenched by addition of water (30 mL) and extracted with EA (30 mL x 2). The combined organic layers were washed with water (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 mm* 5 um; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 41%-61%, 10min) to give a racemic mixture of the title compounds (250 mg, 65% yield) as a yellow solid.
- Steps 1-3 1-(6-Chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1-one
- the title compound was prepared from 4-bromo-1,6-dichloro-2,7-naphthyridine and 2,2,2-trifluoroethan-1-ol using a similar procedure as described in Step 1 of Intermediate 44 and Steps 2-3 of Intermediate 20.
- reaction mixture was stirred at 40 °C for 0.5 h, then was quenched by addition of saturated aqueous ammonium chloride solution (30 mL) and extracted with EA (3 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue.
- the residue was purified by prep-HPLC column (Phenomenex Gemini-NX C1875*30mm*3um; mobile phase: [water (0.1%TFA)-ACN]; B%: 55%-65%, 7min) to give a racemic mixture of the title compounds (50.0 mg, 15% yield) as a yellow solid.
- racemic mixture was separated by chiral SFC (column: Daicel Chiralpak AD-H (250mm*30mm, 5um); mobile phase: [0.1%NH3H2O IPA]; B%: 20%-20%) to give the first one of (S)-1-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol or (R)-1-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol (peak 1, Intermediate 49, 35.0 mg, 39% yield) as a white oil and the second one of (S)-1-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol or (R)-1
- Step 1 1-(6-Chloro-1-hydroxy-2,7-naphthyridin-4-yl)ethan-1-one
- aqueous HCl (6 M, 20 mL)
- the reaction mixture was stirred at 25 °C for 16 h, then was diluted with water (80 mL) and extracted with EA (60 mL ⁇ 3).
- Step 2 1-(1,6-Dichloro-2,7-naphthyridin-4-yl)ethan-1-one
- 1-(6-Chloro-1-hydroxy-2,7-naphthyridin-4-yl)ethan-1-one (1.00 g, 4.49 mmol) was added to POCl3 (10 mL), and the reaction mixture was stirred at 100 °C and stirred for 2 h. The reaction mixture was then cooled to 23 °C and slowly poured into saturated aqueous sodium bicarbonate solution (500 mL). The mixture was extracted with EA (200 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated.
- Step 3 1-(6-Chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4- yl)ethan-1-one
- THF 10 mL
- NaH 199 mg, 4.98 mmol, 60% purity
- reaction mixture was stirred at 25 °C for 0.5 h, then 1-(1,6-dichloro-2,7-naphthyridin-4-yl)ethan-1-one (1.00 g, 4.15 mmol) was added and the mixture was stirred at 25 °C for 0.5 h.
- the reaction mixture was then diluted with saturated aqueous sodium chloride solution (50 mL) and extracted with EA (50 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue.
- Step 4 2-(6-Chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4- yl)propan-2-ol
- 1-(6-chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin- 4-yl)ethan-1-one 350 mg, 986 ⁇ mol
- THF 10 mL
- MeMgBr 3 M, 1.64 mL
- the cooling bath was removed, and the reaction mixture was stirred at 25 °C for 15 min.
- the reaction mixture was quenched by addition of water (50 mL) and extracted with EA (50 mL x 3). The organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue.
- Step 3 6-Chloro-4-(2-methylprop-1-en-1-yl)-1-((1-(methylsulfonyl)azetidin-3- yl)oxy)-2,7-naphthyridine
- 4-bromo-6-chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7- naphthyridine (2.00 g, 5.09 mmol)
- 4,4,5,5-tetramethyl-2-(2-methylprop-1-en-1-yl)-1,3,2- dioxaborolane (974 mg, 5.35 mmol), Pd(dppf)Cl 2 (373 mg, 509 ⁇ mol), and K 2 CO 3 (1.41 g, 10.2 mmol) in dioxane (40 mL) and water (1 mL) was stirred at 80 °C for 16 h.
- Step 4 6-Chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridine-4- carbaldehyde
- 6-chloro-4-(2-methylprop-1-en-1-yl)-1-((1-(methylsulfonyl)azetidin-3- yl)oxy)-2,7-naphthyridine (1.20 g, 3.26 mmol) in MeOH (1.2 mL) and DCM (36 ml) was cooled to -78 °C.
- Step 5 (S)-1-(6-Chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4- yl)propan-1-ol and ®-1-(6-chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin- 4-yl)propan-1-ol
- EtMgBr 3 M, 1.46 ml
- Example 2aa Intermediates 57 and 58: (R)-2-(6-Chloro-1-(((2R,4R)-4-(methylsulfonyl)pentan-2- yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(((2R,4R)-4- (methylsulfonyl)pentan-2-yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol Step 1: (2R,4R)-4-((tert-Butyldimethylsilyl)oxy)pentan-2-ol To a solution of (2R,4R)-pentane-2,4-diol (3.80 g, 36.5 mmol) in THF (120 mL) was added NaH (1.75 g, 43.8 mmol, 60% purity) at 0 °C.
- reaction mixture was stirred for 30 min, then tert-butyldimethylsilyl chloride (6.05 g, 40.1 mmol) was added and the reaction mixture was stirred at 25 °C for 1.5 h.
- the reaction mixture was then added to water (200 mL) and extracted with EA (150 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue.
- Step 3 (2S,4R)-4-((tert-Butyldimethylsilyl)oxy)pentan-2-ol
- (2S,4R)-4-((tert-butyldimethylsilyl)oxy)pentan-2-yl 4-nitrobenzoate (1.50 g, 4.08 mmol) in THF (12 mL) and water (4 mL) was added LiOH•H2O (977 mg, 40.8 mmol).
- the reaction mixture was stirred at 60 °C for 1 h, then was diluted with water (50 mL) and extracted with EA (40 mL ⁇ 3).
- Step 4 (2S,4R)-4-((tert-Butyldimethylsilyl)oxy)pentan-2-yl methanesulfonate
- TEA 1.24 g, 12.2 mmol
- MsCl 934 mg, 8.15 mmol
- reaction mixture was stirred for 1 h, then was diluted with water (100 mL) and extracted with DCM (80 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (1.20 g, 99% yield) as a yellow oil that was used in the next step without further purification.
- Step 5 tert-Butyldimethyl(((2R,4R)-4-(methylthio)pentan-2-yl)oxy)silane
- 2S,4R)-4-((tert-butyldimethylsilyl)oxy)pentan-2-yl methanesulfonate (1.20 g, 4.05 mmol) in DMF (30 mL) was added sodium methanethiolate (709 mg, 10.1 mmol).
- the reaction mixture was stirred at 25 °C for 0.5 h, then was diluted with water (80 mL) and extracted with EA (60 mL ⁇ 3).
- reaction mixture was stirred at 25 °C for 0.5 h, then was quenched by addition of saturated aqueous sodium sulfite solution (30 mL) and extracted with EA (20 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (1.10 g, 97% yield) as a yellow oil that was used without further purification.
- Step 7 (2R,4R)-4-(Methylsulfonyl)pentan-2-ol
- aqueous HCl (6 M, 2 mL)
- the reaction mixture was stirred at 25 °C for 0.5 h, then was diluted with water (50 mL) and extracted with EA (40 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue.
- Step 8 2-(1,6-Dichloro-2,7-naphthyridin-4-yl)butan-2-ol
- 1-(1,6-dichloro-2,7-naphthyridin-4-yl)ethan-1-one 540 mg, 2.24 mmol
- EtMgBr 3 M, 2.24 mL
- the reaction mixture was stirred at 25 °C for 0.5 h, then was quenched by addition of saturated aqueous ammonium chloride solution (20 mL), diluted with water (10 mL) and extracted with EA (40 mL ⁇ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash silica gel chromatography (Eluent of 0 ⁇ 40% EA/PE) to give the title compound (320 mg, 50% yield) as a yellow solid.
- Step 9 (R)-2-(6-Chloro-1-(((2R,4R)-4-(methylsulfonyl)pentan-2-yl)oxy)-2,7- naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(((2R,4R)-4-(methylsulfonyl)pentan-2- yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol
- 2R,4R)-4-(methylsulfonyl)pentan-2-ol 290 mg, 1.07 mmol
- THF 12 mL
- Example 2ab Intermediate 59: 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-phenylethan- 1-ol
- Step 1 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-phenylethan-1-ol
- 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one (0.15 g, 0.571 mmol) was stirred in THF (5.71 ml) at 23 °C and phenylmagnesium bromide (1.0 M, 0.685 ml, 0.685 mmol) was added.
- Example 2ac Intermediate 60: 4-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)tetrahydro-2H- pyran-4-ol Step 1: -(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)tetrahydro-2H-pyran-4-ol n-Butyllithium (421 ⁇ l, 1.052 mmol) was added dropwise to a solution of 4-bromo-6- chloro-1-cyclopropoxy-2,7-naphthyridine (300 mg, 1.001 mmol) in THF (7 mL) at -78 °C.
- Example 3a Synthetic Method 1 (7S,8R)-2-((5-(2-Hydroxypropan-2-yl)-8-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7- naphthyridin-3-yl)amino)-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (Compound 57) Step 1: (7S,8R)-2-((5-(2-Hydroxypropan-2-yl)-8-((1-(methylsulfonyl)azetidin-3- yl)oxy)-2,7-naphthyridin-3-yl)amino)-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5- one To a solution of 2-(6-chloro-1-((1-(methylsulfony
- Example 4 Inhibition of MAP4K1 Biochemical Enzymatic Activity MAP4K1 (HPK1) and relevant off-target enzymatic activity was monitored using the Perkin Elmer electrophoretic mobility shift technology platform – the EZReader 2. Fluorescent labeled substrate peptide was incubated in the presence of kinase and ATP, and in the presence of dosed compound, such that each dose of compound resulted in a reflective proportion of the peptide to be phosphorylated.
- the mixed pool of phosphorylated (product) and non- phosphorylated (substrate) peptides was passed through the microfluidic system of the PerkinElmer EZ Reader 2, under an applied electric potential difference.
- the presence of the phosphate group on the product peptide provided a difference in mass and charge between that of the substrate peptide, resulting in a separation of the substrate and product pools in the sample (Perrin et al. 2010).
- Enzyme Activity Inhibition Assay Protocol Inhibitors were dissolved in 100% DMSO at a stock concentration of 10 mM. A 100X, 10-point, 4-fold serial dilution of each inhibitor was created in 100% DMSO either manually or on a Hamilton STAR liquid handler, starting at a relevant concentration, usually 1 mM. A volume of 0.130 ⁇ L of each concentration was transferred to the relevant wells of a 384-well plate (Greiner 781 201) in duplicate using a TTPLabtech Mosquito nano-litre dispenser.
- Enzyme activity assays at the APP K M for ATP or 1 mM ATP were added to the 130 nL of dosed compound as follows (see table below for final reaction details): Enzyme activity assays at the APP K M for ATP or 1 mM ATP: In each well of a 384- well plate, 0.1 - 15 nM of untreated enzyme was incubated in a total of 13 ⁇ L of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl2, 1mM DTT) with 1.5 ⁇ M fluorescent peptide and 20 - 1000 ⁇ M ATP, at 25 o C, for 60 - 180 minutes in the presence or absence of a dosed concentration series of compound (1% DMSO final concentration).
- buffer 100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl2, 1mM DTT
- the kinase reactions were stopped by the addition of 70 ⁇ l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 35 mM EDTA and 0.2% of Coating Reagent 3 (Caliper Lifesciences)). The plates were read on a Caliper EZReader 2 as described above.
- Stop buffer 100 mM HEPES pH 7.5, 0.015% Brij 35, 35 mM EDTA and 0.2% of Coating Reagent 3 (Caliper Lifesciences)
- T Cell Enhancement of Cytokines Isolation and Expansion of T cells from whole blood T cells are isolated from whole blood of healthy donors by immunomagnetic negative selection following manufacture’s protocol (StemCell Technologies, human T cell isolation kit). Purity of isolated cells is assessed by flow cytometry and yields 95-98% CD3 + T cells.
- T cells 1x10 6 cells/well are plated in serum free cell expansion media (ThermoFisher) containing 30U of recombinant human IL2 (R&D) and stimulated with 25ul of CD3/CD28 beads (Invitrogen) in 24 well plates for 3-4 days.
- T cells are then expanded in 175cm flasks and maintained at a cell density of 1 to 2.5x10 6 cells/ml days by addition of 2/3 of fresh media every 2-3 days. After 10-14 days, cells are frozen in BamBanker freezing media (Thermo) and stored in liquid nitrogen. Phenotypic analysis of expanded T cells by flow cytometry, routinely shows 60% cells are CD8 + T cells upon freezing. Cytokine Measurement For IL2 measurement, expanded CD3 + T cells are dispensed at 100K cells/well (cultured in X-VIVO 10 Serum-free media) and are stimulated with plate-bound anti-CD3 and soluble anti-CD28 in the presence of vehicle or compound of the disclosure at various concentrations for 24h.
- mice are randomized into treatment groups, 10 mice per group, with tumors in the size range of 30-70 mm 3 .
- Compounds of the disclosure 10-30 mg/kg, anti-mouse PD-L1 mAb (B7 H1, clone # 10F.9G2 Bio-X-cell, Riverside, NH) and vehicle either alone or in different combinations are administered to tumor bearing mice. Reduction in tumor volume is measured [mm 3 ] over time.
- Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
- the disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
- the disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
- the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims are introduced into another claim.
- any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
- elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.
- certain embodiments of the disclosure or aspects of the disclosure consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. Where ranges are given, endpoints are included.
Abstract
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
Description
MAP4K1 INHIBITORS RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application Serial No. 63/222,341, filed July 15, 2021, the entire teachings of which are incorporated herein by reference. FIELD This application is directed to MAP4K1 inhibitors and methods for their use, such as to control the activity of MAP4K1 in a subject. BACKGROUND MAP4K1, also known as hematopoietic progenitor kinase 1 (HPKl), was originally cloned from hematopoietic progenitor cells (Hu, M.C., et al., Genes Dev, 1996.10(18): p. 2251-64). MAP4K1 is of particular interest as a target, because it is predominantly expressed in hematopoietic cells such as T cells, B cells, macrophages, dendritic cells, neutrophils, and mast cells (Hu, M.C., et al, Genes Dev, 1996.10(18): p.2251-64; Kiefer, F., et al, EMBO J, 1996.15(24): p.7013-25). MAP4K1 kinase activity has been shown to be induced upon activation of T cell receptors (TCR) (Liou, J., et al., Immunity, 2000.12(4): p.399-408), B cell receptors (BCR) (Liou, J., et al., Immunity, 2000.12(4): p.399-408), transforming growth factor receptor (TGF- R) (Wang, W., et al, J Biol Chem, 1997.272(36): p.22771-5; Zhou, G., et al, J Biol Chem, 1999.274(19): p.13133-8), or Gs-coupled PGE2 receptors (EP2 and EP4) (Ikegami, R, et al, J Immunol, 2001.166(7): p.4689-96). As such, MAP4K1 regulates diverse functions of various immune cells. MAP4K1 is important in regulating the functions of various immune cells and it has been implicated in autoimmune diseases and anti-tumor immunity (Shui, J.W., et al, Nat Immunol, 2007.8(1): p.84-91; Wang, X., et al, J Biol Chem, 2012.287(14): p.11037-48). Those observations suggested that attenuation of MAP4K1 activity may contribute to autoimmunity in patients. Furthermore, MAP4K1 may also control anti-tumor immunity via T cell-dependent mechanisms. In the PGE2-producing Lewis lung carcinoma tumor model, the tumors developed more slowly in MAP4K1 knockout mice as compared to wild-type mice (see US 2007/0087988). In addition, it was shown that adoptive transfer of MAP4K1 deficient T cells was more effective in controlling tumor growth and metastasis than wild- type T cells (Alzabin, S., et al., Cancer Immunol Immunother, 2010.59(3): p.419-29). Similarly, bone marrow derived dendritic cells (BMDCs) from MAP4K1 knockout mice were
more efficient to mount a T cell response to eradicate Lewis lung carcinoma as compared to wild-type BMDCs (Alzabin, S., et al., J Immunol, 2009.182(10): p.6187-94). Data obtained from MAP4K1 kinase dead mice demonstrated that MAP4K1 kinase activity is critical in conferring suppressive functions of MAP4K1 in a wide range of immune cells including CD4+, CD8+, DC, NK to T regulatory cells (Tregs) and inactivation of kinase domain was sufficient to elict robust anti-tumor immune responses. Liu et al., PLoS ONE 14(3):e0212670 https://doi.org/10.1371/journal.pone.0212670. Moreover, loss of MAP4K1 kinase function suppresses tumor growth in preclinical tumor models and therapeutic co-blockade of MAP4K1 kinase and PD-L1 enhances anti-tumor responses. Hernandez S. et al., Cell Reports 201825: p.80-94. Recently presented results show tumor growth inhibition in a CT-26 syngeneic mouse model using a small molecule MAP4K1 inhibitor (Seungmook, L., Cancer research.AACR Journal, 2019, Abstract 4150). These data have validated MAP4K1 as a novel drug target for enhancing antitumor immunity. Accordingly, there is a need for new compounds that modulate MAP4K1 activity for the treatment of MAP4K1-dependent diseases or disorders such as cancer, viral infection, and other diseases and disorders. Of particular importance is the need for new compounds that selectively modulate MAP4K1 activity. SUMMARY Provided herein are compounds, or pharmaceutically acceptable salts thereof, and compositions which inhibit MAP4K1, thereby enhancing an immune response in a subject. For example, the IC50 values for inhibition of MAP4K1 provided in Table 3 demonstrate that these compounds are potent inhibitors of MAP4K1. Also disclosed are methods of using the compounds and compositions described herein for treating cancer and viral infection. A first embodiment of the disclosure is a compound represented by Formula I:
I, or a pharmaceutically acceptable salt thereof, wherein: A1 is selected from N and CH; A2 is selected from CH and N; X is selected from C1-3 alkyl, OR3, NHR4 and halogen; B is selected from CR5 and N, Y is CR6, or Y and B, taken together, form a 5 to 7-membered heterocycle or C5-6 cycloalkyl, wherein said heterocycle or cycloalkyl is optionally substituted with 1-6 R7; R1 and R2 are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl substituted with OR8, phenyl, C3-6 cycloalkyl and 4 to 6-membered heterocycle, or R1 and R2, taken together with the atoms to which they are attached, form a C3-6 cycloalkyl or 4 to 6-membered heterocycle; R3 is selected from C1-3 alkyl, C3-6 cycloalkyl and 4 to 6-membered heterocycle, wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1-3 R9; R4 is selected from hydrogen, C1-3 alkyl, C3-5 cycloalkyl and 4 to 6-membered heterocycle, wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1- 3 R10; R5 is selected from hydrogen, COOH, CN, halogen, and C1-3 alkoxy; R6 is selected from C1-5 alkyl, C4-6 cycloalkyl, 3 to 6-membered heterocycle, NHR11, NR12R13 and OR14, wherein said alkyl, cycloalkyl or heterocycle is optionally substituted with OH, NH2, 1-4 halogen or R15; each R7 is independently selected from C1-3 alkyl, halogen and OH, wherein said alkyl is optionally substituted with 1-3 halogen, or two R7 attached to the same carbon form an oxo, or two R7 attached to the same carbon atom taken together with the carbon atom to which they are attached form a C3-5 cycloalkyl; R8 is H or C1-3 alkyl. each R9 is independently selected from C1-3 alkyl, C3-6 cycloalkyl substituted with halogen, halogen, C(O)Me, SO2Me, C(O)NR16R17, C1-3 alkoxy, and OH; each R10 is independently selected from C1-3 alkyl, C3-6 cycloalkyl substituted with halogen, halogen, SO2Me, C(O)NR16R17, C1-3 alkoxy, and OH; R11 is selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R18;
R12 and R13 are each is independently selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R18; R14 is selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R18; R15 is OH, C1-3 alkyl or C3-5 cycloalkyl; R16 and R17 are each is independently selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R19; each R18 is independently halogen; and each R19 is independently halogen. Another embodiment of the disclosure is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound disclosed herein or a pharmaceutically acceptable salt thereof. Another embodiment of the disclosure is a method of inhibiting MAP4K1 in a subject in need thereof, comprising contacting MAP4K1 with an effective amount of the compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof. Another embodiment of the disclosure is a method for enhancing an immune response in a subject in need thereof, comprising administering to said subject an effective amount of the compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof. Another embodiment of the disclosure is a method of treating a MAP4K1-dependent disorder or disease (e.g., treating a cancer) in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound(s). Another embodiment of the disclosure is the use of a compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound(s), for the preparation of a medicament for treating a MAP4K1-dependent disorder or disease (e.g., treating a cancer) in a subject in need thereof. Another embodiment of the disclosure is a compound disclosed herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the
compound(s), for use in treating a MAP4K1-dependent disorder or disease (e.g., treating a cancer) in a subject in need thereof. DETAILED DESCRIPTION The disclosed compounds or pharmaceutically acceptable salts thereof are MAP4K1 inhibitors, which can be used for treating a MAP4K1-dependent disorder or disease. Such diseases or disorders include cancer and viral infection. Compound Embodiments Example embodiments include: First embodiment: a compound represented by Formula I:
I, or a pharmaceutically acceptable salt thereof. The variables in Formula I are described in the summary above. Second embodiment: a compound represented by Formula II:
or a pharmaceutically acceptable salt thereof. The variables in Formula II are described above in the first embodiment.
Third embodiment: a compound represented by Formula III:
or a pharmaceutically acceptable salt thereof. The variables in Formula III are described above in the first embodiment. Fourth embodiment: a compound represented by Formula IV(A) or IV(B):
or a pharmaceutically acceptable salt thereof. The variables in Formulae IV(A) and IV(B) are described above in the first embodiment.
Fifth embodiment: a compound represented by Formula V:
or a pharmaceutically acceptable salt thereof, wherein Y and B, taken together, form a 5 to 7- membered heterocycle or C5-6 cycloalkyl, and said heterocycle or cycloalkyl is optionally substituted with 1-6 R7. The variables in Formula V are described above in the first embodiment. Sixth embodiment: a compound represented by Formula VI:
or a pharmaceutically acceptable salt thereof, wherein: each R7 is independently selected from C1-3 alkyl, halogen and OH, wherein said alkyl is optionally substituted with 1-3 halogen, or two R7 attached to the same carbon atom taken together with the carbon atom to which they are attached form a C3-5 cycloalkyl; n is 0, 1, 2, 3, 4, 5 or 6; and m is 0, 1 or 2. The remainder of the variables in Formula VI are described above in the first embodiment.
Seventh embodiment: a compound represented by Formula VII:
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3 or 4. The remainder of the variables in Formula VII are described above in the first and/or sixth embodiment. Eighth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein X is NHR4, and R4 is CH3 or cyclopropyl. The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth and/or seventh embodiments. Ninth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein X is OR3. The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth and/or seventh embodiments. Tenth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are each independently selected from hydrogen, C1-2 alkyl, C1-2 haloalkyl, C1-3 alkyl substituted with OR8, phenyl and C3-4 cycloalkyl, or R1 and R2, taken together with the atoms to which they are attached, form a 4 to 6-membered heterocycle; and R8 is C1-2 alkyl. The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, eighth and/or ninth embodiments. Eleventh embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are each independently selected from hydrogen, CH3, CH2CH3, CH2OCH3, CHF2, CF3, cyclobutyl, cyclopropyl and phenyl, or R1 and R2, taken together with the atoms to which they are
attached, form tetrahydropyran. The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, eighth and/or ninth embodiments. Twelfth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, R1 and R2 are each independently selected from hydrogen, CH3, CH2CH3, CH2OCH3, CHF2, CF3, cyclobutyl, cyclopropyl and phenyl, or R1 and R2, taken together with the atoms to which they are attached, form
. The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, eighth and/or ninth embodiments. Thirteenth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: R3 is selected from C1-3 alkyl, C3-4 cycloalkyl and 4-membered heterocycle; wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1-3 R9; and each R9 is independently selected from C1-3 alkyl, halogen, C(O)Me and SO2Me. The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, ninth, tenth, eleventh and/or twelfth embodiments. Fourteenth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: R3 is 4-membered heterocycle containing nitrogen; R9 is C(O)Me; and a ring nitrogen of the 4-membered heterocycle is bonded to
The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, ninth, tenth, eleventh and/or twelfth embodiments. Fifteenth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: R3 is selected from CH3, CH2CH3, CH2CH2CH3, cyclopropyl, cyclobutyl, azetidinyl, each optionally substituted with 1-3 R9; and each R9 is independently selected from CH3, F, C(O)Me and SO2Me. The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, ninth, tenth, eleventh and/or twelfth embodiments. Sixteenth embodiment: a compound represented by Formulae I, II, III, IV(A), IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein R3 is selected from CH3, CH2CH3, CH2CHF2, CH2CF3, CH2CH2CH3, cyclopropyl, :
and
The remainder of the variables in Formulae I, II, III, IV(A), IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, ninth, tenth, eleventh and/or twelfth embodiments. Seventeenth embodiment: a compound represented by Formulae I, II, III or IV(B), or a pharmaceutically acceptable salt thereof, wherein R5 is CN. The remainder of the variables in Formulae I, II, III and IV(B) are describe above in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth and/or sixteenth embodiments. Eighteenth embodiment: a compound represented by Formulae I, II, III, IV(A) or IV(B), or a pharmaceutically acceptable salt thereof, wherein: R6 is selected from C1-4 alkyl, and 4 to 5-membered heterocycle, wherein said alkyl or heterocycle is optionally substituted with 1-4 halogen or R15; and R15 is C1-2 alkyl. The remainder of the variables in Formulae I, II, III, IV(A) and IV(B) are describe above in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth and/or seventeeth embodiments. Nineteenth embodiment: a compound represented by Formulae I, II, III, IV(A) or IV(B), or a pharmaceutically acceptable salt thereof, wherein R6 is selected from CH(CH3)2, CF(CH3)2, C(CH3)3,
The remainder of the variables in Formulae I, II, III, IV(A) and IV(B) are describe above in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth and/or seventeeth embodiments. Twentieth embodiment: a compound represented by Formulae I, II, III, IV(B), V, VI or VII, or a pharmaceutically acceptable salt thereof, wherein: each R7 is independently CH3, or two R7 attached to the same carbon form an oxo, or two R7 attached to the same carbon atom taken together with the carbon atom to which they are attached form cyclopropyl. The remainder of the variables in Formulae I, II, III, IV(B), V, VI and VII are described above in the first, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth and/or sixteenth embodiments.
Twentyfirst emboidment: a compound represented by Formulae I, II, III, IV(B) or V, or a pharmaceutically acceptable salt thereof, wherein Y and B, taken together, form: and
wherein represents a bond to A2, and ―^ represents a bond to N. The remainder of the variables in Formulae I, II, III, IV(B), V, VI and VII are describe above in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth and/or sixteenth embodiments. In one embodiment, the Compounds 71-74 in Table 4, and pharmaceutically acceptable salts thereof, are excluded from the disclosure. The disclosure also includes the compounds depicted in Table 1 and prepared in the Exemplification, both the neutral form and pharmaceutically acceptable salts thereof. The synthetic protocol used to prepare compounds in Table 1 is listed in the last column of Table 1 and full details for each synthetic protocol are described in Scheme 1 in the General Synthetic Methods and Intermediates section.
Table 1
Included in the present teachings are pharmaceutically acceptable salts of the compounds disclosed herein (including compounds 1-70 disclosed in Table 1 and Exemplification) as well as the corresponding charge neutral form e.g., free base.
Another embodiment of the disclosure is a compound disclosed herein, including a compound of Formulae I, II, III, IV(A), IV(B), V, VI or VII or a compound in Table 1 or in the exemplification or a pharmaceutically acceptable salt of any of the foregoing, in which one or more hydrogen atoms is replaced with deuterium. The deuterium enrichment at any one of the sites where hydrogen has been replaced by deuterium is at least 50%, 75%, 85%, 90%, 95%, 98% or 99%. Deuterium enrichment is a mole percent and is obtained by dividing the number of compounds with deuterium enrichment at the site of enrichment with the number of compounds having hydrogen or deuterium at the site of enrichment. Definitions As used herein, the term “pharmaceutically acceptable salt” refers to pharmaceutical salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describes pharmacologically acceptable salts in J. Pharm. Sci. (1977) 66:1-19. Compounds of the present teachings with basic groups can form pharmaceutically acceptable salts with pharmaceutically acceptable acid(s). Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, nitric, and sulfuric acids) and of organic acids (such as acetic acid, benzenesulfonic, benzoic, methanesulfonic, and p-toluenesulfonic acids). Compounds of the present teachings with acidic groups can form pharmaceutically acceptable salts with pharmaceutically acceptable base(s). Suitable pharmaceutically acceptable basic salts include ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts). The term “alkyl” used alone or as part of a larger moiety, such as “alkoxy”, “hydroxyalkyl” and the like, means a saturated aliphatic straight-chain or branched monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group typically has 1 to 6 carbon atoms (C1-6 alkyl), (i.e., 1, 2, 3, 4, 5 or 6) alternatively, 1 to 3 carbon atoms (C1-3 alkyl) (i.e., 1, 2 or 3). “C1–6 alkyl” is means a radical having 1 to 6 carbon atoms in a linear or branched arrangement, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like.
The term “alkylene” means a bivalent alkyl group, for example C1-C6 alkyl is a group ‒(CH2)n‒ where n is 1 to 6, C1-C3 alkyl is a group ‒(CH2)n‒ where n is 1 to 3, unless otherwise specified. “Cycloalkyl” means a saturated aliphatic cyclic hydrocarbon ring radical. Unless otherwise specified, a cycloalkyl has 3 to 8 ring carbon atoms (C3-8 cycloalkyl) (i.e., 3, 4, 5, 6, 7, or 8), alternatively, 3 to 6 ring carbon atoms (C3-6 cycloalkyl) (i.e., 3, 4, 5, or 6), alternatively, 3 to 5 carbon atoms (C3-5 cycloalkyl) (i.e., 3, 4, or 5). “C3-6 Cycloalkyl” means a radical having from 3 to 6 carbon atoms arranged in a monocyclic ring. A C3-6 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. A C3-5 cycloalkyl includes cyclopropyl, cyclobutyl, and cyclopentyl. The term “cycloalkyl” also means to include a saturated aliphatic cyclic hydrocarbon fused to an aromatic group such as in Formula (I) wherein “Y and B taken together form a C5-6cycloalkyl.” The term “halogen” or “halo” means fluorine or fluoro (F), chlorine or chloro (Cl), bromine or bromo (Br), or iodine or iodo (I). The term “heterocycle” refers to a monocyclic non-aromatic ring radical containing unless otherwise specified, 3 to 8 ring atoms (i.e., “3, 4, 5, 6, 7, or 8 membered”) selected from carbon atom and 1 or 2 heteroatoms. Each heteroatom is independently selected from nitrogen, quaternary nitrogen, oxidized nitrogen (e.g., NO); oxygen; and sulfur, including sulfoxide and sulfone. For example, 4-6 membered heterocycle containing nitrogen refers to a monocyclic non-aromatic ring radical containing 2-5 carbon atoms and 1 or 2 nitrogen atoms; 4-6 membered heterocycle containing oxygen atoms refers to a monocyclic non-aromatic ring radical containing 2-5 carbon atoms and 1 or 2 oxygen. Representative heterocycles include azetidinyl, morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like. The term “hydroxyl” or “hydroxy” refers to the group OH. The term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of a hydrogen substituent in a given structure with a non-hydrogen substituent. Thus, for example, a substituted alkyl is an alkyl wherein at least one non-hydrogen substituent is in the place of a hydrogen substituent on the alkyl group. To illustrate, monofluoroalkyl is an alkyl substituted with a fluoro substituent, and difluoroalkyl is an alkyl substituted with two fluoro substituents. It should be recognized that if there is more than one
substitution on a substituent, each non-hydrogen substituent can be identical or different (unless otherwise stated). If a group is described as “optionally substituted”, the group can be either (1) not substituted or (2) substituted. If a group is described as optionally substituted with up to a particular number of non- hydrogen substituents, that group can be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a group is described as a cycloalkyl optionally substituted with up to 3 non-hydrogen substituents, then any cycloalkyl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen substituents as the cycloalkyl has substitutable positions. The term “sulfone” refers to the group –S(O)2–. Compounds having one or more chiral centers can exist in various stereoisomeric forms, i.e., each chiral center can have an R or S configuration or can be a mixture of both. Stereoisomers are compounds that differ only in their spatial arrangement. Stereoisomers include all diastereomeric and enantiomeric forms of a compound. Enantiomers are stereoisomers that are non-superimposable mirror images of each other. Diastereomers are stereoisomers having two or more chiral centers that are not identical and are not mirror images of each other. When the stereochemical configuration at a chiral center in a compound having one or more chiral centers is depicted by its chemical name (e.g., where the configuration is indicated in the chemical name by “
” or “S”) or structure (e.g., the configuration is indicated by “wedge” bonds), the enrichment of the indicated configuration relative to the opposite configuration is greater than 50%, 60%, 70%, 80%, 90%, 99% or 99.9% (except when the designation “rac” or “racemate accompanies the structure or name, as explained in the following two paragraphs). “Enrichment of the indicated configuration relative to the opposite configuration” is a mole percent and is determined by dividing the number of compounds with the indicated stereochemical configuration at the chiral center(s) by the total number of all of the compounds with the same or opposite stereochemical configuration in a mixture. When the stereochemical configuration at a chiral center in a compound is depicted by chemical name (e.g., where the configuration is indicated in the name by “R” or “S”) or
structure (e.g., the configuration is indicated by “wedge” bonds) and the designation “rac” or “racemate” accompanies the structure or is designated in the chemical name, a racemic mixture is intended. When two or more stereoisomers are depicted by their chemical names or structures, and the names or structures are connected by an “or”, one or the other of the two or more stereoisomers is intended, but not both. The enrichment of one stereoisomer relative to the other is as indicated above. When a disclosed compound having a chiral center is depicted by a structure without showing a configuration at that chiral center, the structure is meant to encompass the compound with the S configuration at that chiral center, the compound with the R configuration at that chiral center, or the compound with a mixture of the R and S configuration at that chiral center. When a disclosed compound having a chiral center is depicted by its chemical name without indicating a configuration at that chiral center with “S” or “R”, the name is meant to encompass the compound with the S configuration at that chiral center, the compound with the R configuration at that chiral center or the compound with a mixture of the R and S configuration at that chiral center. A racemic mixture means a mixture of 50% of one enantiomer and 50% of its corresponding enantiomer. The present teachings encompass all enantiomerically-pure, enantiomerically-enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures, and diastereomeric mixtures of the compounds described herein. Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods. “Peak 1” or “first eluting isomer” in the Experimental section refers to an intended reaction product compound obtained from a chromatography separation/purification that elutes earlier than a second intended reaction product compound from the same preceding reaction. The second intended product compound is referred to as “peak 2” or “second eluting isomer”.
When a compound is designated by a name or structure that indicates a single enantiomer, unless indicated otherwise, the compound is at least 60%, 70%, 80%, 90%, 99% or 99.9% optically pure (also referred to as “enantiomerically pure”). Optical purity is the weight in the mixture of the named or depicted enantiomer divided by the total weight in the mixture of both enantiomers. When the stereochemistry of a disclosed compound is named or depicted by structure, and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair), it is to be understood that, unless otherwise indicated, one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers are included. It is to be further understood that the stereoisomeric purity of the named or depicted stereoisomers at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight. The stereoisomeric purity in this case is determined by dividing the total weight in the mixture of the stereoisomers encompassed by the name or structure by the total weight in the mixture of all of the stereoisomers. Use Embodiments Compounds of the disclosure are MAP4K1 inhibitors. The use of the word “inhibitor” means that a compound or a pharmaceutically acceptable salt thereof inhibits activity of MAP4K1. By “inhibit” herein is meant to decrease the activity of the target enzyme as compared to the activity of that enzyme in the absence of the inhibitor. In some alternatives, the term “inhibit” means a decrease in MAP4K1 activity of at least 5%, at least 10%, at least 20%, at least 50%, at least 60%, at least 79%, at least 80%, at least 90% or at least 95%. In other alternatives, inhibit means a decrease in MAP4K1 activity of 5% to 25%, 25% to 50%, 50 to 70%, 75 to 100%. In some embodiments, inhibit means a decrease in MAP4K1 activity about 95% to 100%, e.g., a decrease in activity of 95%, 96%, 97%, 98%, 99%, or 100%. Such decreases can be measured using a variety of techniques that would be recognizable by one of skill in the art, including in vitro kinase assays. Compounds of the disclosure are selective MAP4K1 inhibitors. As used herein, a “selective MAP4K1 inhibitor” refers to a compound or a pharmaceutically acceptable salt thereof, which has the ability to selectively inhibit MAP4K1 kinase over other targets. More specifically, a selective MAP4K1 inhibitor has the ability to selectively inhibit MAP4K1 over another kinase. A selective MAP4K1 inhibitor has the ability to selectively reduce target signaling activity relative to off-target signaling activity, via direct or indirect interaction with the target. The ability to selectively target MAP4K1 with a compound or pharmaceutically
acceptable salt thereof provides advantages in terms of improved potency, less off-target activity and an increased probability of clinical success in comparison with a non-selective compound or salt. A MAP4K1 inhibitor that selectively inhibits MAP4K1 may have an activity that is at least 2-fold relative to another kinase (e.g., at least 10-fold; at least 15-fold; at least 20-fold; at least 30-fold; at least 40-fold selectivity; at least 50-fold; at least 60-fold; at least 70-fold; at least 80-fold; at least 90-fold; at least 100-fold; at least 125-fold; at least 150-fold; at least 175-fold; or at least 200-fold. In some alternatives, a selective MAP4K1 inhibitor exhibits at least 15-fold selectivity over another kinase, e.g., LCK and MAP4K family members (MAP4K4 (HGK) and MAP4K3 (GLK)). In some alternatives, the selective MAP4K1 inhibitors are selective over EGFR and L858R/T790M EGFR. In some alternatives, the selective MAP4K1 inhibitors of the disclosure are selective over BTK. In some alternatives, the selective MAP4K1 inhibitors of the disclosure are selective over JNK. The disclosure provides methods of modulating (e.g., inhibiting) MAP4K1 activity in a subject in need thereof, said method comprising administering to the subject a compound provided herein, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for therapeutic administration to enhance, stimulate and/or increase immunity in subjects in need thereof, e.g., in cancer patients or patients with viral infection. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof reduce, inhibit, or otherwise diminish pSLP76. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for therapeutic administration to enhancing at least one of activation, priming, migration, proliferation, survival and cytolytic activity of T cells relative to prior to administration. In certain aspects, T cell activation is characterized by enhanced levels of IL- 2, IFN-gamma, or granzyme B production by T cells relative to prior to administration of the compound or pharmaceutically acceptable salt thereof. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for therapeutic administration to induce a change in cell cycle or cell viability. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for improving function of T effector cells. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for inhibiting the suppressive effects of T regulatory cells or improving the T cell response to
immune suppressive factors including adenosine and PGE2. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for increasing the frequency of CD8+ tumor infiltrating lymphocytes (TILS). In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for enhancing CD3+/Treg ratios. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for enhancing cytokines. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for enhancing cytokines with no impact on IL-6. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, indirectly inhibit the growth of cancer cells. In some instances, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are useful for priming of the immune response (i.e., vaccines) to tumors or viruses for booting or generating anti-viral/anti-tumor immunity. In one instance, the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are used for enhancing or boosting response to a vaccine (such as a cancer vaccine or a personalized cancer vaccine (PCV)) or a CAR-T cell therapy. Methods of treating a MAP4K1-dependent disease or disorder can include administering to a subject in need thereof a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof. For example, the MAP4K1- dependent disease or disorder is a cancer. The term “cancer” encompasses all forms of cancer including, but not limited to, all forms of carcinoma, melanomas, blastomas, sarcomas, lymphomas, leukemias. In some embodiments, cancer includes metastatic forms. Additionally, the disclosure includes refractory or recurrent malignancies whose growth may be inhibited using the compounds of the disclosure. For the uses described herein, any of the compounds of the disclosure, or pharmaceutically acceptable salts thereof, may be used alone or in combination with other therapeutic agents. In some embodiments, the treatment results in a sustained response in the subject after cessation of the treatment. “Sustained response” refers to the sustained effect on reducing tumor growth after cessation of a treatment. For example, the tumor size may remain the same or smaller as compared to the size at the beginning of the administration phase. In some embodiments, the sustained response has a duration at least the same as the treatment duration, at least 1.5X, 2.0X, 2.5X, or 3.0X length of the treatment duration.
The treatment methods disclosed herein may result in a partial or complete response. As used herein, “complete response” or “CR” refers to disappearance of all target lesions; “partial response” or “PR” refers to at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD; and “stable disease” or “SD” refers to neither sufficient shrinkage of target lesions to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started. As used herein, “overall response rate” (ORR) refers to the sum of complete response (CR) rate and partial response (PR) rate. The treatment methods disclosed herein can lead to an increase in progression free survival and overall survival of the subject administered the selective MAP4K1 inhibitor. As used herein, “progression free survival” (PFS) refers to the length of time during and after treatment during which the disease being treated (e.g., cancer) does not get worse. Progression-free survival may include the amount of time subjects have experienced a complete response or a partial response, as well as the amount of time subjects have experienced stable disease. As used herein, “overall survival” (OS) refers to the percentage of subjects in a group who are likely to be alive after a particular duration of time. In some embodiments, cancers treatable with compounds of the disclosure or pharmaceutically acceptable salt thereof, include colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, bladder cancer, stomach cancer, liver cancer, gastric cancer, cancer of the head and neck, lymphoma, leukemia, urothelial carcinoma, merkel cell carcinoma, gastroesophageal junction carcinoma, esophageal squamous cell carcinoma, skin squamous cell carcinoma and melanoma. In some embodiments, cancers treatable with compounds of the disclosure or pharmaceutically acceptable salts thereof include colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, bladder cancer, stomach cancer, liver cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma. In some embodiments, cancers that are treatable using the compounds of the disclosure or pharmaceutically acceptable salts thereof include, but are not limited to, solid tumors, including prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, brain cancer, and bladder
cancer and hematological cancer, including lymphoma, leukemia (chronic and acute forms) such as ALL, AML, CLL, CML, DLBCL, mantle cell lymphoma, Non-Hodgkin’s lymphoma (NHL), including relapsed or refractory NHL and recurrent follicular, Hodgkin’s lymphoma and multiple myeloma, and myeloproliferative diseases. In some embodiments, diseases and indications that are treatable using the compounds of the disclosure or pharmaceutically acceptable salts thereof include, but are not limited to hematological cancer, sarcomas, respiratory cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, and skin cancer. Exemplary hematological cancer includes, for example, lymphomas and leukemias such as ALL, AML, acute promyelocyte leukemia (APL), CLL, CML, DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (NHL), including Primary mediastinal B-cell lymphoma (PMBCL), relapsed or refractory NHL, recurrent follicular, and primary CNS lymphoma, Hodgkin’s lymphoma, myeloproliferative diseases, including, primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma, and Burkitt's lymphoma. Exemplary sarcoma includes, for example, chondrosarcoma, Ewing's sarcoma, Kaposi’s sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, sarcoma of the soft tissue, and teratoma. Exemplary respiratory tract cancer includes, for example, lung cancer such as non- small cell lung cancer (NSCLC), small cell lung cancer, epidermoid cancer, bronchogenic carcinoma, including squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma, alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, and pleuropulmonary blastoma. Exemplary gastrointestinal cancer includes, for example, cancers of the esophagus, including squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; stomach, including carcinoma, lymphoma, and leiomyosarcoma; pancreas, including ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; small instestine, including adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; large intestine, including
adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma; colon; and gall bladder, including adenocarcinoma; and intestinal type and diffuse type gastric adenocarcinoma, rectum carcinoma, familiar adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer. Exemplary genitourinary tract cancer includes, for example, cancers of the kidney, including adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma, urothelial carcinoma, juxtaglomerular cell tumor (reninoma), angiomyolipoma, renal oncocytoma, Bellinio duct carcinoma, clear-cell sarcoma of the kidney, and mesoblastic nephroma; adrenal gland; renal pelvis; bladder, including transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma, and small cell carcinoma; urethra, including squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; prostate, including adenocarcinoma, sarcoma, and carcinoma; testis, including seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma; penis; and pancreas. Exemplary liver cancer includes, for example, hepatoma, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, biliary tract cancer, and hemangioma. Exemplary bone cancer includes, for example, osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, including reticulum cell sarcoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, including osteocartilaginous exostoses, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors Exemplary nervous system cancer includes, for example, cancer of the skull, including osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; meninges including, meningioma, meningiosarcoma, and gliomatosis; brain, including astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), neuroectodermal tumor, glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, brain stem and hypopthamic glioma; and spinal cord, including neurofibroma, meningioma, glioma, and sarcoma; as well as neuroblastoma and Lhermitte- Duclos disease. Exemplary gynecological cancer includes, for example, cancer of the uterus, including endometrial carcinoma; cervix, including cervical carcinoma, pre-tumor cervical dysplasia, squamouse cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell
carcinoma, neuroendocrine tumor, glassy cell carcinoma and villoglandular adenocarcinoma; ovaries, including ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, endometroid tumor, high-grade serous carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma, and arrhenoblastoma; vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; vagina, including clear cell carcinoma, squamous cell carcinoma, and botryoid sarcoma (embryonal rhabdomyosarcoma); labia; and fallopian tubes. Exemplary skin cancer includes, for example, melanoma, sebaceous gland carcinoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids. Examples of breast cancer include, for example, ER+/HER2- breast cancer, triple- negative breast cancer (TNBC), invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ. Exemplary head and neck cancer includes, for example, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, throat cancer, including oropharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancer, salivary gland cancer, mouth cancer, eye cancer, acoustic neuroma, pituitary adenoma, hypopharngx, and thyroid (medullary and papillary) and parathyroid cancer. Other cancers include, for example, sweat gland cancer, spinal axis tumor, chest cancer, sickle cell anemia, and environmentally induced cancers including those induced by asbestos. In some embodiments, compounds of the disclosure or pharmaceutically acceptable salts thereof are for the treatment of advanced melanoma, advanced NSCLC, or advanced head and neck squamous cell cancer, including where the subject was refractory to, or had a partial response to, immune checkpoint inhibitor therapy. In some instances, the MAP4K1-dependent disease or disorder is a viral infection, such as infection caused by hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella zoster virus, coxsackie virus, and human immunodeficiency virus (HIV).
Combination Therapies Compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered as the sole pharmaceutical agent or in combination with one or more other anti- cancer agents for the treatment of cancel, where the combination causes no unacceptable adverse effects. In some embodiments, the other anti-cancer agents are immune-oncology agent, anticancer agents that are enzyme/protein/receptor inhibitors, radiation or chemotherapy. Compounds of the disclosure or pharmaceutically acceptable salts thereof can be co- formulated with an immuno-oncology agent. Immuno-oncology agents include, for example, a small molecule drug, antibody, or other biologic or small molecule. Examples of biologic immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In one aspect, the antibody is a monoclonal antibody. In another aspect, the monoclonal antibody is humanized or human. In another aspect, the antibody is a bispecific antibody. In one aspect, the immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co-inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses (often referred to as immune checkpoint regulators, in some instances immune checkpoint inhibitors). Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF). One important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane bound ligands that bind to co-stimulatory or co- inhibitory receptors is the TNF family of molecules that bind to cognate TNF receptor family members, which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fnl4, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTfiR, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2,TNFRl, Lymphotoxin α/ΤΝΡβ, TNFR2, TNF a, LT R, Lymphotoxin a 1β2, FAS, FASL, RELT, DR6, TROY, NGFR. In one aspect, T cell responses can be stimulated by a combination of a compound of the disclosure and one or more of (i) an antagonist of a protein that inhibits T cell activation
(e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4, and (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H. In one aspect, compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered in combination with at least one other immune checkpoint inhibitor. In other aspects, compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered for the treatment of immune checkpoint inhibitor-resistant NSCLC, including where the subject is refractory to, or had a partial response to, platinium and/or paclitaxel and/or docetaxel therapy. Optionally, compounds of the diclosure or pharmaceutically acceptable salts thereof can be administered in combination with at least one other anti-cancer agent, such as paclitaxel, docetaxel or platinum anticancer therapy. Compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered for the first line treatment of NSCLC expressing high PD-L1 (≥50% Tumor Proportion Score (TPS), wild-type EGFR, or wild-type ALK). Other agents that can be combined with compounds of the disclosure for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, compounds of the disclosure can be combined with antagonists of KIR, such as lirilumab. Yet other agents for combination therapies include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 or FPA-008. In another aspect, compounds of the disclosure or pharmaceutically acceptable salts thereof can be used with one or more of agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-Ll/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti- CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
In some embodiments, the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonistic CTLA-4 antibody. Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab. In another aspect, the immuno-oncology agent is a PD-1 antagonist, such as an antagonistic PD-1 antibody. Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP- 514; WO2012/145493). The immuno-oncology agent may also include pidilizumab (CT- 011), though its specificity for PD-1 binding has been questioned. Another approach to target the PD-1 receptor is the recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgGl, called AMP-224 In another aspect, the immuno-oncology agent is a PD-L1 antagonist, such as an antagonistic PD-L1 antibody. Suitable PD-L1 antibodies include, for example, TECENTRIQ (atezolizumab) (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS-936559 (WO2007/005874), and MSB0010718C (WO2013/79174). In another aspect, the immuno-oncology agent is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody. Suitable LAG3 antibodies include, for example, BMS-986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601, WO09/44273). In another aspect, the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody. Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (W012/32433). In another aspect, the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody. Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06/105021, WO09/009116) and MK-4166 (WOl 1/028683). In another aspect, the immuno-oncology agent is an IDO antagonist. Suitable IDO antagonists include, for example, INCB-024360 (WO2006/122150, WO07/75598, WO08/36653, WO08/36642), indoximod, or NLG-919 (WO09/73620, WO09/1156652, WOl1/56652, W012/142237). In another aspect, the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody. Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469. In another aspect, the immuno-oncology agent is an OX40L antagonist, such as an antagonistic OX40 antibody. Suitable OX40L antagonists include, for example, RG-7888 (WO06/029879). In another aspect, the immuno-oncology agent is a CD40 agonist, such as an agonistic CD40 antibody. In yet another embodiment, the immuno-oncology agent is a CD40
antagonist, such as an antagonistic CD40 antibody. Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab. In another aspect, the immuno-oncology agent is a CD27 agonist, such as an agonistic CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab. In another aspect, the immuno-oncology agent is MGA271 (to B7H3) (WOl 1/109400). The compounds of the disclosure or pharmaceutically acceptable salts thereof can be used in combination with anticancer agents that are enzyme/protein/receptor inhibitors, exhibiting different preferences in the targets which they modulate the activities of, to treat such conditions. Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment. The compounds of the disclosure or pharmaceutically acceptable salts thereof can be used in combination with one or more other enzyme/protein/receptor inhibitors for the treatment of cancer. For example, the compounds of the disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF-βΡν, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFotR, PDGFpR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK, and B-Raf. In some embodiments, the compounds of the disclosure or pharmaceutically acceptable salts thereof can be combined with one or more of the following inhibitors for the treatment of cancer. Non-limiting examples of inhibitors that can be combined with the compounds of the disclosure or pharmaceutically acceptable salts thereof for treatment of cancers include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., fisogatinib, AZD4547, BAY 1187982, ARQ087, BGJ398, BIBF1120, TKI258, lucitanib, dovitinib, TAS- 120, J J-42756493, Debiol347, INCB54828, INCB62079, and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib, or itacitinib (INCB39110)), an IDO inhibitor (e.g., epacadostat and NLG919), an LSD1 inhibitor (e.g., GSK2979552, INCB59872 and INCB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g., INCB50797 and INCB50465), a PI3K-gamma inhibitor such as a PI3K-gamma selective inhibitor (eganelisib) or a dual PI3K-delta/gamma selective inhibitor (duvelisib), a CSF1R inhibitor (e.g.,
PLX3397 and LY3022855), a TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer), an angiogenesis inhibitor (Such as Avastin (bevacizumab)), an interleukin receptor inhibitor, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors such as OTX015, CPI-0610, INCB54329, and INCB57643), and an adenosine receptor antagonist or combinations thereof. Inhibitors of HDAC such as panobinostat and vorinostat can be combined with the compounds of the disclosure. Inhibitors of c-Met such as onartumzumab, tivantnib, and capmatinib (INC-280) be combined with the compounds of the disclosure. Inhibitors of BTK such as ibrutinib can be combined with the compounds of the present disclosure. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus can be combined with the compounds of the present disclosure. Inhibitors of Raf, such as vemurafenib and dabrafenib can be combined with the compounds of the present disclosure. Inhibitors of MEK such as trametinib, selumetinib and GDC-0973 can be combined with the compounds of the present disclosure. Inhibitors of KIT, including avapritinib, BLU-263, imatinib, sunitinib, regorafenib, ripritinib (DCC2618), PLX9486, PLX3397, crenolanib, CDX-0158, CDX-0159. Inhibitors of RET including pralsetinib, selperctinib, alectinib, levatinib, cabozantinib, BOS172738 (DS-5010), SL-1001, TPX-0046, sitravatinib (MGCD516), and RXDX-105. Inhibitors of Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), PARP (e.g., olaparib) and Pim kinases (LGH447, INCB053914, and SGI-1776) can also be combined with compounds of the disclosure. Compounds of the disclosure or pharmaceutically acceptable salts thereof can be used in combination with one or more agents for the treatment of cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include bendamustine, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes, uracil mustard, chlormethine, cyclophosphamide (CYTOXAN), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). The compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutics. Example chemotherapeutics include any of: abarelix, abiraterone,
afatinib, aflibercept, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab, bexarotene, baricitinib, bicalutamide, bleomycin, bortezombi, bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carmustine, cediranib, cetuximab, chlorambucil, cladribine, clofarabine, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dacomitinib, dactinomycin, dalteparin sodium, dasatinib, dactinomycin, daunorubicin, decitabine, degarelix, denileukin, denileukin diftitox, deoxycoformycin, dexrazoxane, docetaxel, doxorubicin, droloxafine, dromostanolone propionate, eculizumab, enzalutamide, epidophyllotoxin, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, flutamide, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, idelalisib, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mithramycin, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, navelbene, necitumumab, nelarabine, neratinib, nilotinib, nilutamide, nofetumomab, oserelin, paclitaxel, pamidronate, panitumumab, pazopanib, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pilaralisib, pipobroman, plicamycin, cisplatin, carboplatin, oxaliplatin, ponatinib, prednisone, procarbazine, quinacrine, rasburicase, regorafenib, reloxafine, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, tegafur, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, triptorelin, uracil mustard, valrubicin, vandetanib, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate. Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin). Compounds of the disclosure or pharmaceutically acceptable salts thereof can be administered as the sole pharmaceutical agent or in combination with one or more anti-viral agents for the treatment of chronic viral infections, where the combination causes no unacceptable adverse effects. Chronic viral infections include, but are not limited to, diseases caused by: hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella zoster virus, coxsackie virus, human immunodeficiency virus (HIV). Parasitic infections (e.g. , malaria) may also be
treated by the above methods wherein compounds known to treat the parasitic conditions are optionally added in place of the antiviral agents. Suitable antiviral agents contemplated for use in combination with the compound of the disclosure or a pharmaceutically acceptable salt thereof can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs. Examples of suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-I0652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2',3'-dicleoxy-5-fluoro-cytidene); DAPD, ((- )-beta-D-2,6-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721 ; AG-1549; MKC-442 (l-(ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)- (2,4(lH,3H)-pyrirnidinedione); and (+)-calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK- 639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607. When more than one pharmaceutical agent is administered to a subject, they can be administered simultaneously, separately, sequentially, or in combination (e.g., for more than two agents). For examples, when administered together with an additional anti-cancer or antiviral agent, the disclosed compounds or pharmaceutically acceptable salts thereof can be administered simultaneously in the same pharmaceutical formulation or simultaneously in separate pharmaceutical formulations. Alternatively, when administered together with an additional anti-cancer or antiviral agent, the disclosed compounds or pharmaceutically acceptable salts thereof can be administered at separate times, depending the dosing requirements of the additional anti-cancer or antiviral agent. Pharmaceutical compositions are disclosed that include one or more compounds provided herein (such as the compound of Formulas I, II, III, IV(A), IV(B), V, VI and VII), and typically at least one additional substance, such as an excipient, a known therapeutic other than those of the disclosure, and combinations thereof. In some embodiments, the disclosed compounds or pharmaceutically acceptable salts thereof can be used in combination with other agents known to have beneficial activity targeting diseases or disorders listed
above. For example, disclosed compounds or pharmaceutically acceptable salts thereof can be administered alone or in combination with one or more anti-cancer or antiviral agent. The terms “administer”, “administering”, “administration”, and the like, as used herein, refer to methods that may be used to enable delivery of compositions to the desired site of biological action. These methods include, but are not limited to, intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, orally, topically, intrathecally, inhalationally, transdermally, rectally, and the like. Administration techniques that can be employed with the agents and methods described herein are found in e.g., Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa. A “subject” is a mammal in need of medical treatment, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like). The precise amount of compound or pharmaceutically acceptable salt thereof administered to provide an “effective amount” to the subject will depend on the mode of administration, the type, and severity of the disease or condition, and on the characteristics of the subject, such as general health, age, sex, body weight, and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. When administered in combination with other therapeutic agents, e.g., when administered in combination with an anti-cancer or antiviral agent, an “effective amount” of any additional therapeutic agent(s) will depend on the type of drug used. Suitable dosages are known for approved therapeutic agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of a compound of the disclosure or a pharmaceutically acceptable salt thereof being used by following, for example, dosages reported in the literature and recommended in the Physician’s Desk Reference (57th ed., 2003). The term “effective amount” means an amount when administered to the subject which results in beneficial or desired results, including clinical results, e.g., inhibits, suppresses or reduces the symptoms of the condition being treated in the subject as compared to a control. For example, a therapeutically effective amount can be given in unit dosage form (e.g., 0.1 mg to about 50 g per day, alternatively from 1 mg to about 5 grams per day; and in another alternatively from 10 mg to 1 gram per day).
The particular mode of administration and the dosage regimen will be selected by the attending clinician, taking into account the particulars of the case (e.g. the subject, the disease, the disease state involved, the particular treatment, and whether the treatment is prophylactic). Treatment can involve daily or multi-daily or less than daily (such as weekly or monthly etc.) doses over a period of a few days to months, or even years. The pharmaceutical composition of the disclosure is formulated to be compatible with its intended route of administration. In an embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings. In preferred embodiments, the pharmaceutical composition is formulated for intravenous administration. “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the formulation and/or administration of an active agent to and/or absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the subject. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer’s solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with or interfere with the activity of the compounds provided herein. One of ordinary skill in the art will recognize that other pharmaceutical excipients are suitable for use with disclosed compounds.
General Synthetic Methods and Intermediates Scheme 1 shows a synthetic protocol for the preparation of compounds of formula iii. Scheme 1
The alcohol substituted chloro heterocyclic intermediates i can be coupled to the substituted anilines ii under Pd-catalyzed coupling conditions to give compounds iii which are examples of MAP4K1 inhibitors described herein. The following examples are intended to be illustrative and are not meant in any way to be limiting. EXEMPLIFICATION Abbreviations ACN acetonitrile (“MeCN”) ATP adenosine triphosphate BOP benzotriazol-1-yloxytris(dimethylamino)phosphonium hexaflorophosphate BrettPhos Dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2- yl)phosphine C Celsius DAST diethylaminosulfur trifluoride DBU diazabicyclo[5.4.0]undec-7-ene DCM dichloromethane DIAD disopropyl azodicarboxylate DIPEA diisopropylethylamine DMBNH2 2,4-dimethoxybenzylamine DME dimethoxyethane DMF dimethyl formamide
DMSO dimethyl sulfoxide dppf [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium (II) DTT dithiothreitol eq equivalents EA ethyl acetate EDTA ethylenediaminetetracetic acid Et3N triethylamine FA formic acid h hours HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid HPLC high performance liquid chromatography IBX 2-iodoxybenzoic acid IC50 inhibitory concentration 50% IPA isopropanol LiHMDS lithium bis(trimethylsilyl)amide mCPBA meta-chloroperbenzoic acid Me2S dimethyl sulfide MeMgBr methyl magnesium bromide min minutes MTBE methyl tert-butyl ether MeOH methanol 2-MeTHF 2-methyltetrahydrofuran MsCl methanesulfonyl chloride NBS N-bromosuccinimide NMO N-methylmorpholine N-oxide NMP N-methyl-2-pyrrolidone Oxone® potassium peroxymonosulfate PE petroleum ether SFC supercritical fluid chromatography TBAB tetrabutylammonium bromide TBAF tetrabutylammonium fluoride TEA trimethylamine THF tetrahydrofuran
TFA trifluoroacetic acid TfOH trifluoromethanesulfonic acid TMSCF3 trifluoromethyltrimethylsilane Methods for preparing compounds of the disclosure can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent’s freezing temperature to the solvent’s boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan. Preparation of compounds of the disclosure can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Wuts and Greene, Protective Groups in Organic Synthesis, 5th ed., John Wiley & Sons: New Jersey, (2014), which is incorporated herein by reference in its entirety. Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance (NMR) spectroscopy (e.g., 1H or 13C), infrared (IR) spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry (MS), or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC). Analytical instruments and methods for compound characterization: LC-MS: Unless otherwise indicated, all liquid chromatography-mass spectrometry (LC-MS) data (sample analyzed for purity and identity) were obtained with an Agilent model-1260 LC system using an Agilent model 6120 mass spectrometer utilizing ES-API ionization fitted with an Agilent Poroshel 120 (EC-C18, 2.7 um particle size, 3.0 x 50mm dimensions) reverse-phase column at 22.4 degrees Celsius. The mobile phase consisted of a mixture of solvent 0.1% FA in water and 0.1% FA in acetonitrile. A constant gradient from
95% aqueous/5% organic to 5% aqueous/95% organic mobile phase over the course of 4 minutes was utilized. The flow rate was constant at 1mL/min. Prep LC-MS: Preparative HPLC was performed on a Shimadzu Discovery VP® Preparative system fitted with a Luna 5u C18(2) 100A, AXIA packed, 250 x 21.2 mm reverse-phase column at 22.4 degrees Celsius. The mobile phase consisted of a mixture of solvent 0.1% FA in water and 0.1% FA in ACN. A constant gradient from 95% aqueous/5% organic to 5% aqueous/95% organic mobile phase over the course of 25 minutes was utilized. The flow rate was constant at 20 mL/min. Reactions carried out in a microwave were done so in a Biotage Initiator microwave unit. Silica gel chromatography: Silica gel chromatography was performed on either a Teledyne Isco CombiFlash® Rf unit or a Biotage® Isolera Four unit. Proton NMR: Unless otherwise indicated, all 1H NMR spectra were obtained with a Varian 400MHz Unity Inova 400 MHz NMR instrument (acquisition time = 3.5 seconds with a 1 second delay; 16 to 64 scans). Where characterized, all protons were reported in DMSO- d6 solvent as parts-per million (ppm) with respect to residual DMSO (2.50 ppm). One of ordinary skill in the art will recognize that modifications of the gradient, column length, and flow rate are possible and that some conditions may be more suitable for compound characterization than others, depending on the chemical species being analyzed. Example 1: Synthesis of arylamine intermediates Example 1a
Intermediates 1 and 2: (7S,8R)-2-Amino-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one (Intermediate 1) and (7R,8S)-2-amino-7,8-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one (Intermediate 2)
each of which is represented by the structures shown below:
Step 1: Methyl (E)-2-(but-2-en-2-yl)-6-methoxynicotinate K3PO4 (120 g, 565 mmol, 3.00 eq) and Pd(dppf)Cl2-CH2Cl2 (7.70 g, 9.42 mmol, 0.05 eq) were added to a solution of methyl 2-chloro-6-methoxynicotinate (38.0 g, 188 mmol, 1.00 eq) and (Z)-2-(but-2-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (44.6 g, 245 mmol, 1.30 eq) in THF (320 mL) and H2O (80.0 mL). The reaction mixture was stirred under N2 at 70 °C for 2 h. The reaction mixture was diluted with water (300 mL) and extracted with EA (250 mL x 3). The organic layers were combined and dried over sodium sulfate, then filtered and concentrated in vacuo to give the residue. The residue was purified by prep-HPLC (ACN-H2O gradient with 0.1% TFA additive). The product-containing fractions were adjusted to pH = 8–9 with solid sodium carbonate and the mixture was extracted with EA (300 mL x 3). The combined organic layers were washed with brine (500 mL), dried over
Na2SO4, filtered and concentrated to give the title compound (37.0 g, 167 mmol, 88.7% yield) as a yellow oil. Step 2: 2-Methoxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one A solution of methyl (E)-2-(but-2-en-2-yl)-6-methoxynicotinate (37.0 g, 167 mmol, 1.00 eq) in TfOH (171 g, 1.15 mol, 101 mL, 6.85 eq) was stirred at 80 °C for 0.5 h. The mixture was then cooled to ambient temperature, poured into saturated aqueous NaHCO3 solution (1000 mL) and extracted with EA (300 mL x 5). The organic layers were dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 1% to 25% EA-PE) to give the title compound (30.0 g, 144 mmol, 86.6% yield) as a yellow oil. Steps 3: 2-Hydroxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one A mixture of 2-methoxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (30.0 g, 144 mmol, 1.00 eq) and pyridine-hydrochloride (41.8 g, 361 mmol, 2.50 eq) was stirred at 150 °C for 0.5 h. The reaction mixture was purified directly by flash-column chromatography on silica gel (gradient elution, 2% to 10% MeOH-DCM) to give the title compound (26.0 g, 134 mmol, 92.9% yield) as a yellow solid. Step 4: rac-(7S,8S)-2-Hydroxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5- one and rac-(7S,8R)-2-hydroxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one DBU (60.8 mL, 403 mmol, 3.00 eq) was added to a solution of 2-hydroxy-7,8- dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (26.0 g, 134 mmol, 1.00 eq) in toluene (290 mL). The reaction mixture was stirred at 100 °C for 12 h, then was cooled to ambient temperature and concentrated under vacuum. The residue was purified by flash-column chromatography on silica gel (gradient elution, 1% to 10% MeOH-DCM) to afford the title compounds as a mixture of isomers that were used in the next step without further purification. Step 5: rac-(7S,8S)-2-Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5- one and rac-(7S,8R)-2-chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one A mixture of rac-(7S,8S)-2-hydroxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one and rac-(7S,8R)-2-hydroxy-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one (26.0 g, 134 mmol, 1 equiv) in POCl3 (150 mL, 1.61 mol, 11.9 equiv) was stirred at 100 °C for 1 h. The reaction mixture was then cooled to ambient temperature and poured into saturated aqueous NaHCO3 solution (2 L) at 0-10 °C. The quenched mixture was extracted with EA (300 mL x 3) and the combined organic layers were washed with brine,
dried over sodium sulfate, filtered, and concentrated. The cis-and trans- racemic isomers were separated by prep-HPLC (column: Phenomenex luna C18250*50mm*10 um; mobile phase: [water(0.1%TFA)-ACN];B%: 35% ACN-55% CAN over 20min). rac-(7S,8S)-2- Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one was the first compound to elute and was obtained as a white solid. MS (ES+) C10H10ClNO2 requires: 211, found: 212[M+H]+.1H NMR: 400 MHz, CDCl3 δ 8.29 (d, J = 8.2 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 4.83 (dq, J = 3.2, 6.6 Hz, 1H), 3.09 (dq, J = 3.2, 7.2 Hz, 1H), 1.49 (d, J = 6.5 Hz, 3H), 1.30 (d, J = 7.2 Hz, 3H). rac-(7S,8R)-2-Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one was the second compound to elute and was obtained as a white solid. MS (ES+) C10H10ClNO2 requires: 211, found: 212[M+H]+.1H NMR: 400 MHz, CDCl3 δ 8.28 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 4.58 - 4.43 (m, 1H), 3.05 (quin, J = 7.2 Hz, 1H), 1.56 - 1.40 (m, 6H). Step 6: (7S,8R)-2-Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one and (7R,8S)-2-chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one rac-(7S,8R)-2-Chloro-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one was separated by SFC (column: DAICEL CHIRALPAK AD (250mm x 50mm,10um); mobile phase: MeOH in CO2) to give the first eluting isomer (peak 1) as a white solid and second eluting isomer (peak 2) as a white solid. Step 7: (7S,8R)-2-((2,4-Dimethoxybenzyl)amino)-7,8-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one DIPEA (7.48 g, 57.8 mmol, 10.1 mL, 2.50 eq) and DMBNH2 (5.03 g, 30.1 mmol, 4.53 mL, 1.30 eq) were added to a solution of (7S,8R)-2-chloro-7,8-dimethyl-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-5-one (1st eluting isomer (peak 1) from Step 6 above) (4.90 g, 23.1 mmol, 1.00 eq) in NMP (50.0 mL). The reaction mixture was stirred at 100 °C for 1 h, then was poured into water (500 mL) and extracted with EA (100 mL x 3). The combined organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered and concentrated to give the title compound (7.93 g, crude) as a yellow oil that was used directly in the next step. MS (ES+) C19H11N2O4 requires: 342, found: 343[M+H]+. Step 8: (7S,8R)-2-Amino-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one A solution of (7S,8R)-2-((2,4-Dimethoxybenzyl)amino)-7,8-dimethyl-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-5-one (7.93 g, 23.1 mmol, 1.00 eq) in HCl/dioxane (4.00 M, 50.0 mL, 8.64 eq) was stirred at 70 °C for 1 h. The reaction mixture was then concentrated and partitioned between saturated aqueous sodium bicarbonate solution (100 mL) and was
extracted with DCM (100 mL x 3). The combined organic layer was washed with brine (200 mL), dried over sodium sulfate, filtered and concentrated. The residue was triturated in MTBE (50 mL) for 10 mins and filtered to get a yellow solid. The yellow solid was dried under vacuum to give the title compound, Intermediate 1(3.23 g, 16.4 mmol, 71.2% yield, 98.1% purity). MS (ES+) C10H12N2O2 requires: 192, found: 193[M+H]+.1H NMR: 400 MHz, DMSO-d6 δ 7.77 (d, J = 8.6 Hz, 1H), 6.97 (s, 2H), 6.40 (d, J = 8.6 Hz, 1H), 4.43 - 4.21 (m, 1H), 2.88 - 2.65 (m, 1H), 1.35 (d, J = 6.4 Hz, 3H), 1.25 (d, J = 7.0 Hz, 3H). The absolute stereochemistry of Intermediate 1 was determined by X-ray crystal structure. Steps 9 and 10: (7R,8S)-2-Amino-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one The title compound (Intermediate 2) was prepared separately from (7R,8S)-2-chloro- 7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (the second eluting isomer (peak 2) of Step 6) using the same two-step procedure as described in Steps 7 and 8 for Intermediate 2. MS (ES+) C10H12N2O2 requires: 192, found: 193[M+H]+.1H NMR: 400 MHz, DMSO-d6 δ 7.77 (d, J = 8.6 Hz, 1H), 6.97 (s, 2H), 6.40 (d, J = 8.6 Hz, 1H), 4.43 - 4.21 (m, 1H), 2.88 - 2.65 (m, 1H), 1.35 (d, J = 6.4 Hz, 3H), 1.25 (d, J = 7.0 Hz, 3H).
Intermediates 3 and 4: (R)-2-amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one and (S)-2-amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one
each of which is represented by the structure shown below:
Steps 1-5: rac 2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one The title compound was prepared from methyl 2-chloro-6-methoxynicotinate and 4,4,5,5-tetramethyl-2-(3-methylbut-2-en-2-yl)-1,3,2-dioxaborolane using similar procedures as described above in Steps 1-3 and 5-7 for Intermediate 1. Step 6: (R)-2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one and (S)-2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8- dihydro-5H-pyrano[4,3-b]pyridin-5-one Rac 2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one was separated by SFC (column: DAICEL CHIRALPAK AS-H (250mm*30mm,5um); mobile phase: [0.1% NH4OH MeOH in CO2]) to give (R)-2-((2,4- dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (1st eluting isomer (Precursor to Intermediate 3), 0.55 g, 79% yield) and (S)-2-((2,4- dimethoxybenzyl) amino)-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (2nd eluting isomer (Precursor to Intermediate 4), 0.55 g, 79% yield). Each intermediate was isolated as a yellow oil. Step 7 and 8: (R)-2-amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5- one and (S)-2-amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one The title compounds (Intermediates 3 and 4) were prepared separately from the 1st and 2nd eluting isomers, i.e., (R)-2-((2,4-dimethoxybenzyl)amino)-7,7,8-trimethyl-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-5-one and (S)-2-((2,4-Dimethoxybenzyl)amino)-7,7,8-trimethyl- 7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one, using the same procedure as described in Step 8 of Intermediate 1. Intermediate 3, (R)-2-amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one, was obtained as a yellow solid. MS (ES+) C11H14N2O2 requires: 206, found: 207[M+H]+.1H-NMR (400 MHz, CD3OD): δ ppm 7.89 (d, J = 8.8 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 2.85-2.80 (m, 1H), 1.41 (s, 6H), 1.27 (d, J = 7.2 Hz, 3H). Intermediate 4, (S)-2- Amino-7,7,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one, was obtained as a yellow solid. MS (ES+) C11H14N2O2 requires: 206, found: 207[M+H]+.1H-NMR (400 MHz, CD3OD): δ ppm 7.89 (d, J = 8.8 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 2.85-2.80 (m, 1H), 1.41 (s, 6H), 1.27 (d, J = 7.2 Hz, 3H). The stereochemistry of Intermediate 3 was determined in the context of compound 16 using an X-ray crystal structure.
Intermediate 5: 2-Amino-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one
Step 1: 7,7-Dimethyl-1,5,7,8-tetrahydro-2H-pyrano[4,3-b]pyridin-2-one A mixture of 2,2-dimethyltetrahydro-4H-pyran-4-one (500 g, 3.90 mol, 1.00 eq) and pyrrolidine (391 mL, 4.68 mol, 1.20 eq) in toluene (4.00 L) was heated at 145 °C with a Dean-Stark trap for 2 h. The water layer (~16 mL) was removed from the Dean-Stark trap and the reaction mixture was cooled to 15 °C. After cooling, prop-2-ynamide (539 g, 7.80 mol, 2.00 eq) was added and the reaction mixture was heated to 150 °C. The reaction mixture was heated at 150 °C for 10 h, then was cooled to ambient temperature. The cooled reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash-column chromatography on silica gel (10% methanol-dichloromethane) to give the title compound (560 g, 62% yield) as a yellow solid. Step 2: 2-Chloro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine A solution of 7,7-dimethyl-1,5,7,8-tetrahydro-2H-pyrano[4,3-b]pyridin-2-one (500 g, 2.23 mol, 1 eq) in POCl3 (350 mL, 3.77 mol, 9.64 eq) was heated to 100 °C for 6 h. The reaction mixture then cooled to ambient temperature and concentrated under vacuum. The residue was poured over ice-water (1.00 L). The mixture was extracted with EA (750 mL x 2). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum to give the title compound (363 g, 82.2% yield) as a brown oil. Step 3: 2-Chloro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one A solution of NaIO4 (487 g, 2.28 mol, 3.00 eq) in water (1.20 L) as added to a mixture of 2-chloro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine (150 g, 759 mmol, 1.00 eq)
in MeCN (50.0 mL) and CCl4 (2.70 L). The mixture was cooled to 0 °C, and then RuCl3 (11.0 g, 53.1 mmol, 0.07 eq) was added. The reaction mixture was stirred at 0 °C for 0.5 h, then was warmed to 20 °C for 11.5 h. Saturated aqueous sodium sulfite solution (1.00 L) was added, and the mixture was filtered. The filtrate was extracted with EA (500 mL x 3), and the organic layers were combined. The combined organic layer was washed with brine (1.00 L), dried over Na2SO4, filtered and concentrated to give the title compound (132 g, 624 mmol, 82.1% yield) as a yellow solid. Step 4: 2-((2,4-Dimethoxybenzyl)amino)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one (2,4-Dimethoxyphenyl) methanamine (160 g, 957 mmol, 1.50 eq) was added to a solution of 2-chloro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (135 g, 638 mmol, 1.00 eq) and DIPEA (222 mL, 1.28 mol, 2.00 eq) in NMP (1.08 L) at ambient temperature. The reaction mixture was heated to 140 °C for 2 h, and then was cooled to ambient temperature. The reaction mixture was then partitioned between water (700 mL) and EA. The layers were separated, and the aqueous layer was further extracted with EA (500 mL x 3). The organic layers were combined and washed with brine (400 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound as a yellow solid (160 g). The crude product was used for next step directly. Step 5: 2-Amino-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one HCl (4.0 M in dioxane, 1.20 L, 11.0 equiv) was added to : 2-((2,4-dimethoxybenzyl) amino)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (150 g, 438 mmol, 1.00 eq) at 20 °C. The reaction mixture was heated to 60 °C for 2 h, then was cooled to ambient temperature and concentrated under vacuum. The residue was poured into saturated NaHCO3 aqueous solution (1.00 L) and extracted with EA (500 mL x 4). The combined organic layer was washed with brine (500 x 2), dried over Na2SO4, filtered and concentrated. The residue was dissolved in EA (300 mL) and petroleum ether (150 mL) was added drop wise to get yellow slurry. The solids were filtered and collected to give the title compound (52.0 g, 60.9% yield) as a yellow solid. MS (ES+) C10H12N2O2 requires: 192, found: 193[M+H]+.1H NMR (400 MHz, DMSO-d6) δ 7.76 (d, J = 8.4 Hz, 1H), 6.98 (s, 2H), 6.39 (d, J = 8.8 Hz, 1H), 2.89 (s, 2H), 1.37 (s, 6H).
Example 1d Intermediate 6: 2-Amino-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one Step 1: 2-Amino-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one The title compound was prepared from tetrahydro-4H-pyran-4-one using the same five-step procedure described in Steps 1-5 for Intermediate 5. MS (ES+) C8H8N2O2 requires: 164, found: 165[M+H]+.1H NMR, 400 MHz, DMSO-d6, δ = 7.77 (d, J = 8.8 Hz, 1H), 7.01 (s, 2H), 6.41 (d, J = 8.8 Hz, 1H), 4.44 - 4.41 (m, 2H), 2.88 – 2.85 (m, 2H). Example 1e Intermediate 7: 2'-Amino-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-5'-one
Step 1: Methyl 2-(3-bromo-6-chloropyridin-2-yl)acetate LiHMDS (1 M, 388 mL) was added to a solution of 3-bromo-6-chloro-2- methylpyridine (20.0 g, 96.9 mmol) in THF (300 mL) at 25 °C under nitrogen. After 2.5 h, dimethyl carbonate (14.0 g, 155 mmol) was added to the mixture and stirred at 25 °C for 13.5 h. The reaction mixture was then was added to saturated aqueous NH4Cl (1000 mL) and extracted with EA (60 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash- column chromatography on silica gel (gradient elution, 0% to 10% EA-petroleum ether) to give the title compound (18.0 g, 70% yield) as a yellow oil.1H NMR (400 MHz, CDCl3): δ ppm 7.81 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 4.039s, 2H), 3.74 (s, 3H). Step 2: Methyl 1-(3-bromo-6-chloropyridin-2-yl)cyclopropane-1-carboxylate Tetrabutylammonium bromide (2.44 g, 7.56 mmol) and NaOH (50 mL, 50 wt% in water) were added to a solution of 1,2-dibromoethane (10.7 g, 56.7 mmol) and methyl 2-(3- bromo-6-chloropyridin-2-yl)acetate (10.0 g, 37.8 mmol) in toluene (50 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 16 h, then was diluted with water (300 mL) and extracted with EA (200 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash- column chromatography on silica gel (gradient elution, 0% to 10% EA-petroleum ether) to give the title compound (6.10 g, 56% yield) as a yellow solid.1H NMR (400 MHz, CDCl3): δ ppm 7.81 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 8.0 Hz, 1H), 3.66 (s, 3H), 1.81-1.75 (m, 2H), 1.46- 1.41 (m, 2H). Step 3: (1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)methanol Diisobutylaluminium hydride (1 M, 56 mL) was added to a solution of methyl 1-(3- bromo-6-chloropyridin-2-yl)cyclopropane-1-carboxylate (5.40 g, 18.6 mmol) in DCM (80 mL) at –78 °C under nitrogen. The reaction mixture was stirred at –78 °C for 0.5 h, then was quenched by addition of aqueous saturated NH4Cl solution (50 mL), diluted with water (200 mL) and extracted with EA (200 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the crude title compound (5.00 g, crude) as a yellow solid which was used in the next step without further purification. Step 4: Methyl 5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridine]-2'- carboxylate Triethylamine (2.31 g, 22.9 mmol) and Pd(dppf)Cl2 (557 mg, 762 μmol) were added to a solution of (1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)methanol in MeOH (25 mL)
and DMF (25 mL) under nitrogen atmosphere. The suspension was degassed under vacuum and purged with carbon monoxide several times. The mixture was stirred under carbon monoxide (50 psi) at 80 °C for 16 h. The reaction mixture was then concentrated to remove methanol, diluted with water (100 mL) and extracted with EA (60 mL × 3). The combined organic layers were washed with brine (100 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The title compound (1.8 g, crude) was obtained as a yellow solid and used in the next step without further purification. MS (ES+) C10H10N2O2 requires: 233, found: 234[M+H]+. Step 5: 5'-Oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridine]-2'-carboxylic acid Lithium hydroxide (555 mg, 23.2 mmol) was added to a solution of methyl 5'-oxo- 5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridine]-2'-carboxylate (1.80 g, 7.72 mmol) in methanol (30 mL) and water (10 mL). The reaction mixture was stirred at 25 °C for 0.5 h, then was concentrated to remove the methanol. The mixture was diluted with water (60 mL) and extracted with EA (50 mL × 3). The aqueous layer was acidified by addition aqueous hydrochloric acid solution (6 M, 5 mL), then the mixture was extracted with EA (50 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (1.20 g, 71% yield) as a brown solid that was used without further purification. Step 6: tert-Butyl (5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'- yl)carbamate Triethylamine (831 mg, 8.21 mmol) and diphenyl phosphoryl azide (2.26 g, 8.21 mmol) were added to a solution of 5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridine]-2'-carboxylic acid (1.20 g, 5.47 mmol) in tert-butanol (20 mL). The reaction mixture was stirred at 100 °C for 1 h, then was cooled to ambient temperature, diluted with water (60 mL), and extracted with EA (50 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0% to 50% EA- petroleum ether) to give the title compound (330 mg, 19% yield) as a yellow solid and 2'- amino-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-5'-one (420 mg, 28% yield) as a yellow oil.
Step 7: 2'-Amino-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-5'-one HCl in dioxane (4.0 M, 0.5 mL) was added to a solution of tert-butyl (5'-oxo-5'H,7'H- spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate (100 mg, 344 μmol) in dioxane (1.5 mL) at 25 °C. The reaction mixture was stirred for 10 min, then was concentrated. DCM (2 mL) and TFA (1 mL, 13.5 mmol) were added to the residue, and the reaction mixture was stirred at 25 °C for 30 min. The reaction mixture was then concentrated and EA (5 mL) was added to the residue. The mixture was neutralized by addition of saturated aqueous NaHCO3 (20 mL) and extracted with EA (15 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under to give the title compound (60.0 mg, 92% yield) as a yellow oil that was used in the next step without further purification. MS (ES+) C12H11NO4 requires: 190, found: 191[M+H]+. Example 1f
Intermediates 8 and 9: (R)-2'-Amino-7'-methyl-5'H,7'H-spiro[cyclopropane-1,8'- pyrano[4,3-b]pyridin]-5'-one and (S)-2'-Amino-7'-methyl-5'H,7'H-spiro[cyclopropane-1,8'- pyrano[4,3-b]pyridin]-5'-one
each of which is represented by one of the structures shown below:
which is represented by one of the structures shown below:
Step 1: 1-(3-Bromo-6-chloropyridin-2-yl)cyclopropane-1-carbaldehyde IBX (6.50 g, 10.7 mmol, 46% purity) was added to a solution of (1-(3-bromo-6- chloropyridin-2-yl)cyclopropyl)methanol (2.65 g, 10.1 mmol) in EA (80 mL). The reaction mixture was stirred at 80 °C for 1 h, then additional IBX (2.00 g, 3.29 mmol, 46% purity) was added. The reaction mixture was stirred at 80 °C for 0.5 h, then was filtered and concentrated to give the title compound (2.60 g, crude) as a yellow solid that was used without further purification. MS (ES+) C9H7BrClNO requires: 261, found: 262 [M+H]+. Step 2: 1-(1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)ethan-1-ol Methylmagnesium bromide (3 M, 17 mL) was added to a solution of 1-(3-bromo-6- chloropyridin-2-yl)cyclopropane-1-carbaldehyde (2.60 g, 9.98 mmol) in THF (80 mL) at 0 °C. The reaction mixture was stirred for 10 min, then was quenched by addition of aqueous saturated NH4Cl solution (80 mL), diluted with water (40 mL) and extracted with EA (80 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (2.70 g, crude) as a yellow oil that was used without further purification. MS (ES+) C10H11N2O2 requires: 277, found: 278 [M+H]+. Steps 3-5: tert-Butyl (7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridin]-2'-yl)carbamate The title compound was prepared from 1-(1-(3-bromo-6-chloropyridin-2- yl)cyclopropyl)ethan-1-ol using a similar procedure as described in Steps 4-6 for Intermediate 7 above.
NMR (400 MHz, CDCl3): δ ppm 8.29 (d, J = 8.8 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 4.63-4.53 (m, 1H), 1.61 (s, 3H), 1.53 (s, 9H), 1.38-1.35 (m,1 H), 1.09-1.00 (m, 2H).
Step 6: tert-Butyl (R)-(7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridin]-2'-yl)carbamate and tert-butyl (S)-(7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane- 1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate tert-Butyl (7'-methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]- 2'-yl)carbamate (400 mg) was separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm × 50 mm, 10 um), EtOH gradient in CO2 with 0.1% NH4OH) to give two separate peaks. The first eluting isomer (100 mg, 24% yield) and second eluting isomer (140 mg, 34% yield) were obtained as yellow solids. Step 7: One of (R or S)-2'-amino-7'-methyl-5'H,7'H-spiro[cyclopropane-1,8'- pyrano[4,3-b]pyridin]-5'-one TFA (2.31 g, 20.3 mmol) was added to a solution of one of tert-butyl (R or S)-(7'- methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate (first eluting isomer from Step 6, 100 mg) in DCM (6 mL). The reaction mixture was stirred at 25 °C for 30 min, then was quenched with saturated aqueous NaHCO3 solution (30 mL) and extracted with DCM (20 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (Intermediate 8, 70 mg, crude) as a yellow oil that was used without further purification. MS (ES+) C11H12N2O2 requires: 204, found: 205[M+H]+. Step 8: The remaining one of (R or S)-2'-amino-7'-methyl-5'H,7'H- spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-5'-one The title compound (Intermediate 9) was prepared from one of tert-butyl (R or S)-(7'- methyl-5'-oxo-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3-b]pyridin]-2'-yl)carbamate (second eluting isomer from Step 6) using the same procedure as described in Step 7 for Intermediate 8. MS (ES+) C11H12N2O2 requires: 204, found: 205[M+H]+. Example 1g
Intermediate 10: 2'-Amino-7',7'-dimethyl-5'H,7'H-spiro[cyclopropane-1,8'- pyrano[4,3-b]pyridin]-5'- one
Step 1: 2-(1-(3-Bromo-6-chloropyridin-2-yl)cyclopropyl)propan-2-ol To a solution of methyl 1-(3-bromo-6-chloropyridin-2-yl)cyclopropane-1-carboxylate (1.3 g, 4.47 mmol) in THF (10 mL) was added MeMgBr (3 M, 14.9 mL) at 25 ⁰C. The reaction mixture was stirred at 25 ⁰C for 10 min, then was poured into water (20 mL) and extracted with EA (50 mL × 3). The organic layers were combined and dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE/EA =1/0 to 50/1) to give the title compound (500 mg, 38% yield) as colorless oil. Steps 2-5: 2'-Amino-7',7'-dimethyl-5'H,7'H-spiro[cyclopropane-1,8'-pyrano[4,3- b]pyridin]-5'-one The title compound was prepared from 2-(1-(3-Bromo-6-chloropyridin-2-yl) cyclopropyl)propan-2-ol using a similar procedure as described in Steps 4-6 for Intermediate 7 and Step 7 of Intermediate 8 above.1H NMR (400 MHz, CDCl3): δ ppm 8.05 (d, J = 8.4 Hz, 1H), 6.36 (d, J = 8.8 Hz, 1H), 4.85 (s, 2H), 1.42-1.32 (m, 8H), 1.06-1.03 (m, 2H). Example 1h
Intermediate 11: 2-Amino-7,7-dimethyl-8,9-dihydrooxepino[4,3-b]pyridin-5(7H)- one
Step 1: Methyl (E)-3-(6-((tert-butoxycarbonyl)amino)pyridin-2-yl)acrylate Pd(OAc)2 (1.23 g, 5.49 mmol) , P(o-tolyl)3 (2.51 g, 8.24 mmol) and diisopropylethylamine (71.0 g, 549 mmol, 95.7 mL) were added to a solution of tert-butyl (6- bromopyridin-2-yl)carbamate (15.0 g, 54.9 mmol) and methyl acrylate (18.9 g, 220 mmol, 19.8 mL) in N,N-dimethyl formamide (150 mL). The reaction mixture was stirred at 100 °C for 1 h, then was diluted EA (200 mL) and washed with brine (200 mL×3). The organic layers were dried over sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 10% to 33% EA-petroleum ether) to give the title compound (7.00 g, 39% yield) as a yellow solid. Step 2: Methyl 3-(6-((tert-butoxycarbonyl)amino)pyridin-2-yl)propanoate Pd/C (100 mg, 10% purity) was added to a solution of methyl (E)-3-(6-((tert-butoxy carbonyl)amino)pyridin-2-yl)acrylate (7.00 g, 25.2 mmol) in methanol (100 mL). The mixture was stirred at 25 °C for 12 h under hydrogen, then was filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 10% to 33% EA-petroleum ether) to give the title compound (6.00 g, 18.6 mmol, 74% yield) as a yellow solid.
Step 3: tert-Butyl (6-(3-hydroxy-3-methylbutyl)pyridin-2-yl)carbamate Methyl magnesium bromide (3 M, 35.7 mL) was added to a solution of methyl 3-(6- ((tert-butoxycarbonyl)amino)pyridin-2-yl)propanoate (6.00 g, 21.4 mmol) in tetrahydrofuran (100 mL) at 0°C. The reaction mixture was stirred at 25 °C for 0.5 h, then was poured into water (200 mL) and extracted with EA (50 mL×3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 15% to 50% EA-petroleum ether) to give the title compound (5.00 g, 15.9 mmol, 74 % yield) as a yellow solid. Step 4: tert-Butyl (5-bromo-6-(3-hydroxy-3-methylbutyl)pyridin-2-yl)carbamate N-Bromosuccinimide (3.17 g, 17.8 mmol) in acetonitrile (50 mL) was added to a solution of tert-butyl (6-(3-hydroxy-3-methylbutyl)pyridin-2-yl)carbamate (5.00 g, 17.8 mmol) in acetonitrile (50 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 1 h, then was poured into water (200 mL) and extracted with EA (50 mL×3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 10% to 33% EA-petroleum ether) to give the title compound (4.00 g, 62% yield) as a yellow solid. 1H-NMR (400 MHz, CDCl3): δ ppm 7.72 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.39 (S, 1H), 2.99-2.93 (m, 2H), 1.87-1.78 (m, 2H), 1.49 (s, 9H), 1.27 (s, 6H). Step 5: 6-((tert-Butoxycarbonyl)amino)-2-(3-hydroxy-3-methylbutyl)nicotinic acid n-Butyllithium (2.5 M, 11.1 mL) was added to a solution of tert-butyl (5-bromo-6-(3- hydroxy-3-methylbutyl)pyridin-2-yl)carbamate (2.00 g, 5.57 mmol) in tetrahydrofuran (50 mL) at -78 °C. The reaction mixture was stirred at -78 °C for 10 min, then carbon dioxide was added, and the mixture was stirred at -78 °C for 20 min. The reaction mixture was then poured into water (100 mL) and extracted with ethyl acetate (30 mL ×3). The organic layers were discarded, and aqueous ammonium chloride solution was added to the aqueous layer to adjust pH <7. The mixture was extracted with EA (30 mL × 5), and the combined organic layers was dried over sodium sulfate, filtered and concentrated to give the title compound (200 mg, crude) as a yellow solid. Step 6: tert-Butyl (7,7-dimethyl-5-oxo-5,7,8,9-tetrahydrooxepino[4,3-b]pyridin-2- yl)carbamate Dicyclohexylcarbodiimide (229 mg, 1.11 mmol, 225 μL) was added to a solution of 6-((tert-butoxycarbonyl)amino)-2-(3-hydroxy-3-methylbutyl)nicotinic acid (180 mg, crude) and 4-N,N-dimethylaminopyridine (33.9 mg, 277 μmol) in dichloromethane (20 mL). The
reaction mixture was stirred at 25 °C for 12 h, then was concentrated to give the residue. The residue purified by prep-TLC on silica gel (33% EA-petroleum ether) to give the title compound (30.0 mg, crude) as a yellow solid. Step 7: 2-Amino-7,7-dimethyl-8,9-dihydrooxepino[4,3-b]pyridin-5(7H)-one The title compound was prepared from tert-butyl (7,7-dimethyl-5-oxo-5,7,8,9- tetrahydrooxepino[4,3-b]pyridin-2-yl)carbamate using a similar procedure as describe in Step 7 of Intermediate 8.1H-NMR (400 MHz, CDCl3): δ ppm 7.92 (d, J = 8.8 Hz, 1H), 6.36 (d, J = 8.8 Hz, 1H), 5.17 (s, 2H), 2.96-2.92 (m, 2H), 2.11-2.09 (m, 2H), 1.33 (s, 6H). Example 1i
Intermediates 12 and 13: (R)-2-Amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-5-one or (S)-2-amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one
Step 1: Methyl 2-(3-bromo-6-chloropyridin-2-yl)-2-methylpropanoate Sodium hydride (2.91 g, 72.8 mmol, 60% purity) was added to a solution of methyl 2- (3-bromo-6-chloropyridin-2-yl)acetate (5.50 g, 20.8 mmol) in tetrahydrofuran (20 mL) at 0 °C. The reaction mixture was stirred for 15 minutes at 0 °C, then iodomethane (7.38 g, 51.9
mmol) was added. The reaction mixture was warmed to 25 °C and stirred for 45 minutes, then was quenched with water (30 mL) and extracted with EA (30 mL× 2). The combined organic layers were concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0% to 10% EA-petroleum ether) to give the title compound (5.5 g, 90% yield) as a yellow oil.1H NMR (400 MHz, CD3OD): δ ppm 7.97 (d, J = 8.4 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 3.95 (s, 2H), 1.50 (s, 6H). Step 2: 2-(3-Bromo-6-chloropyridin-2-yl)-2-methylpropan-1-ol The title compound was prepared from methyl 2-(3-bromo-6-chloropyridin-2-yl)-2- methylpropanoate using a procedure similar to that described in Step 3 of Intermediate 7. Steps 3-7: (rac)-2-Amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-on The title compound was prepared from 2-(3-bromo-6-chloropyridin-2-yl)-2- methylpropan-1-ol using a similar procedure as described in Steps 1-5 of Intermediate 8. C11H14N2O2 requires: 206, found: 207 [M+H]+. Step 8: (R)-2-Amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one or (S)-2-amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (rac)-2-Amino-7,8,8-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (120 mg) was separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm × 50 mm, 10 um), MeOH gradient in CO2 with 0.1% NH4OH) to give two peaks separately. The first eluting isomer (Intermediate 12, 60 mg, 50% yield) and second eluting isomer (Intermediate 13, 60 mg, 50% yield) were obtained as yellow solids. Example 1j
Intermediate 14: 2-(2-Fluoropropan-2-yl)pyrimidin-4-amine
Step 1: Ethyl 4-aminopyrimidine-2-carboxylate Triethylamine (285 g, 2.81 mol, 2.00 equiv) was added dropwise to a solution of ethyl 2-amino-2-iminoacetate hydrochloride (215 g, 1.41 mol, 1.00 equiv) and 2-chloroprop-2- enenitrile (112 mL, 1.41 mol, 1.00 eq) in EtOH (1.8 L) at 0°C. The mixture was allowed to warm to 25 °C and stirred at 25 °C for 6 h. The reaction mixture was concentrated, and the residue was partitioned between water (10.0 L) and EA (5.0 L). The layers were separated, and the aqueous layer was extracted with EA (5.0 L x 2). The organic layers were combined and dried over Na2SO4. The dried solution was filtered, and the filtrate was concentrated to give the title compound (270 g, crude) as a dark brown solid. Step 2: 2-(4-Aminopyrimidin-2-yl)propan-2-ol Methylmagnesium bromide (900 mL, 3.0 M, 5.0 eq) was added to a solution of ethyl 4-aminopyrimidine-2-carboxylate (90.0 g, 538 mmol, 1.00 eq) in 2-MeTHF (1.00 L) at -20 °C. The reaction mixture was allowed warm to 0 °C and stirred at that temperature for 1 h. The reaction mixture was diluted with saturated aqueous ammonium chloride solution (10.0 L) and the aqueous layer was extracted with EA (3.0 L x 4). The organic layers were combined and dried over Na2SO4, and the dried solution was filtered. The filtrate was concentrated to give the title compound (50 g, crude) as a dark brown solid. Step 3: 2-(2-Fluoropropan-2-yl)pyrimidin-4-amine DAST (414 mL, 3.13 mol, 10.0 eq) was added to a solution of 2-(4-aminopyrimidin- 2-yl)propan-2-ol (48.0 g, 313 mmol, 1.00 eq) in DCM (1.30 L) at 0°C. The reaction mixture was stirred at 0°C for 0.5 h, and then was diluted with water (4.50 L). The reaction mixture was adjusted to pH = 7~8 with aqueous sodium hydroxide solution (0.50 L) and sodium carbonate solution (200 mL), then was extracted with EA (2.00 L x 3). The organic layers were combined and dried over Na2SO4, and the dried solution was filtered and concentrated. The residue was purified by rp-HPLC (neutral condition) to give the title compound (13.0 g) as a white solid.
NMR (400MHz DMSO-d6) δ 8.05 - 8.07 (d, J = 5.6Hz), 6.93 (s, 1H), 6.32 - 6.33 (d, J = 5.6Hz, 1H), 1.63 (s, 3H), 1.58 (s, 3H).
Example 1k
Intermediate 15: 5-Amino-3-isopropylpyrazine-2-carbonitrile
Step 1: 5-Amino-3-(prop-1-en-2-yl)pyrazine-2-carbonitrile A mixture of 5-amino-3-chloropyrazine-2-carbonitrile (50.0 g, 324 mmol, 1.00 eq), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (81.54 g, 485.3 mmol, 1.50 eq), K2CO3 (89.42 g, 647.0 mmol, 2.00 eq), and Pd(PPh3)4 (18.69 g, 16.18 mmol, 0.05 eq) in dioxane (250 mL) and H2O (50 mL) was stirred at 100°C for 20 h under N2. The reaction mixture was then cooled to ambient temperature and diluted with EA (800 mL) and H2O (300 mL). The biphasic mixture was then filtered through celite, then partitioned. The organic layer was washed with brine (500 mL x 4), and then the organic layer was dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash-column chromatography on silica gel (gradient elution, 10% to 33% EA-petroleum ether) to give the title compound (41.0 g, 39.0% yield) as a light yellow solid. Step 2: 5-Amino-3-isopropylpyrazine-2-carbonitrile Pd/C (10 wt%, 10.0 g) was added to a solution of 5-amino-3-(prop-1-en-2- yl)pyrazine-2-carbonitrile (45.0 g, 281 mmol, 1.00 eq) in MeOH (800 mL). The suspension was degassed under vacuum and purged with H2 three times. The reaction mixture was stirred under H2 (15 psi) at 25 °C for 16 h. The mixture was filtered through celite and the filtrate was concentrated under vacuum. The residue was treated with petroleum ether/EA (110 mL, 10:1) and stirred at 25°C for 10 min, then filtered. The filter cake was dried under vacuum to give the title compound (39.5 g, 85.6% yield) as a light yellow solid. MS (ES+) C8H10N4 requires: 162, found: 163[M+H]+.1H
NMR: 400 MHz CDCl3 δ: 7.83 (s, 1H), 5.07 (br s, 2H), 3.43-3.33 (m, 1H), 1.28 (s, 3H), 1.26 (s, 3H).
Example 1l
Intermediate 16: (S)-5-Amino-3-(2-methylpyrrolidin-1-yl)pyrazine-2-carbonitrile
Step 1: (S)-5-Amino-3-(2-methylpyrrolidin-1-yl)pyrazine-2-carbonitrile N,N-Diisopropylethylamine (0.237 mL, 1.36 mmol, 3.00 equiv) was added to a mixture of 5-amino-3-chloropyrazine-2-carbonitrile (70.0 mg, 453 umol, 1.00 equiv) and (S)- 2-methylpyrrolidine (HCl salt, 71.6 mg, 589 umol, 1.30 equiv) in 2-methyl-2-butanol (2 mL). The reaction mixture was stirred at 100 °C for 3 h, then was poured into 20 mL of water and extracted with EA (15 mL×3). The organic layers were dried by anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (90.0 mg, crude) as a yellow solid that was used without further purification. MS (ES+) C10H13N5 requires: 203, found: 204[M+H]+. Example 1m
Intermediate 17: (S)-2-(2-Methylpyrrolidin-1-yl)pyrimidin-4-amine
Step 1: (S)-2-(2-Methylpyrrolidin-1-yl)pyrimidin-4-amine A mixture of 2-chloropyrimidin-4-amine (1.0 g, 7.72 mmol), (2S)-2- methylpyrrolidine hydrochloride (1.03 g, 8.49 mmol), and DIPEA (2.02 mL, 11.6 mmol) in IPA (15 mL) was heated to 95 °C in a sealed vial. The reaction mixture was stirred at 95 °C for 16 h, then was concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (0 to 10% MeOH-DCM) to give the title compound as a white solid. MS (ES+) C9H14N4 requires: 178, found: 179[M+H]+. Example 1n
Intermediate 18: (S)-2-(2-Methylazetidin-1-yl)pyrimidin-4-amine
Step 1: (S)-2-(2-Methylazetidin-1-yl)pyrimidin-4-amine The title compound was prepared from 2-chloropyrimidin-4-amine and (S)-2- methylazetidine hydrochloride using a similar procedure as described above for Intermediate 18. MS (ES+) C8H12N4 requires: 164, found: 165[M+H]+. Example 2: Synthesis of arylchloride intermediates Example 2a
Intermediate 19: 4-Bromo-1,6-dichloro-2,7-naphthyridine
Step 1: 4-Bromo-6-chloro-2,7-naphthyridin-1(2H)-one NBS (70.9 g, 398 mmol, 1.20 eq) was added to a solution of 6-chloro-2,7- naphthyridin-1(2H)-one (60.0 g, 332 mmol, 1.00 eq) in DMF (600 mL). The reaction mixture was stirred at 20 °C for 2 h, then was poured into water (1 L) and filtered. The filter cake
was dried under vacuum to give 4-bromo-6-chloro-2,7-naphthyridin-1(2H)-one (90.8 g, crude) as a brown solid. MS (ES+) C8H4BrClN2O requires: 260, found: 261[M+H]+. Step 2: 4-Bromo-1,6-dichloro-2,7-naphthyridine 4-Bromo-6-chloro-2,7-naphthyridin-1(2H)-one (70.8 g, 272 mmol, 1.00 eq) was added in portions to POCl3 (484 g, 3.16 mol, 293 mL, 11.5 eq) at 25 °C. The reaction mixture was then stirred at 110 °C for 3 h. The reaction mixture was then concentrated under vacuum, and the residue was adjusted to pH = 8 with saturated aqueous Na2CO3 at 25 °C. The mixture was extracted with DCM (500 mL × 3), washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under vacuum to give the title compound (75.0 g, 269 mmol, 98.9% yield) as a yellow solid. MS (ES+) C8H3BrCl2N2 requires: 278, found: 279[M+H]+. Example 2b
Intermediate 20: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-ol
Step 1: 4-Bromo-6-chloro-1-methoxy-2,7-naphthyridine A suspension of 4-bromo-1,6-dichloro-2,7-naphthyridine (75.0 g, 269 mmol, 1.00 eq), K2CO3 (111 g, 809 mmol, 3.00 eq) in MeOH (3 L) was stirred at 25 °C for 16 h. The reaction mixture was then concentrated under vacuum, and the residue was dissolved in H2O (300 mL) and extracted with DCM (100 mL x 2). The combined organic layers were concentrated under vacuum to give a residue. The residue was triturated in PE/EA (40 mL 20:1) and filtered. The filter cake was dried under vacuum to give the title compound (47.0 g, 171 mmol, 63.6% yield) as a yellow solid.
Step 2: 6-Chloro-4-(1-ethoxyvinyl)-1-methoxy-2,7-naphthyridine A solution of 4-bromo-6-chloro-1-methoxy-2,7-naphthyridine (47.0 g, 171 mmol, 1.00 eq), tributyl(1-ethoxyvinyl)stannane (74.4 g, 206 mmol, 69.6 mL, 1.20 eq) and Pd(PPh3)4 (19.8 g, 17.1 mmol, 0.10 eq) in toluene (500 mL) was stirred at 80 °C for 16 h under N2. The reaction mixture was then cooled to 20 °C and poured into saturated aqueous KF solution (500 mL) and stirred for 1 h. The aqueous mixture was extracted with EA (300 mL x 3), and the organic layers were combined. The combined organic layer was concentrated under vacuum to give the title compound (64.0 g, crude) as a yellow oil. MS (ES+) C13H13ClN2O2 requires: 264, found: 265[M+H]+. Step 3: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-one Aqueous HCl (1.50 M, 20.1 mL, 0.10 eq) was added to a solution of 6-chloro-4-(1- ethoxyvinyl)-1-methoxy-2,7-naphthyridine (80.0 g, 302 mmol, 1.00 eq) in THF (480 mL) and H2O (80 mL). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was then poured into saturated aqueous NaHCO3 solution (500 mL) and extracted with EA (300 mL x 2). The organic layers were combined and concentrated under vacuum. The residue was purified by flash-column chromatography on silica gel (gradient elution, 5% to 50% EA- PE) to give the title compound (28.0 g, 118 mmol, 39.1% yield) as a white solid. MS (ES+) C11H9ClN2O2 requires: 236, found: 237[M+H]+. Step 4: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-ol To a solution of 1-(6-chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-one (500 mg, 2.11 mmol) in MeOH (10 mL) was added NaBH4 (120 mg, 3.17 mmol). The mixture was stirred at 25 °C for 10 min, then was quenched by addition of water (5 mL) and extracted with EA (5mL x 3). The combined organic layers were concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE/EA = 10/1 to 1:1) to give the title compound (400 mg, 79% yield) as an off-white solid. Example 2c
Intermediate 21: 2-(6-Chloro-1-(methylamino)-2,7-naphthyridin-4-yl)propan-2-ol
Step 1: 4-Bromo-6-chloro-N-methyl-2,7-naphthyridin-1-amine To a solution of 4-bromo-6-chloro-2,7-naphthyridin-1(2H)-one (600 mg, 2.31 mmol) in DMF (15 mL) was added DBU (528 mg, 3.47 mmol, 523 uL) and BOP (1.53 g, 3.47 mmol), then methylamine (2 M, 3.04 g) was added to the reaction mixture and it was stirred at 25 °C for 1 h. The reaction mixture was then diluted with water (10 mL), filtered and the filter cake was dried to give the title compound (440 mg, 70% yield) as a yellow solid that was used without further purification. MS (ES+) C9H7BrClN3 requires: 271, found: 272[M+H]+. Steps 2-3: 1-(6-Chloro-1-(methylamino)-2,7-naphthyridin-4-yl)ethan-1-one The title compound was prepared from 4-Bromo-6-chloro-N-methyl-2,7- naphthyridin-1-amine using a procedure similar to the that described in Steps 2-3 of Intermediate 20. Step 4: 2-(6-Chloro-1-(methylamino)-2,7-naphthyridin-4-yl)propan-2-ol To a solution of 1-(6-chloro-1-(methylamino)-2,7-naphthyridin-4-yl)ethan-1-one (100 mg, 424 umol) in THF (8 mL) was added MeMgBr (3 M, 424 uL) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h, then was quenched by addition of water (17 mL) and extracted with EA (15 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by prep- TLC (silica, PE:EA = 1:1) to give the title compound (50.0 mg, 47% yield) as a yellow solid. MS (ES+) C12H14ClN3O requires: 251, found: 252[M+H]+. Example 2d
Intermediate 22: 2-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)propan-2-ol
Step 1: 2-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)propan-2-ol To a solution of 1-(6-chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-one (220 mg, 930 umol) in THF (10 mL) was added MeMgBr (3 M, 930 uL) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h, then was quenched by addition of water (17 mL) extracted with EA (15 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (200 mg, 85% yield) a yellow solid that was used in the next step without further purification. MS (ES+) C12H13ClN2O2 requires: 252, found: 253[M+H]+. Example 2e
Intermediate 23: 2-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)-1,1-difluoropropan- 2-ol
Step 1: 2-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)-1,1-difluoropropan-2-ol To a solution of 1-(6-chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-one (100 mg, 423 umol) and difluoromethyl(trimethyl)silane (105 mg, 845 umol) in DME (3 mL) was added 18-crown-6 (78.2 mg, 296 umol) and CsF (44.9 mg, 296 umol). The reaction mixture was stirred at 25 °C for 12 h, then was filtered and concentrated to give a residue. The residue was purified by prep-TLC (PE:EA = 5:1) to give the title compound (70.0 mg, 57% yield) as a yellow solid. MS (ES+) C12H11ClF2N2O2 requires: 288, found: 289[M+H]+. Example 2f
Intermediate 24: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)propan-1-ol
Step 1: 6-Chloro-1-methoxy-4-vinyl-2,7-naphthyridine A mixture of 4-bromo-6-chloro-1-methoxy-2,7-naphthyridine (23.5 g, 85.9 mmol), Potassium trifluoro(vinyl)borate (15.0 g, 112 mmol), Et3N (17.4 g, 172 mmol) and Pd(dppf)Cl2 (6.29 g, 8.59 mmol) in H2O (48 mL) and EtOH (480 mL) was stirred at 80 °C for 12 h. The reaction mixture was then diluted with EA (300 mL) and brine (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE/EA = 10/1) to give the title compound (10 g, crude) as a white solid that was used without further purification. Step 2: 6-Chloro-1-methoxy-2,7-naphthyridine-4-carbaldehyde A solution of 6-chloro-1-methoxy-4-vinyl-2,7-naphthyridine (800 mg, 3.63 mmol) in DCM (6 mL) and MeOH (1 mL) was cooled to -78 °C, then ozone was bubbled into the reaction mixture. After 10 min, the reaction mixture was flushed with nitrogen, and then Me2S (4.45 g, 71.6) was added and the mixture was allowed to warm to 25 °C. After stirring for 50 min at 25 °C, the reaction mixture was poured into water (20 mL) and extracted with EA (20 mL × 3). The combined organic layers were washed with water (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue. The residue was purified by flash chromatography on silica gel (PE/EA=10:1-1:1), to give the title compound (400 mg, 50% yield) as a yellow solid. Step 3: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)propan-1-ol To a solution of 6-chloro-1-methoxy-2,7-naphthyridine-4-carbaldehyde (100 mg, 284 umol) in THF (2 mL) was added EtMgBr (5.65 g, 39.8 mmol) in one portion at 20 °C. The reaction mixture was stirred at 20 °C for 1 h, then was quenched with water (20 mL) and extracted with EA (20 mL × 3). The combined organic layers were washed with water (20 mL × 3), dried over sodium sulfate, filtered and concentrated to give the title compound (50 mg, 48% yield) as a yellow oil.
(400MHz, CDCl3) δ ppm 9.41 (s, 1H), 8.20 (s, 1H), 8.03 (s, 1H), 5.00-4.96 (m, 1H), 4.17 (s, 3H), 2.01-1.94 (m, 2H), 1.00 (t, J = 7.6 Hz, 3H).
Example 2g
Intermediate 25: 2-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)butan-2-ol
Step 1: 2-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)butan-2-ol To a solution of 1-(6-chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-one (1 g, 4.23 mmol) in THF (20 mL) was added EtMgBr (3 M, 4.23 mL) at 0 °C. The cooling bath was removed, and the reaction mixture was stirred at 25 °C for 0.5 h. The reaction mixture was then partitioned between EA (60 mL) and saturated aqueous ammonium chloride solution (40 mL). The organic layer was washed with saturated aqueous sodium chloride solution (40 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE/EA = 100/1 to 2/1) to give the title compound (400 mg, 28% yield) as a white solid. MS (ES+) C13H15ClN2O2 requires: 266, found: 267[M+H]+.1H-NMR (400 MHz, CD3OD): δ ppm 9.36 (s, 1H), 8.67 (s, 1H), 8.20 (s, 1H), 4.16 (s, 3H), 2.08-2.04 (m, 2H), 1.70 (s, 3H), 0.81 (d, J = 7.6 Hz, 3H). Example 2h
Intermediate 26: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)-2-methoxyethan-1- ol
Step 1: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)ethane-1,2-diol To a mixture of 6-chloro-1-methoxy-4-vinyl-2,7-naphthyridine (15 g, 68.0 mmol) and NMO (15.9 g, 136 mmol, 14.4 mL) in acetone (300 mL) and H2O (75 mL) was added OsO4 (173 mg, 680 umol) in one portion. The reaction mixture was stirred at 25 °C for 12 h, then was quenched with saturated aqueous Na2SO3 aqueous solution (100 mL). The mixture was
filtered, and the filtrate was concentrated to remove the organic solvents. The water layer was extracted with EA (3 x 200 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give the title compound (9.8 g, crude) as a yellow solid that was used in the next step without further purification. Step 2: 1-(6-Chloro-1-methoxy-2,7-naphthyridin-4-yl)-2-methoxyethan-1-ol To a solution of 1-(6-chloro-1-methoxy-2,7-naphthyridin-4-yl)ethane-1,2-diol (1 g, 3.93 mmol) and TBAB (127 mg, 393 umol) in H2O (4 mL) and THF (20 mL) was added a solution of NaOH (471 mg, 11.8 mmol) in H2O (4 mL), then Me2SO4 (594 mg, 4.71 mmol) was added. The reaction mixture was stirred at 25 °C for 4 h, and then more Me2SO4 (594 mg, 4.71 mmol) was added. The reaction mixture was stirred at 25 °C for an additional 12 h, then the mixture was partitioned between EA (150 mL) and H2O (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column (PE/EA =1:2), then purified by prep-HPLC (column: Waters Xbridge C18150*50 mm * 10 um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 18%-48%, 11 min) to give the title compound as a 1:1 mixture with a regioisomer. The mixture was separated by chiral SFC (column: Daicel Chiralpak AD (250 mm*30 mm, 10 um); mobile phase: [0.1%NH3H2O ETOH]; B%: 25%-25%) to give the title compound as the second eluting peak. MS (ES+) C12H13ClN2O3 requires: 268, found: 269[M+H]+.
NMR (400 MHz, CD3Cl): δ ppm 9.43 (s, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 4.72-4.65 (m, 1H), 4.18 (s, 3H), 3.95-3.85 (m, 1H), 3.76-3.70 (m, 1H), 3.37 (s, 3H), 2.36-2.30 (m, 1H). Example 2i
Intermediates 27 and 28: (R)-2-(6-Chloro-1-(cyclopropylamino)-2,7-naphthyridin-4- yl)butan-2-ol and (S)-2-(6-chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol
Step 1: 4-Bromo-6-chloro-N-cyclopropyl-2,7-naphthyridin-1-amine A solution of 4-bromo-1,6-dichloro-2,7-naphthyridine (2.00 g, 7.20 mmol), cyclopropanamine (493 mg, 8.64 mmol) and DIPEA (2.79 g, 21.6 mmol) in NMP (20 mL) was stirred at 80 °C for 2 h. The reaction mixture was then poured into water (200 mL) and filtered. The filter cake was dried to give the title compound (2.50 g, crude) as a yellow solid that was used in the next step without further purification. MS (ES+) C11H9BrClN3 requires: 297, found: 298[M+H]+. Steps 2-3: 1-(6-Chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)ethan-1-one The title compound was prepared from 4-bromo-6-chloro-N-cyclopropyl-2,7- naphthyridin-1-amine using a procedure similar to the that described in Steps 2-3 of Intermediate 20. Step 4: (R)-2-(6-Chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol To a solution of 1-(6-chloro-1-(cyclopropylamino)-2,7-naphthyridin-4-yl)ethan-1-one (850 mg, 3.25 mmol) in THF (170 mL) was added EtMgBr (3 M, 3 mL). The reaction mixture was stirred at 15 °C for 0.5 h, then was quenched by addition of saturated ammonium chloride solution (200 mL) and extracted with EA (200 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by silica gel chromatography (PE:EA = 1: 0 to 1: 1) to give a racemic mixture of the title compounds (360 mg, 37% yield) a yellow solid. The racemate was separated by chiral SFC (column: Daicel Chiralpak IC (250mm*30mm, 10um); mobile phase: [0.1%NH3H2O MEOH]; B%: 40%-40%) to give the first of (R)-2-(6-chloro-1- (cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1- (cyclopropylamino)-2,7-naphthyridin-4-yl)butan-2-ol (peak 1, Intermediate 27, 120 mg, 33 % yield) as a yellow solid and the second one of (R)-2-(6-chloro-1-(cyclopropylamino)-2,7-
naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1-(cyclopropylamino)-2,7-naphthyridin-4- yl)butan-2-ol (peak 2, Intermediate 28, 120 mg, 33%) as a yellow solid. MS (ES+) C15H18ClN3O requires: 291, found: 292[M+H]+. Example 2j
Intermediate 29: 2-(3-chloro-8-methoxyisoquinolin-5-yl)propan-2-ol
Step 1: N-(5-Bromo-2-methoxybenzyl)-2,2-diethoxyacetimidamide Methyl 2,2-diethoxyethanimidate (8.9 g, 55.5 mmol) was added to a solution of (5- bromo-2-methoxy-phenyl)methanamine (10 g, 46.3 mmol) in MeOH (100 mL) under an atmosphere of N2. The mixture was stirred at 25 °C for 12 h. LCMS showed desired MS was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was diluted with H2O (50 mL) and extracted with DCM 200 mL (50 mL × 4). The combined organic layers were washed with saturated aqueous NaCl solution (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (12 g, crude) as a white solid which was used in the next step without further purification. Step 2: 5-Bromo-8-methoxyisoquinolin-3-amine N-(5-Bromo-2-methoxybenzyl)-2,2-diethoxyacetimidamide (11 g, 31.9 mmol) was added to H2SO4 (111.61 g, 1.1 mol, 60.6 mL, 98% purity) at 0 °C, and then the mixture was
stirred at 25 °C for 3 h under an atmosphere of N2. The reaction mixture was quenched by addition of NaOH (120 g) in H2O (5 L) at 0 °C and extracted with 2-MeTHF (1L × 2). The combined organic layers were washed with saturated aqueous NaCl solution (1L), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase prep-HPLC to give the title compound (3 g, 11.8 mmol, 37% yield) as a yellow solid. Step 3: 5-(1-Ethoxyvinyl)-8-methoxyisoquinolin-3-amine Pd(PPh3)4 (1.02 g, 884.8 µmol) and tributyl(1-ethoxyvinyl)stannane (6.79 g, 18.8 mmol, 6.3 mL) were added to a solution of 5-bromo-8-methoxyisoquinolin-3-amine (2.8 g, 11.1 mmol) in toluene (30 mL) under N2 atmosphere. The mixture was stirred at 100 °C for 4 h under N2 atmosphere. The reaction mixture was quenched by addition of aqueous CsF solution (60 mL) at 0 °C and extracted with EA (40 mL × 3). The combined organic layers were washed with saturated aqueous NaCl solution (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (2.7 g, crude) as a brown oil which was used in the next step without further purification. Step 4: 1-(3-Amino-8-methoxyisoquinolin-5-yl)ethan-1-one A mixture of 5-(1-ethoxyvinyl)-8-methoxyisoquinolin-3-amine (2.7 g, 11.1 mmol) in THF (20 mL) and HCl (1M, 11 mL) was stirred at 25 °C for 30 min under N2 atmosphere. The reaction mixture was filtered to give the title compound (1.1 g, crude) as a yellow solid which was used in the next step without further purification. Step 5: 1-(3-Chloro-8-methoxyisoquinolin-5-yl)ethan-1-one Pyridine hydrochloride (1.03 g, 8.9 mmol), CuCl (25.2 mg, 254.3 umol, 6.08 uL) and NaNO2 (614.2 mg, 8.9 mmol) were added to a solution of 1-(3-amino-8-methoxyisoquinolin- 5-yl)ethan-1-one (550 mg, 2.5 mmol) in DCM (5 mL) under N2 atmosphere. HCl (37.6 mg, 381.5 umol, 36.9 uL, 37% purity) was then added to the reaction mixture at -10 °C, and the mixture was stirred at 0 °C for 30 min. The mixture was stirred at 25 °C for 1 h under N2 atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash-column chromatography to give the title compound (530 mg, 44 % yield) as a white solid. Step 6: 2-(3-Chloro-8-methoxyisoquinolin-5-yl)propan-2-ol MeMgBr (3M in THF, 1.41 mL) was added to a solution of 1-(3-Chloro-8- methoxyisoquinolin-5-yl)ethan-1-one (200 mg, 848.7 umol) in THF (2 mL) under N2 atmosphere, and the reaction mixture was stirred at 25 °C for 1 h under N2 atmosphere. The
reaction mixture was quenched by the addition of H2O (10 mL) at 0 °C. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash-column chromatography to give the title compound (580 mg, 90.5% yield) as a yellow solid. Example 2k
Intermediate 30: 2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)propan-2-ol
Step 1: 4-Bromo-6-chloro-1-cyclopropoxy-2,7-naphthyridine To a solution of 4-bromo-1,6-dichloro-2,7-naphthyridine (10.5 g, 37.78 mmol) and cyclopropanol (4.39 g, 75.6 mmol) in ACN (100 mL) was added K2CO3 (15.7 g, 113 mmol). The reaction mixture was stirred at 60 °C for 16 h, then additional cyclopropanol (4.39 g, 75.6 mmol) was added to the reaction mixture and it was heated to 70 °C for another 3 h. The reaction mixture was then concentrated to give a residue. The residue was diluted with water (200 mL), filtered and the filter cake was dried to give the title compound (11.3 g, 99% yield) as a yellow solid. Steps 2-3: 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one The title compound was prepared from 4-bromo-6-chloro-1-cyclopropoxy-2,7- naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20. Step 4: 2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)propan-2-ol The title compound was prepared from 1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin- 4-yl)ethan-1-one using a procedure similar to the that described in Step 1 of Intermediate 22. MS (ES+) C14H15ClN2O2 requires: 278, found: 279[M+H]+.
Example 2l
Intermediates 31 and 32: (R)-2-(6-Chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2- ol and (S)-2-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol
Step 1: 4-Bromo-6-chloro-1-ethoxy-2,7-naphthyridine A mixture of 4-bromo-1,6-dichloro-2,7-naphthyridine (3.00 g, 10.7 mmol) and K2CO3 (4.48 g, 32.3 mmol) in EtOH (30 mL) was stirred at 50 °C for 16 h, then was concentrated to give a residue. The residue was treated with water (100 mL), filtered, and the filter cake was dried to give the title compound (3.00 g, 97% yield) as white solid. MS (ES+) C10H8BrClN2O requires: 288, found: 289[M+H]+. Steps 2-3: 1-(6-Chloro-1-ethoxy-2,7-naphthyridin-4-yl)ethan-1-one The title compound was prepared from 4-bromo-6-chloro-1-ethoxy-2,7-naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20. Step 4: (R)-2-(6-Chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6- chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol The racemate of the title compound was prepared from 1-(6-Chloro-1-ethoxy-2,7- naphthyridin-4-yl)ethan-1-one using a procedure similar to the that described in Step 4 of Intermediate 27. The mixture was separated by chiral SFC (column: Daicel Chiralpak AD (250mm*30mm, 10um); mobile phase: [0.1%NH3H2O ETOH]; B%: 20%-20%) to give the first of (R)-2-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1- ethoxy-2,7-naphthyridin-4-yl)butan-2-ol (peak 1, Intermediate 31, 50.0 mg, 50% yield) as yellow oil and the second one of (R)-2-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol
or (S)-2-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)butan-2-ol (peak 2, Intermediate 32, 50.0 mg, 50% yield) as yellow oil. Example 2m
Intermediate 33: 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1- cyclopropylethan-1-ol
Step 1: 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol To a solution of 1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one (500 mg, 1.90 mmol) in MTBE (8 mL) was added cyclopropylmagnesium bromide (3 M, 3.17 mL) at 15 °C. The mixture was heated to 60 °C for 1 h, then was quenched by addition of saturated aqueous ammonium chloride solution (20 mL) and diluted with water (20 mL). The resulting mixture was extracted with EA (30 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash silica gel chromatography (Eluent of 0~65% EA/PE) to give the title compound (460 mg, 72% yield) as a white solid. MS (ES+) C16H17ClN2O2 requires: 304, found: 305[M+H]+. Example 2m
Intermediates 34 and 35: (R)-2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4- yl)butan-2-ol and (S)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)butan-2-ol
Step 1: (R)-2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2- (6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)butan-2-ol
To a solution of 1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one (300 mg, 1.14 mmol) in MTBE (10 mL) was added EtMgBr (3 M, 1.14 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 15 min, then was quenched with saturated aqueous ammonium chloride solution (20 mL) and extracted with EA (25 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE: EA=10:1 to 3:1) to give a racemic mixture of the title compounds (300 mg, 84% yield) as a yellow solid.1H-NMR (400 MHz, CDCl3): δ ppm 9.31 (s, 1H), 8.55 (s, 1H), 8.22 (s, 1H), 4.55-4.47 (m, 1H), 2.13-2.05 (m, 2H), 1.75 (s, 3H), 0.94-0.91 (m, 4H), 0.90-0.85 (m, 3H). The mixture was separated by chiral SFC (column: Daicel Chiralpak IG (250mm*30mm, 10 um); mobile phase: [0.1% NH3H2O MeOH]; B%: 30%-30%) to give the first of (R)-2-(6-chloro-1-cyclopropoxy-2,7- naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)butan- 2-ol (peak 1, Intermediate 34, 90.0 mg, 60% yield) as a yellow solid and the second one of (R)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1- cyclopropoxy-2,7-naphthyridin-4-yl)butan-2-ol (peak 2, Intermediate 35 , 105 mg, 70% yield) as a yellow solid. Example 2n
Intermediates 36 and 37: (R)-1-(6-Chloro-1-ethoxy-2,7-naphthyridin-4-yl)-1- cyclopropylethan-1-ol and (S)-1-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)-1- cyclopropylethan-1-ol
Step 1: (R)-1-(6-Chloro-1-ethoxy-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol and (S)-1-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol To a solution of 1-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)ethan-1-one (300 mg, 1.20 mmol) in MTBE (20 mL) was added cyclopropylmagnesium bromide (0.5 M, 11.9 mL). The mixture was stirred at 60 °C 0.5 h, then was quenched by addition of saturated aqueous ammonium chloride solution (30 mL) and extracted with EA (2 x 30 mL). The combined
organic layers were dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was purified by prep-TLC (PE/EA = 1/1) to give a racemic mixture of the title compounds (80.0 mg, 23% yield) as a yellow oil. The mixture was separated by chiral SFC (column: Daicel Chiralpak IG (250mm*30mm, 10um); mobile phase: [0.1%NH3H2O MEOH]; B%: 30%-30%) 4min) to give the first one of (R)-1-(6-chloro-1-ethoxy-2,7- naphthyridin-4-yl)-1-cyclopropylethan-1-ol or (S)-1-(6-chloro-1-ethoxy-2,7-naphthyridin-4- yl)-1-cyclopropylethan-1-ol (peak 1, Intermediate 36, 40.0 mg, 50% yield) as a yellow solid and the second one of (R)-1-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1- ol or (S)-1-(6-chloro-1-ethoxy-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol (peak 2, Intermediate 37, 40.0 mg, 50% yield) as a yellow solid. Example 2o
Intermediates 38 and 39: (S)-2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1- methoxypropan-2-ol and (R)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1- methoxypropan-2-ol
Step 1: 6-Chloro-1-cyclopropoxy-4-(prop-1-en-2-yl)-2,7-naphthyridine A mixture of 4-bromo-6-chloro-1-cyclopropoxy-2,7-naphthyridine (8 g, 26.7 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (4.71 g, 28.0 mmol), Pd(dppf)Cl2 (1.95 g, 2.67 mmol) and K2CO3 (11.1 g, 80.1 mmol) in dioxane (150 mL) and H2O (30 mL) was stirred at 80 °C for 2 h. The reaction mixture was then extracted with EA (100 mL), and the organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and
concentrated. The residue was purified by column chromatography on silica gel (PE/EA = 10/1) to give the title compound (5.7 g, 78% yield) as a colorless oil. Step 2: 6-Chloro-1-cyclopropoxy-4-(2-methyloxiran-2-yl)-2,7-naphthyridine To a solution of 6-chloro-1-cyclopropoxy-4-(prop-1-en-2-yl)-2,7-naphthyridine (5.7 g, 21.9 mmol) in DCM (80 mL) was added mCPBA (7.07 g, 32.8 mmol, 80% purity) in portions. The reaction mixture was stirred at 25 °C for 2 h, then was quenched with saturated aqueous Na2SO3 (100 mL) and extracted with EA (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE/EA = 4/1) to give the title compound (2.2 g, 28% yield) as a white solid. MS (ES+) C14H13ClN2O2 requires: 276, found: 277[M+H]+. Step 3: 2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)propane-1,2-diol To a solution of 6-chloro-1-cyclopropoxy-4-(2-methyloxiran-2-yl)-2,7-naphthyridine (2.2 g, 7.95 mmol) in THF (16 mL) was added a solution of H2SO4 (780 mg, 7.95 mmol) in H2O (4 mL) dropwise at 25 °C. The reaction mixture was stirred at 60 °C for 0.5 h, then was poured into saturated aqueous NaHCO3 solution (50 mL) and extracted with EA (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated to give the title compound (2.1 g, 70% yield) as a yellow oil that was used in the next step without further purification. MS (ES+) C14H15ClN2O3 requires: 294, found: 295[M+H]+. Step 4: (S)-2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-methoxypropan-2- ol and (R)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-methoxypropan-2-ol To a solution of 2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)propane-1,2-diol (500 mg, 1.33 mmol) in THF (10 mL) was added NaH (133 mg, 3.33 mmol, 60% purity) at 25 °C. The reaction mixture was stirred at 25 °C for 0.5 h, and then CH3I (198 mg, 1.40 mmol) was added. The reaction mixture was stirred at 25 °C for 4 h, then was filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18150 * 40 mm * 15 um; mobile phase: [water (0.225% FA) - ACN]; B%: 35%-65%, 10 min) to give a racemic mixture of title compounds (100 mg, 23% yield) as a yellow oil. MS (ES+) C15H17ClN2O3 requires: 308, found: 309[M+H]+. The mixture was separated by chiral SFC (column: Daicel Chiralpak IG (250 mm * 30 mm, 10 um); mobile phase: [0.1% NH3H2O- MEOH]; B%: 25%-25%) to give the first one of (S)-2-(6-chloro-1-cyclopropoxy-2,7- naphthyridin-4-yl)-1-methoxypropan-2-ol or (R)-2-(6-chloro-1-cyclopropoxy-2,7- naphthyridin-4-yl)-1-methoxypropan-2-ol (peak 1, Intermediate 38, 135 mg, 34% yield) as a yellow oil and the second one of (S)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-
methoxypropan-2-ol or (R)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1- methoxypropan-2-ol (peak 2, Intermediate 39, 25 mg, 25% yield). Example 2p
Intermediate 40: 2-(6-Chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridin-4- yl)propan-2-ol
Step 1: 4-Bromo-6-chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridine To a solution of 4-bromo-1,6-dichloro-2,7-naphthyridine-1 (771 mg, 2.77 mmol) and (1-fluorocyclopropyl)methanol (500 mg, 5.55 mmol) in ACN (15 mL) was added K2CO3 (1.15 g, 8.32 mmol) and CsF (422 mg, 2.77 mmol). The reaction mixture was stirred at 60 °C for 12 h, then was concentrated. The residue was purified by silica gel column chromatography [PE : EA = 10:1] to give the title compound (800 mg, 87% yield) as a colorless oil. Steps 2-3: 1-(6-Chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridin-4- yl)ethan-1-one The title compound was prepared from 4-bromo-6-chloro-1-((1-fluorocyclopropyl) methoxy)-2,7-naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20. Step 4: 2-(6-Chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridin-4-yl)propan- 2-ol To a solution of 1-(6-chloro-1-((1-fluorocyclopropyl)methoxy)-2,7-naphthyridin-4- yl)ethan-1-one (310 mg, 1.05 mmol) in MBTE (4.00 mL) was added MeMgBr (3 mol, 1.75mL). The reaction mixture was stirred at 25 °C for 0.5 h, then was poured into saturated aqueous ammonium chloride solution (20 mL) and extracted with EA (40 mL × 3). The
combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography [PE : EA = 20:1 to 2:1] to give the title compound (440 mg, crude) as a yellow oil. Example 2q
Intermediates 41 and 42: (S)-1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1- cyclobutylethan-1-ol and (R)-1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1- cyclobutylethan-1-ol
Step 1: (S)-1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-cyclobutylethan-1- ol (R)-1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-cyclobutylethan-1-ol To a solution of 1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one (300 mg, 1.14 mmol) in MTBE (20 mL) was added cyclobutylmagnesium bromide (0.5 M, 7 mL) at 70 °C. The reaction mixture was stirred at 70 °C for 1 h, then was quenched by addition of water (30 mL) at 20 °C. The mixture was extracted with EA (30 mL × 2), and the combined organic layers were washed with water (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue purified by prep-HPLC (column: Phenomenex luna C18150 × 40 mm × 15 um; mobile phase: [water (0.1% TFA)-ACN]; B%: 47%-77%, 11 min) to give a racemic mixture of the title compounds (110 mg, 27% yield) as a yellow oil. The mixture was separated by chiral SFC (column: Daicel Chiralpak IG (250 mm × 30 mm, 10 um); mobile phase: [0.1% NH3H2O MEOH]; B%: 30%-30%) to give the first one of (S)-1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-cyclobutylethan-1-ol or (R)-1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-cyclobutylethan-1-ol (peak 1, Intermediate 41, 30.0 mg, 27% yield) as a yellow solid and the second one of (S)-1-(6-chloro- 1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-cyclobutylethan-1-ol or (R)-1-(6-chloro-1- cyclopropoxy-2,7-naphthyridin-4-yl)-1-cyclobutylethan-1-ol (peak 2, Intermediate 42, 30.0 mg, 27% yield) as a yellow solid.
Example 2r
Intermediate 43: 1-(3-((6-chloro-4-(2-hydroxypropan-2-yl)-2,7-naphthyridin-1- yl)oxy)azetidin-1-yl)ethan-1-one
Step 1: 1-(3-((4-Bromo-6-chloro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one Sodium hydride (2.15 g, 53.8 mmol, 60 wt%) was added to a solution of 1-(3- hydroxyazetidin-1-yl)ethan-1-one (Combi-Blocks #ST-8959) (5.16 g, 44.8 mmol) in THF (200 mL) at 0 °C. The cooling bath was removed, the reaction mixture was stirred for 0.5 h, and then 4-bromo-1,6-dichloro-2,7-naphthyridine (12.4 g, 44.8 mmol) was added. The reaction mixture was stirred at 25 °C for 1 h in MeOH, then was quenched by addition of water (70 mL). The quenched reaction mixture was extracted with EA, dried over sodium sulfate, filtered, and concentrated to give the title compound (10.0 g, 63% yield). Step 2: 1-(3-((6-Chloro-4-(1-ethoxyvinyl)-2,7-naphthyridin-1-yl)oxy)azetidin-1- yl)ethan-1-one A mixture of compound tributyl(1-ethoxyvinyl)stannane (9.14 g, 25.3 mmol1-(3-((4- bromo-6-chloro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one (8.20 g, 23.0 mmol) and Pd(PPh3)4 (2.66 g, 2.30 mmol) in toluene (150 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 100 °C for 16 h. The reaction mixture was cooled to ambient temperature, quenched by addition aqueous saturated KF (300 mL), diluted with water (100 mL), and extracted with EA (200 mL × 3). The combined organic
layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel to give the title compound (7.50 g, 94% yield) as a yellow solid. Step 3: 1-(3-((4-Acetyl-6-chloro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one Aqueous hydrochloric acid (6 M, 0.5 mL) was added to a solution of 1-(3-((6-chloro- 4-(1-ethoxyvinyl)-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one (6.90 g, 19.8 mmol) in THF (105 mL) and water (35 mL) at 20 °C. The reaction mixture was stirred at 20 °C for 1 h, then was diluted with water (300 mL) and extracted with EA (200 mL × 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0% to 100% EA-PE) to give the title compound (5.00 g, 79% yield) as a yellow solid. Steps 4 and 5: 1-(3-((6-Chloro-4-(2-hydroxypropan-2-yl)-2,7-naphthyridin-1- yl)oxy)azetidin-1-yl)ethan-1-one Methylmagnesium bromide (3 M in diethyl ether, 14 mL) was added to a solution of 1-(3-((4-acetyl-6-chl oro-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1-one (4.50 g, 14.1 mmol) in THF (200 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 15 min, then was quenched with water (200 mL) and extracted with EA (150 mL × 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give a mixture of 1-(3-((6-chloro-4-(2-hydroxypropan-2-yl)-2,7-naphthyridin-1-yl)oxy)azetidin-1-yl)ethan-1- one and 2-(1-(azetidin-3-yloxy)-6-chloro-2,7-naphthyridin-4-yl)propan-2-ol (4.10 g, 99% yield) as a yellow oil. The mixture was dissolved in DCM (50 mL) and TEA (3.53 g, 34.9 mmol) and acetic anhydride (2.14 g, 20.9 mmol) were added. The reaction mixture was stirred at 25 °C for 1 h, then was diluted with water (200 mL) and extracted with DCM (150 mL × 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash-column chromatography on silica gel (gradient elution, 50% to 100% EA-PE, then 5% to 10% MeOH-EA) to give the title compound (4.10 g, 87% yield) as a yellow oil. Example 2s
Intermediate 44: 1-(6-Chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridin-4-yl)-1- cyclopropylethan-1-ol
Step 1: 4-Bromo-6-chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridine NaH (60 wt%, 0.863 g, 21.6 mmol) was added to a solution of 2,2-difluoroethan-1-ol (1.624 g, 19.79 mmol) in DMF (36 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then 4-bromo-1,6-dichloro-2,7-naphthyridine (5.0 g, 18 mmol) was added in one portion. The reaction mixture was removed from the cooling bath and stirred at 25 °C for 3 h. The reaction mixture was then diluted with EA and washed with saturated aqueous sodium bicarbonate solution, brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash-column chromatography on silica gel (20-100% EA-Hexanes) to give the title compound (2.1 g, 36% yield) as a yellow solid. Steps 2-3: 1-(6-Chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1-one The title compound was prepared from 4-bromo-6-chloro-1-(2,2-difluoroethoxy)-2,7- naphthyridine using a procedure similar to the that described in Steps 2-3 of Intermediate 20. Step 4: 1-(6-Chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridin-4-yl)-1- cyclopropylethan-1-ol Cyclopropylmagnesium bromide (0.5 M, 3.49 mL, 1.74 mmol) was added to a solution of 1-(6-chloro-1-(2,2-difluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1-one (0.25 g, 0.87 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 30 min, then was diluted with EA and washed with saturated aqueous sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash- column chromatography on silica gel (20-100% EA:Hexanes) to give the title compound (106 mg, 37.0 % yield). MS (ES+) C15H15ClF2N2O2 requires: 328, found: 329[M+H]+. Example 2t
Intermediates 45 and 46: (R)-2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)- 1,1,1-trifluoropropan-2-ol and (S)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1,1,1- trifluoropropan-2-ol
Step 1: (R)-2-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1,1,1- trifluoropropan-2-ol and (S)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1,1,1- trifluoropropan-2-ol To a solution of 1-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one (300 mg, 1.14 mmol) and TMSCF3 (244 mg, 1.71 mmol) in THF (20 mL) was added TBAF (1 M, 228 uL). The reaction mixture was stirred at 20 °C for 15 min, then was quenched by addition of water (30 mL) and extracted with EA (30 mL x 2). The combined organic layers were washed with water (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 mm* 5 um; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 41%-61%, 10min) to give a racemic mixture of the title compounds (250 mg, 65% yield) as a yellow solid.1H- NMR (400 MHz, CDCl3): δ ppm 9.24 (s, 1H), 8.52 (s, 1H), 8.26 (s, 1H), 4.50-4.45(m, 1H), 2.88(s, 1H), 1.93(s, 3H), 0.86(d, J = 5.2 Hz, 4H). The mixture was separated by chiral SFC (column: Daicel Chiralpak OJ-H (250 mm*30 mm, 5 um); mobile phase: [0.1%NH3H2O IPA]; B%: 15%-15%) to give the first one of (R)-2-(6-chloro-1-cyclopropoxy-2,7- naphthyridin-4-yl)-1,1,1-trifluoropropan-2-ol or (S)-2-(6-chloro-1-cyclopropoxy-2,7- naphthyridin-4-yl)-1,1,1-trifluoropropan-2-ol (peak 1, Intermediate 45, 100 mg, 83% yield) and the second one of (R)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1,1,1- trifluoropropan-2-ol or (S)-2-(6-chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1,1,1- trifluoropropan-2-ol (peak 2, Intermediate 46, 110 mg, 92% yield) as a yellow solid. Example 2u
Intermediates 47 and 48: (R)-2-(6-Chloro-1-(2,2,2-trifluoroethoxy)-2,7- naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin- 4-yl)butan-2-ol
Steps 1-3: 1-(6-Chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1-one The title compound was prepared from 4-bromo-1,6-dichloro-2,7-naphthyridine and 2,2,2-trifluoroethan-1-ol using a similar procedure as described in Step 1 of Intermediate 44 and Steps 2-3 of Intermediate 20. Step 4: (R)-2-(6-Chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)butan-2-ol To a solution of 1-(6-chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1- one (300 mg, 984 umol) in MTBE (10 mL) was added EtMgBr (3 M, 1.64 mL) at 40 °C. The reaction mixture was stirred at 40 °C for 0.5 h, then was quenched by addition of saturated aqueous ammonium chloride solution (30 mL) and extracted with EA (3 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by prep-HPLC column (Phenomenex Gemini-NX C1875*30mm*3um; mobile phase: [water (0.1%TFA)-ACN]; B%: 55%-65%, 7min) to give a racemic mixture of the title compounds (50.0 mg, 15% yield) as a yellow solid. The mixture was separated by chiral SFC (Column: Chiralpak AD-350×4.6mm I.D., 3um; Mobile phase: Phase A for CO2, and Phase B for EtOH (0.05%DEA); Gradient elution: B in A from 5% to 40%) to give the first one of (R)-2-(6-chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4- yl)butan-2-ol or (S)-2-(6-chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)butan-2-ol (peak 1, Intermediate 47, 25 mg, 50% yield) as a yellow oil and the second one of (R)-2-(6- chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)butan-2-ol (peak 2, Intermediate 48, 25 mg, 50% yield) as a yellow oil. Example 2v
Intermediates 49 and 50: (S)-1-(6-Chloro-1-(2,2,2-trifluoroethoxy)-2,7- naphthyridin-4-yl)-1-cyclopropylethan-1-ol and (R)-1-(6-chloro-1-(2,2,2-trifluoroethoxy)- 2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol
Step 1: (S)-1-(6-Chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)-1- cyclopropylethan-1-ol and (R)-1-(6-chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)- 1-cyclopropylethan-1-ol A mixture of 1-(6-chloro-1-(2,2,2-trifluoroethoxy)-2,7-naphthyridin-4-yl)ethan-1-one (200 mg, 656 μmol) in MTBE (5 mL) was degassed and purged with nitrogen 3 times, and then cyclopropylmagnesium bromide (0.5 M, 2.63 mL) was added. The reaction mixture was stirred at 60 °C for 0.5 h, then was quenched by addition of saturated aqueous ammonium chloride solution (30 mL) at 25°C and extracted with EA (30 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE/EA = 1/0 to 5/1) to give a racemic mixture of the title compound (90.0 mg, 40% yield) as a yellow solid. MS (ES+) C15H14ClF3N2O2 requires: 346, found: 347[M+H]+. The racemic mixture was separated by chiral SFC (column: Daicel Chiralpak AD-H (250mm*30mm, 5um); mobile phase: [0.1%NH3H2O IPA]; B%: 20%-20%) to give the first one of (S)-1-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol or (R)-1-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol (peak 1, Intermediate 49, 35.0 mg, 39% yield) as a white oil and the second one of (S)-1-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol or (R)-1-(6-chloro-1-(2,2,2- trifluoroethoxy)-2,7-naphthyridin-4-yl)-1-cyclopropylethan-1-ol (peak 2, Intermediate 50, 45.0 mg, 50% yield) as a white oil. MS (ES+) C15H14ClF3N2O2 requires: 346, found: 347[M+H]+. Example 2w
Intermediate 51: 2-(6-Chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7- naphthyridin-4-yl)propan-2-ol
Step 1: 1-(6-Chloro-1-hydroxy-2,7-naphthyridin-4-yl)ethan-1-one To a solution of 1-(6-chloro-1-methoxy-2,7-naphthyridin-4-yl)ethan-1-one (3.00 g, 12.7 mmol) in THF (30 mL) was added aqueous HCl (6 M, 20 mL). The reaction mixture was stirred at 25 °C for 16 h, then was diluted with water (80 mL) and extracted with EA (60 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (2.80 g, 99% yield) as a white solid that was used in the next step without further purification.1H NMR (400 MHz, 6d-DMSO): δ ppm 12.45 (s, 1H), 9.16 (s, 1H), 8.80 (s, 1H), 8.45 (d, J = 3.2 Hz, 1H), 2.53 (s, 3H). Step 2: 1-(1,6-Dichloro-2,7-naphthyridin-4-yl)ethan-1-one 1-(6-Chloro-1-hydroxy-2,7-naphthyridin-4-yl)ethan-1-one (1.00 g, 4.49 mmol) was added to POCl3 (10 mL), and the reaction mixture was stirred at 100 °C and stirred for 2 h. The reaction mixture was then cooled to 23 °C and slowly poured into saturated aqueous sodium bicarbonate solution (500 mL). The mixture was extracted with EA (200 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (PE : EA = 1:0 to 3:1) to give the title compound (660 mg, 58% yield) as a white solid.1H NMR (400 MHz, CDCl3): δ ppm 9.62 (s, 1H), 9.01 (s, 1H), 8.95 (s, 1H), 2.78 (s, 3H). Step 3: 1-(6-Chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4- yl)ethan-1-one To a solution of cis-3-(methylsulfonyl)cyclobutan-1-ol (685 mg, 4.56 mmol) in THF (10 mL) was added NaH (199 mg, 4.98 mmol, 60% purity) at 0 °C. The reaction mixture was stirred at 25 °C for 0.5 h, then 1-(1,6-dichloro-2,7-naphthyridin-4-yl)ethan-1-one (1.00 g, 4.15 mmol) was added and the mixture was stirred at 25 °C for 0.5 h. The reaction mixture was then diluted with saturated aqueous sodium chloride solution (50 mL) and extracted with EA (50 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate,
filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE/EA = 1:0 to 1:4) to give the title compound (1.05 g, 2.96 mmol, 71% yield) as a yellow solid. MS (ES+) C15H15ClN2O4S requires: 354, found: 355[M+H]+. Step 4: 2-(6-Chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4- yl)propan-2-ol To a solution of 1-(6-chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin- 4-yl)ethan-1-one (350 mg, 986 μmol) in THF (10 mL) was added MeMgBr (3 M, 1.64 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 30 min, then was diluted with saturated aqueous ammonium chloride solution (25 mL) and extracted with EA (25 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE/EA = 0:1 to 1:3) to give the title compound (170 mg, 46% yield) as a yellow solid. MS (ES+) C16H19ClN2O4S requires: 370, found: 371[M+H]+. Example 2x
Intermediates 52 and 53: (R)-2-(6-Chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)- 2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)- 2,7-naphthyridin-4-yl)butan-2-ol
Step 1: (R)-2-(6-Chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4- yl)butan-2-ol and (S)-2-(6-chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4- yl)butan-2-ol To a solution of 1-(6-chloro-1-(cis-3-(methylsulfonyl)cyclobutoxy)-2,7-naphthyridin- 4-yl)ethan-1-one (650 mg, 1.83 mmol, 1 eq) in THF (10 mL) was added EtMgBr (3 M, 1.83 mL, 3 eq) at 0 °C. The cooling bath was removed, and the reaction mixture was stirred at 25 °C for 15 min. The reaction mixture was quenched by addition of water (50 mL) and extracted with EA (50 mL x 3). The organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by column
chromatography (SiO2, PE/EA = 1/0 to 0/1) followed by prep-HPLC (column: Phenomenex Gemini-NX C1875*30mm*3um; mobile phase: [water (0.225%FA) -ACN]; B%: 28%-58%, 7min) to give a racemic mixture of the title compounds (110 mg, 15.6 % yield) as a yellow solid. The mixture was separated by chiral SFC (Column: Chiralpak IG-350×4.6mm I.D., 3um Mobile phase: Phase A for CO2, and Phase B for MeOH (0.05%DEA); Gradient elution: 40% MeOH (0.05% DEA) in CO2) to give the first one of (R)-2-(6-chloro-1-(cis-3- (methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1-(cis-3- (methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4-yl)butan-2-ol (peak 1, Intermediate 52, 40 mg) as a yellow solid and the second one of (R)-2-(6-chloro-1-(cis-3- (methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1-(cis-3- (methylsulfonyl)cyclobutoxy)-2,7-naphthyridin-4-yl)butan-2-ol (peak 2, Intermediate 53, 40 mg) as a yellow solid. MS (ES+) C17H21ClN2O4S requires: 384, found: 385[M+H]+. Example 2y
Intermediate 54: 2-(6-Chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7- naphthyridin-4-yl)propan-2-ol
Step 1: 2-(6-Chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4- yl)propan-2-ol To a solution of 2-(1-(azetidin-3-yloxy)-6-chloro-2,7-naphthyridin-4-yl)propan-2-ol (50 mg, 170 umol) and Et3N (51.7 mg, 511 umol, 71.1 uL) in DCM (5 mL) was added MsCl (14.5 uL, 187 umol). The reaction mixture was stirred at 25 °C for 2 h, then was quenched by addition of water (20 mL) and extracted with EA (20 mL x 3). The combined organic layers were dried over with anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by prep-TLC (PE : EA = 0:1) to give the title compound (40 mg, 61% yield) as a white solid.
Example 2z
Intermediates 55 and 56: (S)-1-(6-Chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)- 2,7-naphthyridin-4-yl)propan-1-ol and (R)-1-(6-chloro-1-((1-(methylsulfonyl)azetidin-3- yl)oxy)-2,7-naphthyridin-4-yl)propan-1-ol
Step 1: 1-(Azetidin-3-yloxy)-4-bromo-6-chloro-2,7-naphthyridine To a solution of TFA (16.5 g, 145 mmol) in DCM (11 mL) was added tert-butyl 3- ((4-bromo-6-chloro-2,7-naphthyridin-1-yl)oxy)azetidine-1-carboxylate (3.00 g, 7.23 mmol) at 20 °C. The reaction mixture was stirred at 20 °C for 30 min, then was concentrated to give the title compound (3.10 g, TFA, crude) as a yellow oil that was used without further purification. Step 2: 4-Bromo-6-chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7- naphthyridine To a solution of 1-(azetidin-3-yloxy)-4-bromo-6-chloro-2,7-naphthyridine (3.10 g, 7.23 mmol, TFA) in DCM (30 mL) was added Et3N (1.83 g, 18.1 mmol) at 0 °C, followed by a solution of MsCl (911 mg, 7.96 mmol) in DCM (2 mL). Thee reaction mixture was stirred at 0 °C for 1 h, then was quenched with water (10 mL) and extracted with DCM (20 ml x 3). The combined organic layers were washed with water (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash
silica gel chromatography (Eluent of 0~50% EA/PE) to give the title compound (2.00 g, 67%yield) as an off-white solid. Step 3: 6-Chloro-4-(2-methylprop-1-en-1-yl)-1-((1-(methylsulfonyl)azetidin-3- yl)oxy)-2,7-naphthyridine A mixture of 4-bromo-6-chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7- naphthyridine (2.00 g, 5.09 mmol), 4,4,5,5-tetramethyl-2-(2-methylprop-1-en-1-yl)-1,3,2- dioxaborolane (974 mg, 5.35 mmol), Pd(dppf)Cl2 (373 mg, 509 μmol), and K2CO3 (1.41 g, 10.2 mmol) in dioxane (40 mL) and water (1 mL) was stirred at 80 °C for 16 h. The reaction mixture was then concentrated, and the residue was purified by flash silica gel chromatography (Eluent of 0~30% EA/DCM) to give the title compound (1.40 g, 75% yield) as an off-white solid. Step 4: 6-Chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridine-4- carbaldehyde A solution of 6-chloro-4-(2-methylprop-1-en-1-yl)-1-((1-(methylsulfonyl)azetidin-3- yl)oxy)-2,7-naphthyridine (1.20 g, 3.26 mmol) in MeOH (1.2 mL) and DCM (36 ml) was cooled to -78 °C. Ozone was bubbled into the reaction mixture for 5 minute under 15psi. The reaction mixture was then purged with N2, and then Me2S (2.03 g, 32.6 mmol) was added into the reaction mixture. The reaction mixture was warmed to 25 °C and stirred for 2 h, then was concentrated to give the title compound (1.10 g, crude) as a white solid. MS (ES+) C13H12ClN3O4S requires: 341, found: 342[M+H]+. Step 5: (S)-1-(6-Chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4- yl)propan-1-ol and ®-1-(6-chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin- 4-yl)propan-1-ol To a solution of 6-chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridine- 4-carbaldehyde (500 mg, 1.46 mmol) in THF (6 ml) was added EtMgBr (3 M, 1.46 ml) at 20 °C in one portion. The reaction mixture was stirred at 20 °C for 10 min, then was quenched with brine (1 mL) and concentrated to give a residue. The residue was purified by flash silica gel chromatography (Eluent of 0~50% EA/PE) to give a racemic mixture of the title compounds (400 mg, 70% yield) as a white solid.1H NMR: (400 MHz, CD3OD): δ ppm 9.45 (s, 1H), 8.15 (s, 1H), 7.90-8.15 (m, 1H), 5.60-5.40 (m, 1H), 5.10-4.90 (m, 1H), 4.50-4.40 (m, 2H), 4.30-4.10 (m, 2H), 2.95 (s, 3H), 2.00-1.90 (m, 2H), 1.10-0.90 (m, 3H). The mixture was separated by chiral SFC (column: Daicel Chiralpak IG (250mm*30mm, 10μm); mobile phase: [Neu-MeOH]; B%: 60%-60%) to give the first one of (S)-1-(6-chloro-1-((1-
(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4-yl)propan-1-ol or ®-1-(6-chloro-1- ((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4-yl)propan-1-ol (peak 1, Intermediate 55, 170 mg, 42% yield) and the second one of (S)-1-(6-chloro-1-((1- (methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4-yl)propan-1-ol or ®-1-(6-chloro-1- ((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4-yl)propan-1-ol (peak 2, Intermediate 56, 170 mg, 42% yield) was obtained as a white solid. Example 2aa
Intermediates 57 and 58: (R)-2-(6-Chloro-1-(((2R,4R)-4-(methylsulfonyl)pentan-2- yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(((2R,4R)-4- (methylsulfonyl)pentan-2-yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol
Step 1: (2R,4R)-4-((tert-Butyldimethylsilyl)oxy)pentan-2-ol To a solution of (2R,4R)-pentane-2,4-diol (3.80 g, 36.5 mmol) in THF (120 mL) was added NaH (1.75 g, 43.8 mmol, 60% purity) at 0 °C. The reaction mixture was stirred for 30 min, then tert-butyldimethylsilyl chloride (6.05 g, 40.1 mmol) was added and the reaction mixture was stirred at 25 °C for 1.5 h. The reaction mixture was then added to water (200 mL) and extracted with EA (150 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by silica gel column chromatography (PE/EA = 1:0 to 5:1) to give the title compound (7.80 g, 98% yield) as a colorless oil. Step 2: (2S,4R)-4-((tert-Butyldimethylsilyl)oxy)pentan-2-yl 4-nitrobenzoate To a solution of (2R,4R)-4-((tert-butyldimethylsilyl)oxy)pentan-2-ol (1.00 g, 4.58 mmol), compound 4-nitrobenzoic acid (1.53 g, 9.16 mmol), and triphenylphosphine (3.60 g, 13.7 mmol) in THF (34 mL) was added DIAD (2.78 g, 13.74 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then was stirred at 25 °C for 15.5 h, diluted with water (50 mL) and extracted with EA (40 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by silica gel column chromatography (PE/EA = 1:0 to 10:1) to give the title compound (1.50 g, 78% yield) as a yellow oil. Step 3: (2S,4R)-4-((tert-Butyldimethylsilyl)oxy)pentan-2-ol To a solution of (2S,4R)-4-((tert-butyldimethylsilyl)oxy)pentan-2-yl 4-nitrobenzoate (1.50 g, 4.08 mmol) in THF (12 mL) and water (4 mL) was added LiOH•H2O (977 mg, 40.8 mmol). The reaction mixture was stirred at 60 °C for 1 h, then was diluted with water (50 mL) and extracted with EA (40 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (890 mg, 100% yield) as a yellow oil that was used in the next step without further purification. Step 4: (2S,4R)-4-((tert-Butyldimethylsilyl)oxy)pentan-2-yl methanesulfonate To a solution of (2S,4R)-4-((tert-butyldimethylsilyl)oxy)pentan-2-ol (890 mg, 4.07 mmol) in DCM (15 mL) was added TEA (1.24 g, 12.2 mmol) and MsCl (934 mg, 8.15 mmol) at 0 °C. The reaction mixture was stirred for 1 h, then was diluted with water (100 mL) and extracted with DCM (80 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (1.20 g, 99% yield) as a yellow oil that was used in the next step without further purification.
Step 5: tert-Butyldimethyl(((2R,4R)-4-(methylthio)pentan-2-yl)oxy)silane To a solution of compound (2S,4R)-4-((tert-butyldimethylsilyl)oxy)pentan-2-yl methanesulfonate (1.20 g, 4.05 mmol) in DMF (30 mL) was added sodium methanethiolate (709 mg, 10.1 mmol). The reaction mixture was stirred at 25 °C for 0.5 h, then was diluted with water (80 mL) and extracted with EA (60 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (1.00 g, 99% yield) as a yellow oil that was used in the next step without further purification. Step 6: tert-Butyldimethyl(((2R,4R)-4-(methylsulfonyl)pentan-2-yl)oxy)silane To a solution of tert-butyldimethyl(((2R,4R)-4-(methylthio)pentan-2-yl)oxy)silane (1.00 g, 4.02 mmol) in THF (14 mL) and water (7 mL) was added Oxone® (4.95 g, 8.05 mmol). The reaction mixture was stirred at 25 °C for 0.5 h, then was quenched by addition of saturated aqueous sodium sulfite solution (30 mL) and extracted with EA (20 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (1.10 g, 97% yield) as a yellow oil that was used without further purification. Step 7: (2R,4R)-4-(Methylsulfonyl)pentan-2-ol To a solution of tert-butyldimethyl(((2R,4R)-4-(methylsulfonyl)pentan-2- yl)oxy)silane (1.10 g, 3.92 mmol) in THF (8 mL) was added aqueous HCl (6 M, 2 mL). The reaction mixture was stirred at 25 °C for 0.5 h, then was diluted with water (50 mL) and extracted with EA (40 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by silica gel column chromatography (PE/EA = 1:0 to 0:1) to give the title compound (230 mg, 35% yield) as a yellow oil. Step 8: 2-(1,6-Dichloro-2,7-naphthyridin-4-yl)butan-2-ol To a solution of 1-(1,6-dichloro-2,7-naphthyridin-4-yl)ethan-1-one (540 mg, 2.24 mmol) in MTBE (216 mL) was added EtMgBr (3 M, 2.24 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 0.5 h, then was quenched by addition of saturated aqueous ammonium chloride solution (20 mL), diluted with water (10 mL) and extracted with EA (40 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by flash silica gel chromatography (Eluent of 0~40% EA/PE) to give the title compound (320 mg, 50% yield) as a yellow solid.
Step 9: (R)-2-(6-Chloro-1-(((2R,4R)-4-(methylsulfonyl)pentan-2-yl)oxy)-2,7- naphthyridin-4-yl)butan-2-ol and (S)-2-(6-chloro-1-(((2R,4R)-4-(methylsulfonyl)pentan-2- yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol To a solution of (2R,4R)-4-(methylsulfonyl)pentan-2-ol (290 mg, 1.07 mmol) in THF (12 mL) was added NaH (51.3 mg, 1.28 mmol, 60% purity) at 0 °C. The cooling bath was removed, and the reaction mixture was stirred at 25°C for 0.5 h, then 2-(1,6-dichloro-2,7- naphthyridin-4-yl)butan-2-ol (267 mg, 1.60 mmol) was added. The reaction mixture was stirred at 25°C for 0.5 h, then was quenched with H2O (30 mL) and extracted with EA (40 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO2, PE/EA = 1/0 to 1/1) to give a mixture of the title compounds (320 mg, 74 % yield) as a yellow oil. MS (ES+) C18H25ClN2O4S requires: 400, found: 401[M+H]+. The mixture was separated by chiral SFC (column: Daicel Chiralpak AD-H (250mm×30mm, 5μm); mobile phase: [0.1%NH3H2O EtOH]; B%: 30%-30%) to give the first one of (R)-2-(6-chloro-1- (((2R,4R)-4-(methylsulfonyl)pentan-2-yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6- chloro-1-(((2R,4R)-4-(methylsulfonyl) pentan-2-yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol (peak 1, Intermediate 57, 130 mg, 41% yield) as a white oil and the second one of (R)-2-(6- chloro-1-(((2R,4R)-4-(methylsulfonyl)pentan-2-yl)oxy)-2,7-naphthyridin-4-yl)butan-2-ol or (S)-2-(6-chloro-1-(((2R,4R)-4-(methylsulfonyl) pentan-2-yl)oxy)-2,7-naphthyridin-4- yl)butan-2-ol (peak 2, Intermediate 58, 130 mg, 41% yield) as a white oil. Example 2ab
Intermediate 59: 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-phenylethan- 1-ol
Step 1: 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)-1-phenylethan-1-ol 1-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)ethan-1-one (0.15 g, 0.571 mmol) was stirred in THF (5.71 ml) at 23 °C and phenylmagnesium bromide (1.0 M, 0.685 ml, 0.685 mmol) was added. The reaction mixture was stirred at 23 °C for 30 min, then was diluted with EA, washed with saturated aqueous sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash- column chromatography on silica gel (20-100% EA:Hexanes) to give the title compound (65 mg, 33%). MS (ES+) C19H17ClN2O2 requires: 340, found: 341[M+H]+. Example 2ac
Intermediate 60: 4-(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)tetrahydro-2H- pyran-4-ol
Step 1: -(6-Chloro-1-cyclopropoxy-2,7-naphthyridin-4-yl)tetrahydro-2H-pyran-4-ol n-Butyllithium (421 µl, 1.052 mmol) was added dropwise to a solution of 4-bromo-6- chloro-1-cyclopropoxy-2,7-naphthyridine (300 mg, 1.001 mmol) in THF (7 mL) at -78 °C. The reaction mixture was stirred for 30 min at -78 °C, then tetrahydro-4H-pyran-4-one (111 µl, 1.202 mmol) was added dropwise. The reaction mixture was stirred at -78 °C for 40 min, then was quenched by addition of saturated aqueous ammonium chloride solution (4 mL). The cooling bath was removed, and the reaction mixture was diluted with water and extracted with EA. The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash-column chromatography on silica gel (0-90% EA/hexanes) to give the title compound (108 mg, 33.6 % yield).
Example 3a: Synthetic Method 1
(7S,8R)-2-((5-(2-Hydroxypropan-2-yl)-8-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7- naphthyridin-3-yl)amino)-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5-one (Compound 57)
Step 1: (7S,8R)-2-((5-(2-Hydroxypropan-2-yl)-8-((1-(methylsulfonyl)azetidin-3- yl)oxy)-2,7-naphthyridin-3-yl)amino)-7,8-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-5- one To a solution of 2-(6-chloro-1-((1-(methylsulfonyl)azetidin-3-yl)oxy)-2,7-naphthyridin-4- yl)propan-2-ol (30 mg, 80.7 umol) and (7S,8R)-2-amino-7,8-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-5-one (17.1 mg, 88.8 umol) in dioxane (2 mL) was added BrettPhos (Pd, G4) (7.43 mg, 8.07 umol), BrettPhos (4.33 mg, 8.07 umol) and potassium acetate (23.8 mg, 242 umol). The mixture was stirred at 80 °C for 1 hour under nitrogen. The reaction mixture was then filtered and concentrated under reduced pressure to give a residue. The reaction mixture was purified by pre-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%FA)-ACN]; B%: 29%-59%, 10min) to give the title compound (15.4 mg, 30 % yield) as a light yellow solid. MS (ES+) C25H29N5O6S requires: 527, found: 528[M+H]+.1H
NMR (400 MHz, CD3OD)δ ppm 9.40 (s, 1H), 9.27 (s, 1H), 8.15 (s, 1H), 8.13 (s, 1H), 7.32 (d, J = 8.8 Hz, 1H), 5.60 (s, 1H), 4.70-4.56 (m, 1H), 4.44 (t, J = 7.8 Hz, 2H), 4.28-4.11 (m, 2H), 3.33 (s, 6H), 3.05 (s, 4H), 1.82 (s, 6H), 1.57-1.45 (m, 6H). Example 4: Inhibition of MAP4K1 Biochemical Enzymatic Activity MAP4K1 (HPK1) and relevant off-target enzymatic activity was monitored using the Perkin Elmer electrophoretic mobility shift technology platform – the EZReader 2.
Fluorescent labeled substrate peptide was incubated in the presence of kinase and ATP, and in the presence of dosed compound, such that each dose of compound resulted in a reflective proportion of the peptide to be phosphorylated. Within the linear, steady-state phase of the kinase enzymatic reaction, the mixed pool of phosphorylated (product) and non- phosphorylated (substrate) peptides was passed through the microfluidic system of the PerkinElmer EZ Reader 2, under an applied electric potential difference. The presence of the phosphate group on the product peptide provided a difference in mass and charge between that of the substrate peptide, resulting in a separation of the substrate and product pools in the sample (Perrin et al. 2010). As the product and substrate peptide mixture passes the lasers within the instrument, these pools are detected (λex = 488 nm, λem = 568 nm) and resolved as separate peaks. The ratio between these peaks reflects the activity of the compound at that concentration, in that well, under those conditions. Enzyme Activity Inhibition Assay Protocol: Inhibitors were dissolved in 100% DMSO at a stock concentration of 10 mM. A 100X, 10-point, 4-fold serial dilution of each inhibitor was created in 100% DMSO either manually or on a Hamilton STAR liquid handler, starting at a relevant concentration, usually 1 mM. A volume of 0.130 µL of each concentration was transferred to the relevant wells of a 384-well plate (Greiner 781 201) in duplicate using a TTPLabtech Mosquito nano-litre dispenser. Using a Multidrop Combi, the remaining constituents of the kinase reaction were added to the 130 nL of dosed compound as follows (see table below for final reaction details): Enzyme activity assays at the APPKM for ATP or 1 mM ATP: In each well of a 384- well plate, 0.1 - 15 nM of untreated enzyme was incubated in a total of 13 µL of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl2, 1mM DTT) with 1.5 µM fluorescent peptide and 20 - 1000 µM ATP, at 25oC, for 60 - 180 minutes in the presence or absence of a dosed concentration series of compound (1% DMSO final concentration). The kinase reactions were stopped by the addition of 70 µl of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 35 mM EDTA and 0.2% of Coating Reagent 3 (Caliper Lifesciences)). The plates were read on a Caliper EZReader 2 as described above.
Table 2 Kinase Reaction Conditions
S6K2tide; Carna Biosciences (5-FAM-Proprietary Sequence-CONH2) FL4tide; Perkin Elmer (5-FAM-EGIYGVLFKKK (SEQ ID NO: 1)-CONH2) FL25tide; Perkin Elmer (5-FAM-VDGKEIYNTIRRK (SEQ ID NO: 2)-CONH2) PKAtide; Anaspec Peptide Co.(5-FAM-GRTGRRNSI (SEQ ID NO: 3)-CONH2) Perrin D, Frémaux C, Shutes A. Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery. Expert Opin Drug Discov.2010, 5(1):51-63. The results obtained in these experiments for compounds prepared according to the examples are summarized in Table 3 below. Table 3
Additional Compounds 71-74 falling within the scope of Formula (I), see Table 4 below, were also tested in the MAP4K1 (HPK1) enzymatic assay of Example 4 and all of these compounds had inhibitory activities of greater than 10 micromolar.
Table 4
Example 5: T Cell Enhancement of Cytokines Isolation and Expansion of T cells from whole blood T cells are isolated from whole blood of healthy donors by immunomagnetic negative selection following manufacture’s protocol (StemCell Technologies, human T cell isolation
kit). Purity of isolated cells is assessed by flow cytometry and yields 95-98% CD3+ T cells. For expansion of T cells, 1x106 cells/well are plated in serum free cell expansion media (ThermoFisher) containing 30U of recombinant human IL2 (R&D) and stimulated with 25ul of CD3/CD28 beads (Invitrogen) in 24 well plates for 3-4 days. T cells are then expanded in 175cm flasks and maintained at a cell density of 1 to 2.5x106 cells/ml days by addition of 2/3 of fresh media every 2-3 days. After 10-14 days, cells are frozen in BamBanker freezing media (Thermo) and stored in liquid nitrogen. Phenotypic analysis of expanded T cells by flow cytometry, routinely shows 60% cells are CD8+ T cells upon freezing. Cytokine Measurement For IL2 measurement, expanded CD3+ T cells are dispensed at 100K cells/well (cultured in X-VIVO 10 Serum-free media) and are stimulated with plate-bound anti-CD3 and soluble anti-CD28 in the presence of vehicle or compound of the disclosure at various concentrations for 24h. As outlined in the manufacturer’s protocol (Cisbio), 16 µL of conditioned media is transferred to a white 384-well low volume plate. Following a 24h incubation with the anti-IL2 antibodies, the homogenous time resolved fluorescence (HTRF) is measured. Example 6: Inhibition of Anti-Tumor Activity in a Syngeneic Mouse Model Generation of the MCA205 Syngeneic xenograft anti-tumor efficacy study Six to eight-week-old female, C57BL/6 mice (Jackson Labs, Bar Harbor, ME) are implanted subcutaneously on the left flank with 1 x 106 MCA205 cells / mouse. After tumors reach an average volume of 50 mm3, mice are randomized into treatment groups, 10 mice per group, with tumors in the size range of 30-70 mm3. Compounds of the disclosure 10-30 mg/kg, anti-mouse PD-L1 mAb (B7 H1, clone # 10F.9G2 Bio-X-cell, Lebanon, NH) and vehicle either alone or in different combinations are administered to tumor bearing mice. Reduction in tumor volume is measured [mm3] over time. Equivalents In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the
context. The disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims are introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the disclosure, or aspects of the disclosure, is/are referred to as comprising particular elements and/or features, certain embodiments of the disclosure or aspects of the disclosure consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described and claimed herein. Such equivalents are intended to be encompassed by the following claims.
Claims
What is claimed is: 1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein: A1 is selected from N and CH; A2 is selected from CH and N; X is selected from C1-3 alkyl, OR3, NHR4 and halogen; B is selected from CR5 and N, Y is CR6, or Y and B, taken together, form a 5 to 7-membered heterocycle or C5-6 cycloalkyl, wherein said heterocycle or cycloalkyl is optionally substituted with 1-6 R7; R1 and R2 are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl substituted with OR8, phenyl, C3-6 cycloalkyl and 4 to 6-membered heterocycle, or R1 and R2, taken together with the atoms to which they are attached, form a C3-6 cycloalkyl or 4 to 6-membered heterocycle; R3 is selected from C1-3 alkyl, C3-6 cycloalkyl and 4 to 6-membered heterocycle, wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1-3 R9; R4 is selected from hydrogen, C1-3 alkyl, C3-5 cycloalkyl and 4 to 6-membered heterocycle, wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1- 3 R10; R5 is selected from hydrogen, COOH, CN, halogen, and C1-3 alkoxy; R6 is selected from C1-5 alkyl, C4-6 cycloalkyl, 3 to 6-membered heterocycle, NHR11, NR12R13 and OR14, wherein said alkyl, cycloalkyl or heterocycle is optionally substituted with OH, NH2, 1-4 halogen or R15;
each R7 is independently selected from C1-3 alkyl, halogen and OH, wherein said alkyl is optionally substituted with 1-3 halogen, or two R7 attached to the same carbon form an oxo, or two R7 attached to the same carbon atom taken together with the carbon atom to which they are attached form a C3-5 cycloalkyl; R8 is H or C1-3 alkyl. each R9 is independently selected from C1-3 alkyl, C3-6 cycloalkyl substituted with halogen, halogen, C(O)Me, SO2Me, C(O)NR16R17, C1-3 alkoxy, and OH; each R10 is independently selected from C1-3 alkyl, C3-6 cycloalkyl substituted with halogen, halogen, SO2Me, C(O)NR16R17, C1-3 alkoxy, and OH; R11 is selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R18; R12 and R13 are each is independently selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R18; R14 is selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R18; R15 is OH, C1-3 alkyl or C3-5 cycloalkyl; R16 and R17 are each is independently selected from C1-6 alkyl and C3-6 cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with 1-3 R19; each R18 is independently halogen; and each R19 is independently halogen.
6. The compound of claim 4, wherein the compound is represented by Formula VI: X
VI, or a pharmaceutically acceptable salt thereof, wherein: each R7 is independently selected from C1-3 alkyl, halogen and OH, wherein said alkyl is optionally substituted with 1-3 halogen, or two R7 attached to the same carbon atom taken together with the carbon atom to which they are attached form a C3-5 cycloalkyl; n is 0, 1, 2, 3, 4, 5 or 6; and m is 0, 1 or 2.
8. The compounds of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein: X is NHR4; and R4 is CH3 or cyclopropyl.
9. The compounds of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein X is OR3.
10. The compounds of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are each independently selected from hydrogen, C1-2 alkyl, C1-2 haloalkyl, C1-3 alkyl substituted with OR8, phenyl and C3-4 cycloalkyl, or R1 and R2, taken together with the atoms to which they are attached, form a 4 to 6- membered heterocycle; and R8 is C1-2 alkyl.
11. The compounds of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are each independently selected from hydrogen, CH3, CH2CH3, CH2OCH3, CHF2, CF3, cyclobutyl, cyclopropyl and phenyl, or R1 and R2, taken together with the atoms to which they are attached, form tetrahydropyran.
12. The compounds of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are each independently selected from hydrogen, CH3, CH2CH3, CH2OCH3, CHF2, CF3, cyclobutyl, cyclopropyl and phenyl, or R1 and R2, taken together with the atoms to which they are attached, form
.
13. The compounds of any one of claims 1-7 and 9-12, or a pharmaceutically acceptable salt thereof, wherein: R3 is selected from C1-3 alkyl, C3-4 cycloalkyl and 4-membered heterocycle; wherein said alkyl, cycloalkyl, and heterocycle are optionally substituted with 1-3 R9; and each R9 is independently selected from C1-3 alkyl, halogen, C(O)Me and SO2Me.
14. The compound of any one of claims 1-7 and 9-12, or a pharmaceutically acceptable salt thereof, wherein: R3 is 4-membered heterocycle containing nitrogen; R9 is C(O)Me; and a ring nitrogen of the 4-membered heterocycle is bonded to ^–C(O)Me.
15. The compounds of any one of claims 1-7 and 9-12, or a pharmaceutically acceptable salt thereof, wherein: R3 is selected from CH3, CH2CH3, CH2CH2CH3, cyclopropyl, cyclobutyl, azetidinyl, each optionally substituted with 1-3 R9; and each R9 is independently selected from CH3, F, C(O)Me and SO2Me.
17. The compounds of any one of claims 1-4 and 8-15, or a pharmaceutically acceptable salt thereof, wherein R5 is CN.
18. The compounds of any one of claims 1-4 and 8-16, or a pharmaceutically acceptable salt thereof, wherein: R6 is selected from C1-4 alkyl, and 4 to 5-membered heterocycle, wherein said alkyl or heterocycle is optionally substituted with 1-4 halogen or R15; and R15 is C1-2 alkyl.
20. The compounds of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein: each R7 is independently CH3, or two R7 attached to the same carbon form an oxo, or
two R7 attached to the same carbon atom taken together with the carbon atom to which they are attached form cyclopropyl.
22. A compound of Table 1 or a pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition comprising the compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
24. A method of inhibiting MAP4K1 in a subject in need thereof, comprising contacting MAP4K1 with an effective amount of the compound of any one of claims 1-22 or a pharmaceutically acceptable salt thereof; or the pharmaceutical composition of claim 23.
25. A method for enhancing an immune response in a subject in need thereof, comprising administering to said subject an effective amount of the compound of any one of claims 1-22 or a pharmaceutically acceptable salt thereof; or the pharmaceutical composition of claim 23.
26. A method for treating a MAP4K1-dependent disorder or disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound of any one of claims 1-22 or a pharmaceutically acceptable salt thereof; or the pharmaceutical composition of claim 23.
27. The method of claim 26, wherein said MAP4K1-dependent disease or disorder is a cancer.
28. The method of claim 27, wherein the cancer comprises at least one cancer selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, bladder cancer, stomach cancer, liver cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.
29. The method of claim 26 or 27, wherein said method further comprises administering an additional anti-cancer agent to said subject.
30. The method of claim 26, wherein the MAP4K1-dependent disorder or disease is a viral infection.
31. A compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof, for use in the treatment of a MAP4K1-dependent disease or disorder.
32. A compound for use according to claim 31, wherein the MAP4K1-dependent disease or disorder is a cancer.
33. The use of a compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment a MAP4K1-dependent disease or disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163222341P | 2021-07-15 | 2021-07-15 | |
US63/222,341 | 2021-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023288264A1 true WO2023288264A1 (en) | 2023-01-19 |
Family
ID=82839174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/073718 WO2023288264A1 (en) | 2021-07-15 | 2022-07-14 | Map4k1 inhibitors |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR126453A1 (en) |
TW (1) | TW202321238A (en) |
WO (1) | WO2023288264A1 (en) |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029879A2 (en) | 2004-09-17 | 2006-03-23 | F.Hoffmann-La Roche Ag | Anti-ox40l antibodies |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
WO2007075598A2 (en) | 2005-12-20 | 2007-07-05 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036653A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008132601A1 (en) | 2007-04-30 | 2008-11-06 | Immutep | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
WO2009044273A2 (en) | 2007-10-05 | 2009-04-09 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
WO2009156652A1 (en) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Cellular structure containing aluminium titanate |
WO2010019570A2 (en) | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2010028683A1 (en) | 2008-09-10 | 2010-03-18 | Widex A/S | Method for sound processing in a hearing aid and a hearing aid |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
WO2012032433A1 (en) | 2010-09-09 | 2012-03-15 | Pfizer Inc. | 4-1bb binding molecules |
WO2012142237A1 (en) | 2011-04-15 | 2012-10-18 | Newlink Geneticks Corporation | Fused imidazole derivatives useful as ido inhibitors |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2014008218A1 (en) | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2020023551A1 (en) * | 2018-07-24 | 2020-01-30 | Genentech, Inc. | Naphthyridine compounds and uses thereof |
WO2021133809A1 (en) * | 2019-12-23 | 2021-07-01 | Blueprint Medicines Corporation | Inhibitors of mutant forms of egfr |
WO2021146370A1 (en) * | 2020-01-15 | 2021-07-22 | Blueprint Medicines Corporation | Map4k1 inhibitors |
-
2022
- 2022-07-14 TW TW111126410A patent/TW202321238A/en unknown
- 2022-07-14 WO PCT/US2022/073718 patent/WO2023288264A1/en unknown
- 2022-07-14 AR ARP220101849A patent/AR126453A1/en unknown
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029879A2 (en) | 2004-09-17 | 2006-03-23 | F.Hoffmann-La Roche Ag | Anti-ox40l antibodies |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
WO2007075598A2 (en) | 2005-12-20 | 2007-07-05 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036653A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008132601A1 (en) | 2007-04-30 | 2008-11-06 | Immutep | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
WO2009044273A2 (en) | 2007-10-05 | 2009-04-09 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
WO2009156652A1 (en) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Cellular structure containing aluminium titanate |
WO2010019570A2 (en) | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2010028683A1 (en) | 2008-09-10 | 2010-03-18 | Widex A/S | Method for sound processing in a hearing aid and a hearing aid |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
WO2012032433A1 (en) | 2010-09-09 | 2012-03-15 | Pfizer Inc. | 4-1bb binding molecules |
WO2012142237A1 (en) | 2011-04-15 | 2012-10-18 | Newlink Geneticks Corporation | Fused imidazole derivatives useful as ido inhibitors |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2014008218A1 (en) | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2020023551A1 (en) * | 2018-07-24 | 2020-01-30 | Genentech, Inc. | Naphthyridine compounds and uses thereof |
WO2021133809A1 (en) * | 2019-12-23 | 2021-07-01 | Blueprint Medicines Corporation | Inhibitors of mutant forms of egfr |
WO2021146370A1 (en) * | 2020-01-15 | 2021-07-22 | Blueprint Medicines Corporation | Map4k1 inhibitors |
Non-Patent Citations (17)
Title |
---|
ALZABIN, S. ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 59, no. 3, 2010, pages 419 - 29 |
ALZABIN, S. ET AL., J IMMUNOL, vol. 182, no. 10, 2009, pages 6187 - 94 |
GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 2003, MACK PUBLISHING CO. |
HERNANDEZ S. ET AL., CELL REPORTS, vol. 25, 2018, pages 80 - 94 |
HU, M.C. ET AL., GENES DEV, vol. 10, no. 18, 1996, pages 2251 - 64 |
IKEGAMI, R ET AL., J IMMUNOL, vol. 166, no. 7, 2001, pages 4689 - 96 |
KIEFER, F. ET AL., EMBO J, vol. 15, no. 24, 1996, pages 7013 - 25 |
LIOU, J. ET AL., IMMUNITY, vol. 12, no. 4, 2000, pages 399 - 408 |
LIU ET AL., PLOS ONE, vol. 14, no. 3, pages e0212670, Retrieved from the Internet <URL:https://doi.org/10.1371/journal.pone.0212670> |
PERRIN DFREMAUX CSHUTES A: "Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery", EXPERT OPIN DRUG DISCOV, vol. 5, no. 1, 2010, pages 51 - 63 |
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
SEUNGMOOK, L., CANCER RESEARCH.AACR JOURNAL, 2019 |
SHUI, J.W. ET AL., NAT IMMUNOL, vol. 8, no. 1, 2007, pages 84 - 91 |
WANG, W. ET AL., J BIOL CHEM, vol. 272, no. 36, 1997, pages 22771 - 5 |
WANG, X. ET AL., J BIOL CHEM, vol. 287, no. 14, 2012, pages 11037 - 48 |
WUTSGREENE: "Protective Groups in Organic Synthesis", 2014, JOHN WILEY & SONS |
ZHOU, G. ET AL., J BIOL CHEM, vol. 274, no. 19, 1999, pages 13133 - 8 |
Also Published As
Publication number | Publication date |
---|---|
AR126453A1 (en) | 2023-10-11 |
TW202321238A (en) | 2023-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11401279B2 (en) | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | |
JP7372255B2 (en) | Heterocyclic compounds as immunomodulators | |
US11534441B2 (en) | MAP4K1 inhibitors | |
CN111527084B (en) | Isofuranone compounds useful as HPK1 inhibitors | |
CN110831600A (en) | Indole AHR inhibitors and uses thereof | |
JP2020514272A (en) | Bicyclic heteroaromatic compounds as immunomodulators | |
WO2022192145A1 (en) | Map4k1 inhibitors | |
KR20190026902A (en) | Novel pyrimidinecarboxamide as an inhibitor of vanin-1 enzyme | |
WO2023288264A1 (en) | Map4k1 inhibitors | |
TW202304881A (en) | Pyridinyl substituted oxoisoindoline compounds | |
WO2023288254A1 (en) | Heterocyclic compounds as map4k1 inhibitors | |
CN117940406A (en) | MAP4K1 inhibitors | |
CN115175734B (en) | Pyrido [3,2-D ] pyrimidine compounds as immunomodulators | |
CN117940438A (en) | Heterocyclic compounds as MAP4K1 inhibitors | |
CN117157286A (en) | Pyridyl-substituted oxo-isoindoline compounds | |
CN117295748A (en) | MAP4K1 inhibitors | |
TW202132283A (en) | Compounds useful as inhibitors of helios protein | |
TW202313014A (en) | Heterocyclic compounds as immunomodulators of pd-l1 interactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22751627 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |